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2 Abstract	  	  Human	  papillomavirus	  (HPV)	  is	  a	  sexually	  transmitted	  virus	  associated	  with	  cervical	  cancer.	  The	  East	  African	  region	  has	  one	  of	  the	  highest	  incidences	  and	  mortality	  rates	  from	  cervical	  cancer	  but	  limited	  studies	  on	  HPV	  are	  available.	  	  Research	  aims	  were	  to	  describe:	  HPV	  genotypes,	  risk	  factors	  and	  rate	  of	  acquisition	  of	  prevalent	  and	  incident	  HPV	  in	  girls	  before	  and	  after	  reported	  first	  sex;	  rate	  and	  risk	  factors	  associated	  with	  HPV	  clearance,	  and	  to	  examine	  sexual	  behaviour	  reporting	  in	  face-­‐to-­‐face	  (FtF)	  interviews	  compared	  to	  Audio	  Computer-­‐Assisted	  Self-­‐Interviews	  (ACASI).	  A	  total	  of	  503	  girls	  aged	  15	  and	  16	  years	  in	  Mwanza,	  Tanzania,	  were	  enrolled	  and	  followed	  3-­‐monthly	  for	  18	  months	  with	  FtF-­‐interviews	  and	  self-­‐administered	  vaginal	  swabs.	  At	  enrolment,	  474	  girls	  reported	  no	  previous	  sex,	  and	  HPV	  was	  detected	  in	  40/474(8.4%).	  During	  follow-­‐up	  of	  girls	  who	  reported	  sex,	  new	  HPV	  incidence	  was	  225/100	  person-­‐years(pys).	  Reporting	  sex	  in	  the	  past	  3	  months,	  and	  knowing	  the	  most	  recent	  sexual	  partner	  for	  a	  longer	  period	  before	  sex	  were	  associated	  with	  HPV	  acquisition.	  Median	  time	  from	  reported	  sexual	  debut	  to	  first	  HPV	  infection	  was	  5	  months,	  and	  median	  duration	  of	  infection	  6	  months.	  No	  factors	  were	  associated	  with	  HPV	  clearance.	  In	  girls	  who	  reported	  not	  having	  sex,	  HPV	  incidence	  was	  29.4/100pys.	  	  	  ACASI	  was	  compared	  to	  FtF-­‐interview	  in	  203	  girls	  at	  the	  12-­‐month	  visit.	  Although	  ACASI	  was	  feasible	  and	  acceptable,	  there	  was	  no	  increase	  in	  reporting	  of	  sex	  or	  other	  sexual	  behaviours,	  with	  the	  exception	  of	  kissing,	  compared	  to	  FtF-­‐interviews.	  A	  very	  high	  incidence	  of	  HPV	  was	  seen	  in	  girls	  following	  sexual	  debut,	  and	  a	  higher	  than	  expected	  HPV	  prevalence	  and	  incidence	  were	  seen	  in	  girls	  who	  reported	  no	  previous	  sex.	  This	  emphasises	  the	  importance	  of	  HPV	  vaccination	  well	  before	  sexual	  debut.	  ACASI	  did	  not	  lead	  to	  increased	  reporting	  of	  vaginal	  sex	  and	  should	  be	  evaluated	  further	  in	  different	  settings.	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  of	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  the	  data	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  study	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  previous	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  HPV	  genotyping	  tests	  were	  performed	  by	  laboratory	  staff	  under	  the	  guidance	  of	  Nacho	  Bravo	  at	  the	  Catalan	  Institute	  of	  Oncology.	  	  I	  visited	  the	  Catalan	  Insitute	  of	  Oncology	  to	  understand	  and	  review	  the	  testing	  procedures.	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1 Background	  
1.1 Human	  papillomavirus	  (HPV):	  infection,	  natural	  history	  and	  immune	  
response	  Over	  120	  different	  genotypes	  of	  HPV	  have	  been	  described,	  of	  which	  40	  infect	  human	  epithelial	  cells	  lining	  the	  ano-­‐genital	  region	  and	  orophaynx[1].	  A	  causal	  relationship	  has	  been	  established	  between	  HPV	  and	  both	  adeno	  and	  squamous	  cell	  cancer	  of	  the	  cervix,	  and	  HPV	  has	  been	  implicated	  in	  the	  pathogenesis	  of	  other	  ano-­‐genital	  and	  oro-­‐pharyngeal	  cancers[2–4].	  The	  virus	  initially	  infects	  epithelial	  basal	  membrane	  cells,	  which	  are	  usually	  accessed	  through	  micro-­‐abrasions	  in	  the	  superficial	  epithelial	  layer[5].	  Once	  infected,	  the	  HPV	  viral	  genome	  is	  incorporated	  into	  that	  of	  the	  basal	  membrane	  cell,	  and	  HPV	  avoids	  the	  host	  immune	  response	  by	  replicating	  in	  small	  numbers	  in	  these	  cells	  without	  causing	  cell	  lysis	  or	  viraemia.	  Active	  viral	  replication	  occurs	  later,	  in	  the	  superficial	  epithelial	  cells	  of	  the	  mucosa	  which	  are	  distant	  from	  immune	  surveillance,	  and	  which	  slough	  off.	  This	  method	  of	  host	  immune	  response	  avoidance,	  combined	  with	  replication	  in	  the	  superficial	  epithelial	  layers	  of	  mucosal	  tissue,	  particularly	  those	  of	  the	  genital	  tract,	  allows	  HPV	  to	  be	  a	  highly	  efficient	  sexually	  transmitted	  infection	  (STI).	  	  HPV	  genotypes	  have	  been	  classified	  by	  the	  International	  Agency	  for	  Research	  on	  Cancers	  (IARC)	  into	  those	  with	  clear	  evidence	  that	  they	  are	  associated	  with	  cancer	  in	  humans	  (HPV	  types	  -­‐16,	  -­‐18,	  -­‐31,	  -­‐33,	  -­‐35,	  -­‐39,	  -­‐45,	  -­‐51,	  -­‐52,	  -­‐56,	  -­‐58	  and	  -­‐59,	  referred	  to	  as	  Group	  1),	  genotypes	  probably	  associated	  with	  cancer	  in	  humans	  (HPV68,	  referred	  to	  as	  Group	  2A),	  genotypes	  which	  are	  
possibly	  associated	  with	  cancer	  in	  humans	  (HPV	  types	  -­‐26,	  -­‐53,	  -­‐66,	  -­‐67,	  -­‐70,	  -­‐73,	  -­‐82,	  Group	  2B),	  and	  other	  genotypes	  which	  are	  sufficiently	  similar	  in	  their	  viral	  structure	  and	  grouping	  to	  those	  associated	  with	  cancer	  (types	  -­‐30,	  -­‐34,	  -­‐69,	  -­‐	  85	  and	  -­‐97,	  also	  called	  Group	  2B)[6].	  HPV	  genotypes	  with	  a	  strong	  association	  with	  cervical	  cancer	  are	  referred	  to	  as	  oncogenic,	  or	  high-­‐risk	  (HR)	  and	  in	  epidemiological	  studies	  usually	  encompass	  genotypes	  in	  Group	  1;	  or	  Group	  1	  and	  2A;	  or	  Group	  1,	  2A	  and	  2B.	  HPV	  genotypes	  not	  associated	  with	  cervical	  cancer	  are	  termed	  non-­‐oncogenic	  or	  low-­‐risk	  (LR).	  LR	  types	  include	  HPV6	  and	  -­‐11	  which	  cause	  over	  90%	  of	  cases	  of	  genital	  warts[7].	  HPV	  has	  been	  associated	  with	  other	  cancers:	  cancer	  of	  the	  penis,	  vulva,	  vagina,	  anus	  and	  an	  emerging	  epidemic	  of	  HPV-­‐associated	  mouth	  and	  oropharyngeal	  cancers[3].	  A	  recent	  review	  of	  cases	  of	  invasive	  oropharyngeal	  squamous	  cell	  carcinomas	  detected	  HPV	  in	  72%[4].	  The	  natural	  history	  of	  HPV	  infection	  and	  the	  development	  of	  cervical	  cancer	  are	  illustrated	  in	  Figure	  1.1.	  A	  range	  of	  histological	  abnormalities	  are	  seen	  at	  the	  cervix	  after	  HR	  HPV	  infection,	  ranging	  from	  mild	  dysplasia	  (cervical	  intra-­‐epithelial	  neoplasia	  type	  1	  (CIN-­‐1)),	  to	  moderate	  dysplasia	  (cervical	  intra-­‐epithelial	  neoplasia	  type	  2	  (CIN-­‐2))	  which	  can	  spontaneously	  resolve,	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to	  severe	  dysplasia	  or	  squamous-­‐cell	  carcinoma	  in	  situ	  (cervical	  intra-­‐epithelial	  neoplasia	  type	  3	  (CIN-­‐3)).	  HPV	  is	  also	  associated	  with	  adeno-­‐carcinoma,	  for	  which	  the	  precursor	  is	  adenocarcinoma	  in	  situ	  (Figure	  1.1). Although infection with HPV can lead to the development of 
cervical cancer or genital warts, the	  majority	  of	  HR	  and	  LR	  HPV	  genotype-­‐specific	  infections	  will	  be	  cleared[8].	  The	  reported	  median	  duration	  of	  HPV	  infections	  with	  an	  individual	  genotype	  ranges	  from	  8-­‐31	  months,	  and	  is	  longer	  for	  HR	  types	  than	  LR	  types[9–11].	  
	  	   	  


















in	  studies	  with	  the	  median	  time	  between	  sample	  collection	  ranging	  from	  2	  months	  to	  6	  years[14,15].	  Thus	  an	  infection	  classified	  in	  one	  study	  as	  persistent,	  could	  be	  classified	  as	  transient	  in	  another	  if,	  for	  example,	  a	  long	  testing	  interval	  is	  employed	  and	  an	  infection	  clears	  and	  is	  then	  re-­‐acquired,	  or	  is	  latent	  and	  then	  reactivates.	  A	  number	  of	  HPV	  vaccine	  trials	  have	  used	  end-­‐points	  of	  both	  6-­‐month	  and	  12-­‐month	  persistence	  [16,17].	  The	  IARC	  recently	  clarified	  this	  for	  use	  in	  vaccine	  studies	  by	  recommending	  a	  definition	  of	  persistence	  of	  cervical	  HPV	  as	  detection	  of	  the	  same	  genotype	  in	  two	  samples	  taken	  at	  least	  6	  months	  apart[12].	  Clearance	  of	  HPV	  infection	  predominantly	  occurs	  through	  cell-­‐mediated	  immune	  responses	  whereby	  cytotoxic	  CD8,	  and	  to	  a	  lesser	  extent	  CD4	  T-­‐cells,	  destroy	  HPV-­‐infected	  cells[18].	  Antibody-­‐mediated	  responses,	  which	  are	  genotype-­‐specific,	  are	  detectable	  in	  less	  than	  60%	  of	  women	  who	  have	  evidence	  of	  incident	  cervical	  HPV	  DNA[19,20].	  There	  are	  conflicting	  data	  on	  whether	  re-­‐infection	  with	  the	  same	  genotype	  in	  women	  with	  genotype-­‐specific	  antibodies	  is	  possible.	  No	  protection	  from	  incident	  HPV	  infection	  was	  shown	  in	  a	  large	  population-­‐based	  cohort	  study	  of	  older	  women	  in	  Costa	  Rica	  who	  had	  antibodies	  to	  HPV16,	  -­‐18	  or	  -­‐31[21].	  However,	  young	  women	  in	  the	  USA	  who	  had	  antibodies	  to	  HPV16	  detectable	  for	  at	  least	  one	  year	  had	  a	  lower	  incidence	  of	  genital	  HPV16[22].	  A	  possible	  explanation	  for	  these	  conflicting	  results	  is	  that	  effective	  antibody	  responses	  reduce	  with	  age,	  allowing	  acquisition	  of	  a	  new	  infection.	  An	  alternative	  explanation	  is	  that	  HPV	  can	  behave	  as	  a	  latent	  infection	  (i.e.	  remain	  dormant	  in	  basal	  membrane	  cells	  without	  actively	  replicating)	  and	  can	  begin	  replication	  as	  immune-­‐mediated	  protection	  wanes	  with	  age[23,24].	  The	  state	  of	  an	  individual’s	  immune	  system	  has	  a	  strong	  influence	  on	  the	  outcome	  of	  genital	  HPV	  infection.	  Human	  immunodeficiency	  virus	  (HIV)	  infection	  leads	  to	  increased	  prevalence	  of	  HPV,	  duration	  of	  cervical	  HPV	  detection,	  and	  higher	  rates	  of	  disease	  progression	  to	  HPV-­‐related	  pre-­‐cancerous	  lesions,	  and	  invasive	  cervical	  cancer[25].	  The	  level	  of	  immunosuppression,	  estimated	  by	  the	  level	  of	  CD4	  cells,	  is	  inversely	  correlated	  with	  persistence	  of	  HPV	  and	  the	  risk	  of	  development	  of	  cervical	  pre-­‐cancerous	  lesions[25,26].	  The	  prevalence	  and	  incidence	  of	  genital	  warts	  are	  also	  increased	  in	  the	  presence	  of	  HIV	  infection,	  with	  reduced	  rates	  of	  regression[27,28].	  	  However,	  a	  recent	  study	  has	  demonstrated	  that	  treatment	  with	  anti-­‐retroviral	  therapy	  does	  not	  lead	  to	  regression	  of	  HPV-­‐associated	  cervical	  lesions[29].	  Other	  immunosuppressive	  states,	  such	  as	  systemic	  lupus	  erythematosis	  and	  being	  the	  recipient	  of	  a	  solid	  organ	  transplant,	  have	  been	  shown	  to	  lead	  to	  increased	  prevalence	  of	  HPV	  infection	  and	  its	  consequences,	  including	  invasive	  cervical	  cancer[30].	  	  World-­‐wide,	  cervical	  cancer	  is	  the	  second	  most	  common	  cancer	  in	  women,	  and	  the	  second	  most	  common	  cause	  of	  cancer	  related	  mortality[31].	  Over	  85%	  of	  the	  world’s	  cervical	  cancer	  deaths	  
17	  	  
occur	  in	  developing	  countries	  and	  the	  highest	  cervical	  cancer	  incidence	  and	  mortality	  occur	  in	  the	  East	  African	  region	  where	  these	  rates	  are	  over	  twice	  as	  high	  as	  the	  world	  average	  (east	  Africa	  42.7/100,000person	  years	  (pys),	  world	  14.0/100,000pys)[31].	  	  
1.2 HPV	  epidemiology	  in	  sub-­‐Saharan	  Africa	  Systematic	  reviews	  have	  summarised	  published	  data	  on	  the	  prevalence	  of	  HPV	  in	  women	  with	  normal	  cytology	  in	  different	  world-­‐regions	  suggest	  and	  found	  that	  the	  highest	  prevalences	  are	  seen	  in	  Africa[24,32].	  Within	  Africa,	  countries	  in	  East	  Africa	  have	  the	  highest	  reported	  prevalences[32,33].	  However,	  in	  these	  world-­‐wide	  summaries,	  women	  in	  Africa	  are	  less	  well	  represented	  than	  women	  in	  America	  or	  Europe:	  in	  one	  review,	  8,568	  women	  in	  Africa	  contributed	  data,	  compared	  to	  692,964	  from	  America,	  or	  229,628	  from	  Europe[32].	  This	  review	  attempted	  to	  take	  into	  account	  the	  age	  of	  included	  women,	  the	  type	  of	  HPV	  test	  used,	  the	  type	  of	  population	  sampled,	  and	  the	  year	  of	  the	  study,	  and	  suggested	  that	  the	  prevalence	  of	  HPV	  in	  East	  Africa	  in	  women	  with	  normal	  cytology	  was	  33.6%	  (95%	  CI:30.2-­‐37.1),	  almost	  triple	  the	  overall	  world	  prevalence	  of	  11.7%	  (95%	  CI:11.6-­‐11.7).	  It	  is	  unclear	  why	  the	  overall	  HPV	  prevalence	  was	  found	  to	  be	  higher	  in	  the	  East	  African	  region	  compared	  to	  other	  regions	  in	  SSA	  which	  have	  higher	  HIV	  prevalences	  and	  a	  similar	  lack	  of	  national	  HPV	  vaccination	  campaigns[34].	  	  Possible	  explanations	  include	  differing	  sexual	  behaviour[35],	  viral	  or	  host	  genetics[36,37].	  HPV	  genotype	  distribution	  has	  been	  examined	  in	  women	  randomly	  selected	  from	  the	  general	  population[38].	  In	  women	  with	  normal	  cytology,	  HPV16	  was	  the	  most	  common	  type	  detected,	  followed	  by	  HPV42,	  -­‐58,	  -­‐31	  and	  HPV18.	  In	  SSA,	  HPV	  positive	  women	  were	  significantly	  less	  likely	  to	  be	  infected	  with	  HPV16	  than	  HPV	  positive	  women	  from	  Europe	  and	  South	  America;	  however	  HPV16	  remained	  the	  most	  common	  genotype	  detected[38].	  	  	  Few	  studies	  have	  described	  HPV	  incidence,	  clearance	  and	  persistence	  in	  SSA.	  HPV	  incidence	  has	  been	  reported	  in	  studies	  which	  followed	  HIV	  negative	  women	  annually	  for	  12-­‐24	  months,	  and	  reported	  incidences	  of	  HPV	  ranging	  from	  28.7	  per	  100pys	  in	  women	  in	  Uganda	  with	  median	  age	  37	  years[39],	  to	  76.0	  per	  100pys	  in	  women	  with	  a	  median	  age	  of	  18	  years	  in	  Tanzania[40].	  These	  are	  higher	  than	  reported	  incidence	  rates	  from	  Columbia	  of	  6.2	  per	  100pys	  in	  women	  with	  a	  median	  age	  32.3	  years[41]	  and	  2.5	  per	  100pys	  in	  women	  with	  a	  mean	  age	  of	  24.6	  years	  in	  the	  USA[42].	  Incidence	  rates	  are	  difficult	  to	  compare	  between	  studies,	  since	  the	  number	  of	  genotypes	  tested	  for,	  sensitivity	  of	  the	  test	  used,	  frequency	  of	  follow-­‐up	  visits,	  and	  statistical	  methods	  for	  incidence	  analysis	  vary.	  	  The	  proportion	  of	  genotype-­‐specific	  infections	  which	  have	  cleared	  varies	  between	  studies	  in	  SSA,	  and	  with	  other	  studies	  in	  different	  world	  regions.	  In	  Uganda,	  HPV	  clearance	  (defined	  as	  lack	  of	  detection	  of	  all	  genotypes)	  was	  31%	  after	  a	  median	  follow	  up	  time	  of	  18.5	  months[43].	  In	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Tanzania,	  64%	  of	  genotype	  specific	  infections	  had	  cleared	  (not	  detected	  at	  one	  follow-­‐up	  visit)	  at	  12	  months[40].	  This	  was	  similar	  to	  a	  study	  in	  women	  in	  women	  in	  Brazil	  in	  which	  clearance	  was	  similarly	  defined:	  65%	  of	  women	  had	  cleared	  infections	  at	  12	  months[9].	  In	  studies	  from	  SSA	  which	  have	  examined	  clearance	  separately	  for	  HR	  and	  LR	  HPV	  genotypes,	  the	  proportion	  of	  HR	  HPV	  infections	  cleared	  was	  less	  than	  that	  of	  LR	  HPV	  infections[39,40,43],	  consistent	  with	  studies	  in	  the	  USA,	  Canada,	  South	  America	  and	  Europe[9,44–46].	  Again,	  studies	  examining	  clearance	  are	  challenging	  to	  compare	  since	  the	  duration	  of	  follow-­‐up	  varies,	  as	  does	  the	  definition	  of	  clearance,	  which	  varies	  from	  requiring	  one	  negative	  test	  (for	  the	  same	  genotype,	  or	  all	  genotypes),	  to	  requiring	  2	  or	  3	  negative	  tests	  for	  the	  same	  genotype,	  and	  finally,	  whether	  only	  new	  infections	  are	  examined	  or	  prevalent	  infections	  are	  also	  included.	  	  
1.3 Risk	  factors	  for	  HPV	  Clear	  differences	  in	  HPV	  prevalence	  are	  seen	  when	  examined	  by	  age,	  with	  the	  highest	  prevalence	  in	  women	  and	  girls	  under	  25	  years	  old	  across	  the	  world[32,47,48].	  The	  high	  prevalence	  in	  young	  girls	  is	  thought	  to	  be	  due	  to	  initial	  infection	  after	  onset	  of	  sexual	  activity	  in	  an	  HPV-­‐naïve	  host	  since	  individuals	  without	  previous	  exposure	  have	  no	  HPV-­‐specific	  immune	  response.	  Further	  explanations	  include	  increased	  cervical	  ectopy	  in	  the	  immature	  cervix	  (cervical	  ectopy	  occurs	  when	  columnar	  epithelium	  which	  line	  the	  uterus	  and	  cervical	  canal	  extends	  to	  the	  surface	  of	  the	  cervix),	  or	  inadequate	  levels	  of	  protective	  cervical	  mucous[49].	  	  In	  some,	  but	  not	  all,	  world	  regions,	  a	  second	  peak	  of	  high	  prevalence	  is	  seen	  in	  older	  age-­‐groups[32,47].	  Explanations	  for	  this	  second	  peak	  in	  older	  age	  are	  either	  behavioural	  i.e.	  changes	  in	  sexual	  behaviour	  in	  later	  life,	  or	  immunological	  i.e.	  waning	  immunological	  suppression	  of	  a	  latent	  infection	  or	  increased	  susceptibility	  to	  a	  new	  infection[23,50].	  Risk	  factors	  for	  prevalent	  HPV	  appear	  similar	  across	  geographical	  regions	  and	  are	  predominantly	  related	  to	  sexual	  behaviour	  and	  partner	  characteristics.	  These	  include	  lifetime	  number	  of	  sexual	  partners,	  older	  age	  of	  sexual	  partner,	  having	  a	  sexual	  partner	  who	  has	  other	  partners[51–56]	  and	  being	  HIV-­‐infected[57–59].	  Other	  risk	  factors	  include	  cigarette	  smoking[52,60,61],	  and	  an	  inverse	  relationship	  with	  parity	  is	  seen[52].	  A	  recent	  cross-­‐sectional	  study	  in	  women	  in	  the	  USA	  found	  that	  cleansing	  the	  vagina,	  called	  ‘douching’,	  was	  associated	  with	  prevalent	  HPV	  infection[56].	  Cohort	  studies	  find	  similar	  risk	  factors	  for	  HPV	  to	  those	  identified	  in	  cross-­‐sectional	  studies.	  Incident	  HPV	  has	  been	  strongly	  and	  consistently	  associated	  with	  lifetime	  and	  recent	  number	  of	  sex	  partners[41,42,45,63–66]	  and	  HIV	  infection[29,67].	  Additionally	  incident	  HPV	  infection	  is	  associated	  with	  inconsistent	  condom	  use[68],	  herpes	  simplex	  virus[66],	  pregnancy[41].	  	  Hormonal	  contraception	  has	  shown	  inconsistent	  results;	  it	  been	  associated	  with	  increased	  risk	  of	  incident	  HPV	  in	  some	  studies[63,65],	  and	  lower	  risk	  in	  others[66].	  Finally,	  a	  study	  in	  Uganda	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demonstrated	  that	  having	  a	  male	  partner	  who	  was	  circumcised	  compared	  to	  an	  uncircumcised	  partner	  was	  clearly	  associated	  with	  a	  lower	  incidence	  of	  cervical	  HPV	  infection	  in	  women[39].	  	  	  
1.4 Collecting	  risk	  factor	  data	  for	  HPV	  research	  In	  order	  to	  establish	  which	  behaviours	  and	  practices	  are	  risk	  factors	  for	  cervical	  HPV	  acquisition,	  sexual	  behaviour	  and	  vaginal	  practice	  information	  must	  be	  collected	  along	  with	  HPV	  DNA	  samples.	  The	  validity	  of	  research	  into	  risk	  factors	  for	  STIs	  relies	  heavily	  on	  the	  accuracy	  of	  the	  sexual	  behaviour	  data	  gathered.	  Certain	  populations	  pose	  a	  challenge	  for	  accurate	  sexual	  behaviour	  data	  collection.	  Women	  and	  adolescent	  girls	  are	  strongly	  influenced	  by	  social	  norms	  and	  expectations	  around	  sexual	  behaviour[69].	  In	  populations	  such	  as	  those	  in	  SSA	  where	  there	  is	  a	  substantial	  burden	  of	  HPV	  infection,	  several	  studies	  have	  illustrated	  the	  inaccuracy	  of	  disclosure	  during	  FtF-­‐interviews	  of	  previous	  sexual	  intercourse	  when	  validated	  against	  biomarkers	  of	  sexual	  activity[70],	  coital	  diaries[71]	  or	  direct	  observation[72].	  	  Alternative	  methods	  of	  data	  collection	  which	  may	  address	  the	  under-­‐reporting	  of	  sexual	  behaviours	  have	  been	  tested	  in	  SSA	  including	  self-­‐completed	  questionnaires,	  FtF-­‐interviews	  with	  responses	  placed	  in	  confidential	  boxes,	  and	  interviews	  using	  ACASI[73].	  	  The	  use	  of	  ACASI	  has	  led	  to	  increased	  disclosure	  of	  lower	  age	  at	  first	  sex,	  higher	  number	  of	  partners	  and	  increased	  disclosure	  of	  sensitive	  behaviours	  in	  studies	  in	  the	  USA,	  Zimbabwe	  and	  Thailand[63-­‐66].	  
1.5 Cervical	  cancer	  screening	  and	  HPV	  vaccination	  In	  most	  countries,	  cervical	  cancer	  prevention	  involves	  screening	  for	  cervical	  cellular	  changes	  using	  the	  Papanicolaou	  (PAP)	  smear	  or	  liquid	  based	  cytology,	  in	  which	  cervical	  cells	  are	  examined	  under	  light	  microscopy.	  Screening	  programmes	  have	  proven	  successful	  at	  increasing	  the	  detection	  of	  early	  pre-­‐cancerous	  changes	  and	  invasive	  cervical	  cancer	  in	  high-­‐income	  countries	  with	  national	  programmes[74].	  However,	  throughout	  sub-­‐Saharan	  Africa	  screening	  coverage	  is	  extremely	  low	  at	  0.4-­‐20.2%[75].	  The	  development	  of	  low-­‐cost	  tests	  such	  as	  visual	  inspection	  of	  the	  cervix	  with	  acetic	  acid	  (VIA)	  or	  visual	  inspection	  with	  Lugol’s	  iodine	  (VILI)	  have	  improved	  access	  to	  screening,	  although	  these	  tests	  are	  less	  sensitive	  and	  specific	  than	  cytological	  examination[76].	  	  A	  battery-­‐powered	  portable	  HPV	  detection	  kit	  with	  pre-­‐prepared	  reagents	  called	  careHPV,	  has	  been	  developed.	  This	  test	  detects	  HR	  HPV	  and	  has	  a	  sensitivity	  for	  the	  detection	  of	  pre-­‐cancerous	  and	  cancerous	  lesions	  (CIN	  grade	  2	  or	  higher)	  of	  86%,	  higher	  than	  a	  conventional	  PAP	  smear	  (53%)[77].	  HPV	  screening	  has	  demonstrated	  a	  significant	  impact	  in	  cervical	  cancer	  detection.	  A	  large	  randomised	  trial	  in	  the	  Nethrelands	  (POBASCAM)	  demonstrated	  that	  cervical	  HPV	  DNA	  testing	  detected	  an	  additional	  79	  pre-­‐cancers	  per	  100,000	  women	  and	  30	  cancers	  per	  100,000	  women	  compared	  to	  standard	  cytology	  alone[78].	  In	  rural	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India,	  a	  similar	  trial	  of	  a	  single	  round	  of	  cervical	  cancer	  screening	  by	  HPV	  DNA	  testing	  led	  to	  a	  significant	  reduction	  in	  incidence	  of	  cervical	  cancer	  and	  cancer-­‐related	  mortality	  during	  follow-­‐up	  compared	  to	  VIA	  or	  cytological	  testing[79].	  	  The	  IARC	  now	  recommend	  that	  screening	  in	  low-­‐income	  setting	  settings	  should	  be	  based	  on	  either	  VIA	  or	  HPV-­‐DNA	  testing[80].	  Despite	  these	  advances	  in	  screening	  methodologies,	  the	  infrastructure	  does	  not	  exist	  in	  many	  developing	  countries	  to	  support	  routine	  screening	  and	  the	  treatment	  and	  follow-­‐up	  of	  women	  with	  pre-­‐cancerous	  cervical	  changes[75].	  Thus,	  the	  World	  Health	  Organization	  (WHO)	  recommends	  an	  integrated	  programme	  for	  cervical	  cancer	  control	  in	  low	  and	  middle-­‐income	  countries,	  combining	  HPV	  vaccination	  and	  screening	  [81].	  There	  are	  two	  currently	  available	  HPV	  vaccines;	  the	  bivalent	  vaccine	  (Cervarix®)	  which	  protects	  against	  infection	  with	  HPV16	  and	  -­‐18,	  and	  the	  quadrivalent	  HPV	  vaccine	  (Gardasil®)	  which	  protects	  against	  HPV6,	  -­‐11,	  -­‐16	  and	  -­‐18.	  Large	  randomised	  controlled	  trials	  have	  indicated	  that	  both	  vaccines	  offer	  more	  than	  95%	  protection	  against	  pre-­‐cancerous	  cervical	  lesions	  (CIN	  grade	  2	  or	  greater),	  caused	  by	  vaccine	  HPV	  genotypes[82–84].	  Long-­‐term	  follow-­‐up	  has	  demonstrated	  protection	  up	  to	  8	  years	  for	  both	  vaccines[85,86].	  These	  vaccines	  are	  effective	  if	  administered	  prior	  to	  the	  acquisition	  of	  vaccine-­‐related	  HPV	  genotypes[82,87].	  The	  HPV	  vaccine	  has	  shown	  only	  50%	  efficacy	  against	  incident	  infection	  with	  vaccine	  genotypes	  in	  those	  with	  serological	  evidence	  of	  previous	  infection[88].	  The	  lack	  of	  effective	  protection	  in	  some	  individuals	  who	  were	  seropositive	  pre-­‐vaccination	  is	  possibly	  explained	  by	  latent	  infection.	  In	  viral	  latency	  the	  virus	  persists	  in	  tissue,	  sometimes	  at	  a	  level	  below	  the	  detection	  threshold	  of	  tests.	  It	  has	  been	  shown	  that,	  in	  those	  with	  detectable	  HPV	  vaccine	  genotype	  DNA	  at	  the	  time	  of	  vaccination,	  the	  vaccine	  has	  no	  effect	  on	  viral	  clearance	  (lack	  of	  detection	  at	  6	  or	  12	  months	  after	  initial	  detection)[89].	  	  Since	  there	  is	  clear	  evidence	  from	  high-­‐income	  countries	  that	  HPV	  vaccination	  is	  less	  effective	  after	  HPV	  has	  been	  acquired,	  and	  further	  evidence	  from	  high-­‐income	  countries	  that	  HPV	  prevalence	  is	  very	  low	  prior	  to	  first	  sex,	  HPV	  vaccination	  administration	  is	  recommended	  before	  first	  sex	  in	  these	  countries.	  There	  are	  few	  data	  on	  the	  prevalence	  of	  HPV	  before	  reported	  sexual	  debut	  in	  SSA	  and	  on	  how	  quickly	  HPV	  is	  acquired	  once	  sexual	  debut	  is	  passed.	  	  
1.6 Research	  aims	  and	  objectives	  
1.6.1 Study	  rationale	  Given	  the	  high	  rate	  of	  cervical	  cancer	  in	  East	  Africa,	  it	  is	  essential	  to	  understand	  the	  HPV	  genotype-­‐specific	  prevalence,	  incidence	  and	  risk	  factors	  for	  acquisition	  of	  HPV	  in	  women	  in	  this	  region.	  Most	  studies	  examining	  risk	  factors	  in	  East	  Africa	  have	  been	  cross-­‐sectional[57,90–93].	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Detailed	  examination	  of	  HPV	  incidence	  and	  sexual	  behaviours	  (including	  non-­‐penetrative	  sex	  behaviours)	  and	  vaginal	  practices	  before	  and	  after	  sexual	  debut	  will	  help	  to	  clarify	  risk	  factors	  for	  HPV	  and	  provide	  data	  on	  how	  quickly	  HPV	  is	  acquired	  after	  initial	  sexual	  intercourse.	  	  This	  study	  will	  also	  clarify	  whether	  HPV	  infection	  is	  detected	  prior	  to	  reported	  sexual	  debut	  in	  Tanzanian	  girls.	  This	  is	  important	  since	  the	  HPV	  vaccine	  is	  being	  primarily	  targeted	  at	  pre-­‐adolescent	  and	  adolescent	  girls	  who	  are	  sexually	  naïve[81]	  and	  age	  for	  vaccination	  is	  based	  on	  the	  assumption	  that	  most	  girls	  will	  be	  HPV	  negative	  prior	  to	  sexual	  debut.	  Studies	  in	  the	  USA	  and	  Canada	  have	  demonstrated	  that	  a	  low	  proportion	  (0-­‐1.7%)	  of	  girls	  have	  detectable	  vaginal	  HPV	  before	  first	  sex[61,94].	  However	  similar	  evidence	  is	  not	  available	  for	  high	  HPV	  prevalence	  regions	  in	  Africa.	  Similarly,	  it	  is	  assumed	  that	  the	  natural	  history	  of	  HPV,	  in	  terms	  of	  initial	  acquisition,	  clearance	  and	  persistence	  of	  the	  virus,	  is	  the	  same	  in	  sub-­‐Saharan	  African	  adolescent	  girls	  as	  it	  is	  in	  girls	  in	  high-­‐income	  countries.	  This	  may	  not	  be	  the	  case;	  a	  higher	  proportion	  of	  girls	  may	  acquire	  HPV	  before	  reported	  sexual	  debut	  and/or	  a	  higher	  rate	  of	  persistent	  HPV	  infections	  in	  this	  population	  may	  partially	  explain	  the	  higher	  rate	  of	  cervical	  cancer	  (in	  addition	  to	  lack	  of	  screening	  services),	  since	  persistent	  infection	  is	  associated	  with	  malignant	  change	  at	  the	  cervix[95].	  HIV	  infection	  has	  a	  significant	  effect	  on	  HPV	  incidence	  and	  duration	  of	  infection,	  as	  well	  as	  risk	  of	  progression	  to	  pre-­‐cancerous	  and	  cancerous	  cervical	  changes[25,26].	  However,	  national	  data	  on	  HIV	  prevalence	  in	  the	  proposed	  age	  group	  is	  less	  than	  1%,	  and	  therefore	  HIV	  is	  unlikely	  to	  influence	  the	  HPV	  incidence	  and	  duration	  estimates	  in	  the	  study	  population[34].	  Differences	  in	  the	  epidemiology	  and	  natural	  history	  of	  HPV	  in	  adolescents	  in	  sub-­‐Saharan	  Africa,	  relative	  to	  those	  in	  higher	  income	  countries	  from	  where	  the	  majority	  of	  natural	  history	  data	  originate,	  may	  lead	  to	  inaccurate	  modelling	  of	  the	  impact	  and	  cost-­‐effectiveness	  of	  screening	  and	  prevention	  programmes.	  In	  countries	  such	  as	  Tanzania,	  where	  resources	  are	  limited,	  the	  accuracy	  of	  predictive	  models	  around	  the	  relative	  benefits	  of	  cervical	  screening	  programmes	  versus	  vaccination	  programmes	  is	  paramount.	  	  Which	  HPV	  genotypes	  girls	  catch	  at	  the	  time	  of	  first	  sex	  is	  also	  unknown	  in	  SSA.	  Rapid	  clearance	  of	  initial	  infection	  often	  occurs,	  and	  since	  some	  individuals	  do	  not	  develop	  antibodies	  to	  a	  specific	  genotype,	  it	  is	  not	  possible	  to	  know	  which	  genotypes	  girls	  have	  previously	  been	  infected	  with[20].	  Identifying	  genotypes	  acquired	  early	  after	  sexual	  debut	  in	  girls	  may	  provide	  further	  information	  on	  the	  epidemiology	  of	  commonly	  circulating	  genotypes	  in	  specific	  populations	  of	  young	  women.	  Documentation	  of	  the	  genotypes	  circulating	  in	  a	  population	  prior	  to	  introduction	  of	  HPV	  vaccination	  will	  also	  be	  important	  for	  monitoring	  post-­‐vaccination	  genotype-­‐replacement,	  a	  WHO	  research	  priority	  for	  HPV[81].	  	  This	  phenomenon	  occurs	  when	  vaccination	  removes	  a	  circulating	  genotype	  from	  the	  population,	  and	  that	  opening	  is	  filled	  by	  another	  genotype.	  Since	  infection	  with	  multiple	  genotypes	  is	  common	  and	  occurs	  irrespective	  of	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genotype	  involved,	  it	  is	  unlikely	  that	  this	  phenomenon	  occurs[96].	  A	  follow-­‐up	  study	  examining	  the	  possibility	  of	  type	  replacement	  four	  years	  after	  vaccination	  found	  no	  evidence	  of	  this	  in	  Finland[97].	  None	  the	  less,	  careful	  observation	  for	  possible	  type	  replacement	  is	  necessary	  since	  this	  may	  lead	  to	  the	  prevention	  of	  a	  smaller	  proportion	  of	  cancers	  than	  expected.	  Finally,	  an	  evaluation	  of	  the	  tools	  used	  in	  sexual	  behaviour	  research	  in	  adolescent	  girls	  in	  Tanzania	  is	  necessary	  in	  view	  of	  the	  problems	  with	  face-­‐to-­‐face	  data	  collection	  techniques	  and	  the	  emerging	  technologies	  aimed	  at	  improving	  them[98].	  
1.7 Objectives	  of	  the	  study	  	  
Primary	  objectives	  The	  primary	  objectives	  of	  the	  study	  were	  to:	  	  1. Describe	  the	  genotype-­‐specific	  prevalence	  of	  HPV	  at	  baseline	  in	  girls	  who	  report	  not	  having	  passed	  sexual	  debut,	  and	  factors	  associated	  with	  baseline	  HPV	  infection.	  2. Identify	  the	  rate	  of	  HPV	  infection,	  clearance	  of	  genotype-­‐specific	  HPV,	  the	  duration	  of	  infection	  after	  initiation	  of	  sexual	  activity,	  and	  the	  rate	  of	  infection	  in	  those	  who	  do	  not	  report	  initiation	  of	  sexual	  activity.	  3. Evaluate	  sexual	  behaviour,	  vaginal	  practice	  and	  demographic	  factors	  associated	  with	  the	  incidence	  of	  genotype-­‐specific	  HPV	  infection	  in	  those	  who	  report	  and	  do	  not	  report	  the	  initiation	  of	  sexual	  activity.	  4. Identify	  risk	  factors	  associated	  with	  HPV	  genotype-­‐specific	  clearance.	  
Secondary	  objectives	  1. A	  comparison	  of	  face-­‐to-­‐face	  interview	  with	  audio	  computer	  assisted	  self-­‐interview	  (ACASI)	  for	  the	  disclosure	  of	  sexual	  behaviour	  and	  intra-­‐vaginal	  practices.	  
1.8 Thesis	  structure	  The	  format	  of	  this	  thesis	  is	  that	  of	  a	  ‘research	  paper	  style’	  thesis.	  The	  thesis	  consists	  of	  manuscripts	  that	  have	  been	  published,	  submitted	  or	  are	  ready	  for	  submission,	  alongside	  background	  and	  methods	  chapters,	  additional	  data	  and	  explanatory	  sections,	  and	  a	  concluding	  chapter.	  Manuscripts	  included	  this	  thesis	  are:	  
• HPV	  prevalence	  in	  adolescent	  girls	  in	  Tanzania	  before	  reported	  sexual	  debut	  (published)	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• HPV	  incidence	  around	  the	  time	  of	  sexual	  debut	  in	  adolescent	  girls	  in	  Tanzania	  (ready	  for	  submission)	  
• HPV	  incidence	  in	  girls	  who	  report	  no	  previous	  sex	  in	  Tanzania	  (ready	  for	  submission)	  
• Audio-­‐computer	  assisted	  self-­‐interview	  compared	  to	  face-­‐to-­‐face	  interview	  for	  the	  reporting	  of	  sexual	  behaviours	  in	  adolescent	  girls	  in	  Tanzania	  (submitted)	  
1.9 Ethical	  approval	  The	  HPV	  Epidemiology	  study	  protocol	  and	  consent	  forms	  were	  submitted	  for	  ethical	  approval	  to	  Medical	  Research	  Coordinating	  Committee	  (MRCC)	  Tanzania,	  and	  the	  London	  School	  of	  Hygiene	  and	  Tropical	  Medicine	  (LSHTM).	  Ethical	  approval	  was	  granted	  on	  13th	  November	  2011	  by	  the	  Ethics	  Committee	  of	  the	  Medical	  Research	  Coordinating	  Committee	  (MRCC)	  in	  Tanzania	  (Ref:	  NIMR/HQ/R.8a/Vol.	  IX/1249,	  Annex	  1)	  and	  on	  3rd	  October	  2011	  by	  the	  London	  School	  of	  Hygiene	  and	  Tropical	  Medicine	  (LSHTM)	  (Ref:	  6040,	  Annex	  2).	  Amendments	  were	  submitted	  to	  MRCC	  Tanzania	  and	  LSHTM	  on	  16th	  August	  2012	  and	  approved	  on	  20th	  September	  2012	  by	  LSHTM	  and	  22nd	  January	  2013	  by	  MRCC	  Tanzania.	  	  
1.10 Funding	  The	  study	  was	  funded	  through	  the	  Wellcome	  Trust	  Clinical	  PhD	  Programme	  in	  International	  Health,	  with	  an	  award	  of	  £130,000	  for	  research	  costs	  for	  3	  years.	  A	  further	  USD	  $29,000	  for	  HPV	  genotyping	  of	  baseline	  samples	  was	  provided	  by	  WHO	  Collaborating	  Centre	  for	  HIV	  Surveillance	  through	  School	  of	  Medicine,	  University	  of	  Zagreb,	  on	  7th	  December	  2011.	  	  The	  Audio	  Computer-­‐Assisted	  Self-­‐Interview	  (ACASI)	  sub-­‐study	  was	  supported	  through	  a	  grant	  of	  £3,000	  from	  the	  MRC	  Tropical	  Epidemiology	  Group,	  awarded	  on	  11th	  April	  2012.	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2 Methods	  
2.1 Study	  design	  In	  order	  to	  describe	  HPV	  genotype-­‐specific	  prevalence	  before	  reported	  sex,	  and	  HPV	  incidence	  and	  duration	  around	  the	  time	  of	  sexual	  debut,	  a	  cohort	  study	  (the	  HPV	  Epidemiology	  Study)	  was	  nested	  within	  a	  cluster-­‐randomised	  trial	  of	  two	  HPV	  vaccination	  strategies	  in	  schools:	  age-­‐based	  (girls	  born	  in	  1998)	  and	  class-­‐based	  (girls	  in	  primary	  school	  class	  6)[1].	  This	  trial	  was	  called	  the	  HPV	  Vaccine	  Project,	  and	  was	  conducted	  in	  2010–2011	  in	  rural	  and	  urban	  schools	  in	  the	  Lake	  Zone	  of	  northern	  Tanzania	  (Figure	  2.1).	  The	  aim	  of	  the	  trial	  was	  to	  determine	  the	  feasibility,	  uptake	  and	  acceptability	  of	  each	  vaccination	  strategy.	  The	  study	  area	  included	  the	  two	  districts	  of	  Mwanza	  City	  (Ilemella	  and	  Nyamangana),	  which	  both	  have	  urban	  and	  peri-­‐urban	  areas,	  and	  the	  neighbouring	  rural	  district	  of	  Misungwi.	  In	  these	  three	  districts	  in	  2010,	  all	  private	  and	  government	  primary	  schools	  (N=242)	  were	  mapped	  and	  lists	  of	  female	  pupils	  born	  in	  1998	  or	  enrolled	  in	  class	  6	  were	  made.	  	  A	  total	  of	  134	  primary	  schools	  were	  randomly	  selected	  and	  allocated	  to	  the	  age-­‐based	  or	  class-­‐based	  vaccination	  strategy.	  Three	  doses	  of	  the	  quadrivalent	  HPV	  vaccine	  were	  given	  at	  0,	  2	  and	  6	  months	  between	  August	  2010	  and	  June	  2011.	  	  A	  total	  of	  4684	  of	  5532	  eligible	  girls	  (84.7%)	  received	  at	  least	  one	  dose	  of	  the	  vaccine,	  with	  three	  doses	  received	  by	  76.1%	  overall[1].	  
	  
Figure	  2:1	  Map	  illustrating	  Mwanza,	  Tanzania	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The	  remaining	  107	  primary	  schools	  that	  were	  not	  randomly	  selected	  for	  vaccination	  included	  82	  government	  primary	  schools,	  24	  private	  schools	  and	  one	  specialist	  school	  for	  albino	  children.	  The	  HPV	  Epidemiology	  Study	  was	  conducted	  in	  girls	  who	  were	  attending	  one	  of	  the	  82	  government	  schools.	  The	  aim	  was	  to	  enrol	  a	  random	  sample	  of	  approximately	  526	  girls,	  aged	  15	  and	  16	  years	  old,	  comprising	  500	  girls	  who	  denied	  having	  passed	  sexual	  debut	  and	  an	  additional	  26	  girls	  who	  reported	  having	  passed	  sexual	  debut	  within	  the	  last	  year.	  Enrolling	  girls	  who	  reported	  having	  passed	  sexual	  debut	  within	  the	  past	  year	  was	  conducted	  in	  order	  to	  prevent	  stigmatization	  of	  girls	  who	  reported,	  or	  who	  did	  not	  report,	  previous	  sex.	  This	  was	  done	  by	  randomly	  selecting	  26	  of	  the	  82	  government	  schools,	  and	  enrolling	  the	  first	  girl	  from	  that	  school	  who	  reported	  previous	  sex,	  if	  she	  reported	  that	  the	  first	  episode	  of	  sex	  had	  occurred	  within	  the	  last	  year.	  	  Eligibility	  criteria	  for	  study	  enrolment	  included	  being	  aged	  15	  or	  16	  years;	  being	  enrolled	  in	  class	  (standard)	  6	  in	  2010	  in	  one	  of	  the	  82	  selected	  schools;	  self-­‐reporting	  not	  being	  pregnant;	  planning	  to	  stay	  in	  the	  study	  area	  for	  18	  months	  or	  able	  to	  travel	  to	  the	  study	  area	  for	  study	  appointments;	  self-­‐reporting	  never	  having	  had	  vaginal	  sex	  or,	  if	  randomly	  selected,	  reporting	  having	  passed	  sexual	  debut	  within	  the	  last	  year;	  and	  being	  willing	  to	  self-­‐administer	  vaginal	  swabs.	  Study	  participants	  were	  followed	  every	  3	  months	  for	  a	  total	  of	  18	  months.	  At	  each	  visit,	  participants	  underwent	  a	  face-­‐to-­‐face	  interview	  with	  one	  of	  three	  trained	  and	  experienced	  study	  nurses.	  Interviews	  covered	  socio-­‐economic	  status,	  demographics,	  smoking,	  alcohol	  and	  drug	  use,	  sexual	  behaviour	  (including	  non-­‐penetrative	  sex	  behaviours),	  female	  circumcision,	  having	  accessed	  the	  internet	  or	  viewed	  pornography,	  and	  menstrual	  and	  vaginal	  hygiene	  practices	  (Annex	  3	  and	  4).	  At	  each	  visit,	  one	  nurse-­‐assisted	  self-­‐administered	  vaginal	  swab	  was	  collected.	  
	  
2.2 Ethical	  issues	  Since	  study	  participants	  were	  under	  18	  years	  old	  at	  the	  time	  of	  enrolment,	  consent	  was	  required	  from	  parents/guardians	  prior	  to	  requesting	  informed	  assent	  from	  participants.	  Guardians	  were	  defined	  as	  the	  named	  responsible	  adult	  on	  the	  school	  register	  or	  the	  head	  of	  household	  in	  which	  a	  girl	  resided.	  Parents/guardians	  of	  girls	  aged	  15	  or	  16	  years	  were	  identified	  from	  school	  lists	  and	  were	  visited	  at	  home	  by	  a	  study	  nurse,	  using	  contact	  information	  collected	  at	  schools	  during	  the	  HPV	  Vaccine	  Project.	  If	  the	  girl	  was	  age-­‐eligible,	  the	  study	  was	  explained	  to	  the	  parent/guardian	  in	  Swahili	  and	  comprehension	  was	  verbally	  checked,	  followed	  by	  a	  request	  for	  signed	  informed	  consent	  (Annex	  5).	  If	  the	  parent/guardian	  was	  illiterate,	  an	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impartial	  literate	  witness	  was	  requested	  to	  provide	  a	  signature,	  and	  the	  parent/guardian	  was	  asked	  to	  place	  a	  thumb-­‐print	  on	  the	  form.	  Informed	  consent	  included	  permission	  for	  the	  participant	  to	  be	  offered	  voluntary	  counselling	  and	  testing	  (VCT)	  for	  HIV	  at	  completion	  of	  the	  study,	  if	  she	  had	  passed	  sexual	  debut,	  without	  disclosure	  of	  results	  to	  parent/guardian.	  After	  informed	  consent	  had	  been	  obtained	  from	  the	  parent/guardian,	  informed	  assent	  was	  requested	  from	  the	  potential	  participant.	  Similar	  procedures	  to	  those	  mentioned	  above	  were	  employed	  if	  the	  potential	  participant	  was	  illiterate.	  Assent	  was	  requested	  (Annex	  6)	  in	  private	  at	  home,	  at	  a	  later	  school	  visit,	  or	  in	  the	  research	  clinic	  at	  Sekou	  Toure	  Regional	  Hospital.	  Assenting	  participants	  were	  assessed	  for	  eligibility	  using	  a	  short	  questionnaire.	  Inclusion	  criteria	  are	  documented	  above.	  Ineligible	  girls,	  and	  girls	  who	  reported	  previous	  sex	  who	  were	  either	  not	  randomly	  selected	  for	  inclusion	  or	  who	  had	  passed	  sexual	  debut	  longer	  than	  1	  year	  ago	  did	  not	  continue	  with	  further	  study	  procedures.	  	  	  Confidentiality	  of	  participant’s	  data	  was	  maintained	  to	  a	  high	  standard	  throughout	  the	  study.	  Each	  study	  participant	  was	  given	  an	  identification	  (ID)	  number	  consisting	  of	  6	  letters	  and	  numbers	  which	  were	  used	  on	  all	  questionnaires	  and	  which	  did	  not	  change	  during	  follow-­‐up.	  Questionnaires	  were	  stored	  in	  locked	  filing	  cabinets	  in	  a	  locked	  office	  at	  the	  Mwanza	  Interventional	  Trials	  Unit	  (MITU)	  and	  submitted	  weekly	  to	  the	  MITU	  data	  team	  who	  signed	  receipt	  of	  them.	  Data	  were	  stored	  on	  a	  secured	  server.	  HPV	  genotyping	  results,	  once	  received	  from	  the	  Catalan	  Institute	  of	  Oncology	  (ICO),	  Barcelona,	  were	  stored	  on	  the	  same	  MITU	  server	  under	  the	  relevant	  specimen	  laboratory	  ID	  number.	  The	  participant’s	  name	  and	  address	  as	  well	  as	  study	  ID	  numbers	  were	  required	  by	  the	  study	  team	  at	  every	  visit	  for	  that	  participant	  in	  order	  that	  they	  could	  be	  located	  and	  identified,	  and	  the	  ID	  number	  applied	  to	  the	  study	  questionnaire.	  The	  documentation	  listing	  the	  participant’s	  name	  and	  address	  was	  stored	  in	  a	  separate	  locked	  cabinet	  from	  the	  questionnaire	  until	  they	  were	  submitted	  to	  the	  data	  team.	  The	  study	  coordinator	  held	  lists	  that	  matched	  the	  participant’s	  name	  and	  address,	  study	  ID	  number	  and	  lab	  ID	  number.	  Confidentiality	  agreements	  were	  signed	  by	  each	  staff	  member	  working	  on	  the	  HPV	  Epidemiology	  Study,	  with	  intermittent	  confidentiality	  spot-­‐checks	  performed	  by	  the	  MITU	  statistician	  (e.g.	  checking	  that	  filing	  cabinets	  were	  locked).	  	  	  
2.3 Study	  Procedures	  Enrolment	  and	  follow-­‐up	  visits	  took	  place	  at	  the	  participant’s	  home,	  at	  school,	  at	  the	  MITU	  research	  clinic	  in	  Sekou	  Toure	  Regional	  Hospital	  in	  Mwanza	  city,	  or	  at	  a	  local	  health	  facility	  depending	  on	  the	  participant’s	  preference,	  and	  the	  study	  nurses	  and	  participant’s	  assessment	  of	  the	  level	  of	  privacy	  available.	  Follow-­‐up	  appointments	  were	  scheduled	  every	  three	  months	  from	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the	  date	  of	  enrolment.	  Participants	  were	  informed	  of	  the	  date	  of	  their	  next	  visit	  when	  they	  were	  seen,	  since	  these	  were	  pre-­‐determined	  from	  enrolment	  to	  study	  completion.	  Depending	  on	  the	  participant’s	  availability,	  study	  nurses	  made	  modifications	  to	  the	  appointment	  date.	  Participants	  could	  be	  seen	  from	  2	  weeks	  before	  until	  4	  weeks	  after	  their	  appointed	  date,	  after	  which	  time	  they	  were	  assumed	  to	  have	  missed	  an	  appointment.	  Since	  participants	  were	  under	  18	  years	  old,	  financial	  compensation	  for	  attending	  study	  appointments	  was	  not	  appropriate.	  Participants	  were	  offered	  a	  free	  health/hygiene-­‐related	  item	  at	  each	  follow-­‐up	  visit.	  These	  included;	  soap,	  toothbrush	  and	  toothpaste,	  cotton	  underwear,	  a	  comb	  and	  mirror	  set,	  and	  at	  the	  final	  visit,	  a	  tub	  of	  petroleum	  jelly	  (Vaseline).	  	  
2.3.1 Specimen	  collection	  	  Participants	  in	  the	  study	  predominantly	  comprised	  girls	  who	  reported	  that	  they	  had	  never	  had	  vaginal	  sex.	  For	  this	  reason,	  a	  speculum	  examination	  was	  not	  performed,	  and	  nurse-­‐assisted	  self-­‐administered	  vaginal	  swabs	  were	  used	  to	  collect	  HPV	  samples.	  The	  procedure	  was	  carefully	  explained	  (Figure	  2.2)	  and	  a	  diagrammatic	  instruction	  sheet,	  with	  written	  explanation	  in	  Swahili,	  was	  used	  (Annex	  7	  and	  8).	  A	  Dacron	  tipped	  swab	  was	  inserted	  by	  the	  participant	  1.5	  inches	  into	  the	  vagina	  and	  rotated	  3	  times.	  The	  nurse	  observed	  the	  quality	  of	  sample	  collection,	  and	  requested	  that	  the	  participant	  repeat	  the	  procedure	  if	  it	  was	  felt	  to	  be	  inadequate.	  She	  would	  also	  assist	  girls	  who	  did	  not	  know	  their	  genital	  anatomy	  by	  showing	  them	  where	  the	  introitus	  was.	  
	  
Figure	  2:2.	  Study	  nurse	  explaining	  how	  to	  collect	  a	  nurse-­‐assisted	  self-­‐administered	  
vaginal	  swab	  to	  a	  study	  participant	  (written	  consent	  from	  the	  participant	  for	  this	  photograph	  was	  obtained).	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  Self-­‐administered	  vaginal	  swabs	  in	  girls	  who	  had	  not	  engaged	  in	  penetrative	  vaginal	  sex	  had	  been	  used	  in	  a	  previous	  study	  in	  the	  Mwanza	  region	  and	  	  were	  found	  to	  be	  acceptable,	  and	  provided	  adequate	  sampling	  of	  vaginal	  cells[2].	  Studies	  have	  demonstrated	  that,	  when	  compared	  to	  clinician	  collected	  cervical	  specimens,	  self-­‐administered	  swabs	  have	  similar	  sensitivity	  for	  HPV	  detection	  by	  PCR[3],	  and	  have	  good	  HPV	  genotype	  concordance[4].	  	  	  Once	  collected,	  specimens	  were	  placed	  dry	  into	  cryotubes	  in	  the	  field,	  and	  transported	  in	  cold	  boxes	  with	  ice	  packs.	  They	  were	  submitted	  daily	  to	  the	  laboratory	  at	  MITU	  where	  they	  were	  stored	  at	  -­‐20oC	  until	  they	  were	  shipped	  to	  ICO,	  Barcelona,	  Spain	  for	  HPV	  genotyping.	  
2.3.2 Laboratory	  testing	  HPV	  cannot	  be	  cultured	  and	  therefore	  accurate	  detection	  and	  identification	  of	  the	  virus	  depends	  predominantly	  on	  molecular	  techniques.	  Molecular	  techniques	  for	  HPV	  genotyping	  currently	  comprise	  nucleic	  acid-­‐hybridization	  assays,	  signal-­‐amplification	  assays	  and	  nucleic-­‐acid	  amplification	  assays.	  	  Nucleic	  acid-­‐hybridization	  assays	  (Southern	  blot,	  in	  situ	  hybridization)	  have	  the	  disadvantage	  that	  a	  large	  amount	  of	  DNA	  is	  required	  in	  order	  for	  detection	  to	  be	  successful.	  Newer	  nucleic	  acid	  detection	  kits	  such	  as	  careHPVTM	  (QIAGEN	  Inc.,	  Gaithersburg,	  MD,	  USA)	  use	  magnetic	  beads	  bound	  to	  antibodies	  which	  capture	  specific	  HPV	  nucleic	  acid	  sequences	  and	  use	  luminescence	  technology	  to	  produce	  a	  signal[5].	  This	  test	  has	  high	  sensitivity	  for	  pre-­‐cancerous	  or	  cancerous	  changes	  associated	  with	  HPV	  (CIN	  2	  or	  greater),	  combined	  with	  low	  cost,	  ease	  of	  use	  and	  rapidity	  of	  result,	  allowing	  them	  to	  be	  used	  in	  low-­‐income	  settings	  for	  cervical	  cancer	  screening[5].	  However,	  these	  nucleic	  acid-­‐hybridization	  assays	  test	  only	  HR	  HPV	  genotypes	  (careHPVTM)	  or	  have	  a	  lower	  sensitivity	  and	  involve	  cumbersome	  laboratory	  methods	  (Southern	  blot),	  limiting	  their	  use	  in	  epidemiological	  studies[6].	  	  Signal-­‐amplification	  assays	  include	  the	  digene®	  HPV	  Genotyping	  PS	  test	  (QIAGEN,	  Hilden,	  Germany),	  and	  the	  Cervista®	  HPV	  Assay.	  Although	  these	  tests	  have	  reasonable	  sensitivity	  and	  specificity	  for	  the	  detection	  of	  abnormal	  cervical	  cytology	  (CIN	  II	  or	  greater),	  they	  either	  only	  detect	  some	  of	  the	  HR	  types	  and	  are	  therefore	  also	  not	  appropriate	  for	  epidemiological	  studies	  where	  individual	  genotype	  results	  may	  be	  required[6,7].	  Nucleic-­‐acid	  amplification	  assays	  involve	  polymerase	  chain	  reactions	  (PCR).	  During	  an	  HPV	  PCR,	  oligonucleotide	  primers	  which	  bind	  to	  the	  part	  of	  the	  HPV	  DNA	  genome	  that	  codes	  for	  the	  L1	  capsid	  protein	  are	  usually	  chosen,	  since	  this	  region	  is	  highly	  conserved[8].	  After	  30	  cycles	  of	  amplification,	  one	  billion	  copies	  of	  HPV	  DNA	  can	  (theoretically)	  be	  generated	  and	  detected	  using	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one	  of	  the	  following	  methods:	  restriction-­‐fragment	  length	  polymorphism;	  linear	  probe	  assay;	  direct	  sequencing	  or	  genotype-­‐specific	  primers.	  Since	  HPV	  infection	  can	  include	  multiple	  genotypes	  in	  one	  specimen[9],	  false	  negative	  HPV	  PCR	  results	  can	  be	  seen	  for	  a	  genotype	  if	  it	  is	  present	  at	  a	  low	  concentration,	  since	  the	  genotype(s)	  at	  higher	  concentration	  may	  be	  more	  likely	  to	  be	  amplified,	  and	  subsequently	  detected.	  The	  sensitivity	  and	  specificity	  of	  a	  genotype-­‐specific	  HPV	  PCR	  assay	  further	  depends	  on	  the	  primers	  used,	  the	  reaction	  conditions	  (since	  these	  influence	  the	  DNA	  polymerase	  enzyme	  which	  is	  key	  to	  the	  amplification	  stage)	  and	  the	  presence	  of	  inhibitors	  to	  the	  reaction,	  or	  contamination	  with	  DNA	  that	  can	  lead	  to	  a	  false	  positive	  reaction[10].	  In	  spite	  of	  this,	  HPV	  PCR	  assays	  are	  considered	  the	  most	  sensitive	  and	  specific	  method	  for	  HPV	  DNA	  detection	  and	  genotyping	  for	  epidemiological	  studies[6,11,12].	  Several	  different	  HPV	  DNA	  PCR	  kits	  are	  available	  and	  in-­‐house	  assays	  can	  be	  developed.	  The	  Linear	  Array	  HPV	  genotyping	  assay	  (Roche,	  CA)	  was	  selected	  for	  the	  HPV	  Epidemiology	  study	  since	  it	  detects	  a	  high	  number	  of	  HPV	  genotypes	  (N=37;	  HPV6,-­‐11,-­‐16,-­‐18,-­‐26,-­‐31,-­‐33,-­‐35,-­‐39,-­‐40,-­‐42,-­‐45,-­‐51,-­‐52,-­‐53,-­‐54,-­‐55,-­‐56,-­‐58,-­‐59,-­‐61,-­‐62,-­‐64,-­‐66,-­‐67,-­‐68,-­‐69,-­‐70,-­‐71,-­‐72,-­‐73,-­‐81,-­‐82,-­‐83,-­‐	  84,	  IS39,	  and	  CP6108)	  and	  has	  a	  high	  sensitivity	  compared	  to	  other	  HPV	  PCR	  tests[13].	  This	  test	  uses	  primers	  that	  amplify	  a	  segment	  of	  the	  L1	  region	  of	  the	  HPV	  genome,	  which	  is	  450	  oligonucleotide	  base	  pairs	  long,	  and	  simultaneously	  amplifies	  a	  region	  of	  the	  human	  β-­‐globin	  gene,	  which	  is	  268	  base	  pairs	  long.	  Amplification	  of	  DNA	  from	  the	  human	  β-­‐globin	  gene	  allows	  validation	  of	  the	  test,	  and	  of	  sampling	  since	  detection	  of	  the	  human	  β-­‐globin	  gene	  confirms	  the	  presence	  of	  human	  cells.	  Specimens	  collected	  during	  the	  HPV	  Epidemiology	  study	  were	  shipped	  to	  ICO	  in	  Barcelona,	  Spain	  for	  the	  Linear	  Array	  HPV	  genotyping	  assay	  to	  be	  performed,	  since	  HPV	  genotyping	  had	  not	  yet	  been	  established	  in	  Mwanza,	  and	  no	  other	  laboratory	  in	  Tanzania	  offered	  this.	  	  Steps	  in	  HPV	  genotype	  identification	  using	  the	  Linear	  Array	  HPV	  Genotyping	  Test	  include:	  specimen	  preparation,	  polymerase	  chain	  reaction	  (PCR),	  hybridization	  of	  the	  amplified	  products	  to	  the	  oligonucleotide	  probes	  and	  finally,	  detection	  of	  the	  amplified	  products	  which	  are	  bound	  to	  the	  probes	  by	  colorimetric	  determination.	  Colorimetric	  determination	  (visible	  bands	  as	  in	  Figure	  2.3),	  permits	  identification	  of	  individual	  HPV	  genotypes.	  A	  reference	  guide	  is	  placed	  over	  these	  strips	  so	  that	  the	  reference	  line	  (the	  black	  line	  at	  the	  top	  of	  each	  strip	  in	  Figure	  2.3)	  is	  in	  line	  with	  the	  reference	  line	  on	  the	  guide.	  One	  potential	  issue	  for	  interpretation	  with	  the	  Linear	  Array	  HPV	  Genotyping	  Test	  is	  that	  the	  strip	  contains	  a	  cross	  reactive	  probe	  that	  hybridizes	  with	  HPV	  genotypes	  33,	  35,	  52	  and	  58	  together.	  Table	  2.1	  summarises	  how	  a	  positive	  signal	  from	  this	  probe	  should	  be	  interpreted.	  Interpretation	  depends	  on	  whether	  this	  probe	  (indicated	  by	  a	  line	  on	  the	  strip)	  is	  positive	  alone,	  or	  positive	  in	  the	  presence	  of	  a	  positive	  signal	  for	  other	  probes.	  When	  a	  band	  is	  seen	  at	  the	  marker	  for	  52/33/35/58,	  along	  with	  a	  positive	  band	  for	  HPV33	  for	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example,	  it	  is	  not	  possible	  to	  rule	  out	  co-­‐infection	  with	  HPV52	  since	  the	  sample	  is	  interpreted	  as	  positive	  for	  HPV33	  alone.	  This	  may	  lead	  to	  under-­‐estimation	  of	  HPV52	  prevalence.	  
Table	  2:1.	  Interpretation	  of	  cross-­‐reactive	  probe	  52/33/35/58	  in	  the	  Linear	  Array	  HPV	  
genotyping	  test	  (Roche,	  CA)	  	  
Band	  Result	   Interpretation	  33,	  	  52/33/35/58	   HPV	  33	  35,	  	  52/33/35/58	   HPV	  35	  58,	  	  52/33/35/58	   HPV	  58	  52/33/35/58	  (without	  33,	  35	  or	  58)	   HPV	  52	  For	  quality	  control	  and	  to	  reduce	  false	  negatives	  or	  false	  positives,	  control	  strips	  are	  included.	  At	  least	  one	  negative	  and	  one	  positive	  control	  are	  included	  for	  every	  22	  specimens	  processed.	  	  
	  
Figure	  2:3.	  Linear	  Array	  HPV	  genotyping	  test	  	  
2.3.3 Sexual	  behaviour	  questionnaires	  and	  pilot	  testing	  Sexual	  behaviour	  language,	  such	  as	  casual	  terms	  for	  oral	  sex,	  is	  different	  in	  different	  generations	  and	  also	  evolves	  over	  time[14,15].	  In	  order	  to	  incorporate	  colloquial	  terminology	  into	  the	  sexual	  behaviour	  questionnaire,	  an	  informal	  focus	  group	  discussion	  (FGD)	  was	  held	  with	  similar	  aged	  
This	  is	  an	  example	  result	  from	  one	  participant.	  The	  top	  black	  band	  is	  the	  reference	  band,	  blue	  bands	  indicate	  a	  positive	  result	  for	  one	  probe,	  and	  the	  corresponding	  genotype	  or	  group	  of	  genotypes	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girls	  to	  those	  eligible	  for	  enrolment	  into	  the	  study.	  This	  was	  carried	  out	  on	  the	  9th	  November	  2011	  in	  Mwanza	  City,	  and	  was	  coordinated	  by	  one	  of	  the	  study	  nurses.	  	  The	  purpose	  and	  project	  were	  explained	  to	  a	  local	  street	  leader	  who	  then	  approached	  girls	  and	  invited	  them	  to	  informally	  participate	  in	  the	  FGD.	  A	  total	  of	  14	  girls	  were	  approached,	  and	  all	  agreed	  to	  participate.	  Girls	  were	  aged	  between	  14	  and	  17	  years	  old.	  Colloquial	  terms	  are	  summarised	  in	  Annex	  9	  and	  were	  included	  in	  the	  enrolment	  and	  follow-­‐up	  questionnaires	  (Annex	  3	  and	  4).	  	  All	  study	  questionnaires	  (enrolment,	  follow-­‐up,	  STI	  screening	  and	  eligibility	  screening),	  consent	  forms	  and	  the	  explanation	  guide	  for	  nurse-­‐assisted	  self-­‐administered	  swabs	  were	  written	  in	  English	  and	  translated	  into	  Swahili	  by	  two	  study	  nurses.	  These	  were	  then	  back-­‐translated	  into	  English	  by	  non-­‐clinical	  tracers	  and	  data	  entry	  staff,	  who	  were	  blinded	  to	  the	  original	  English	  version.	  Modifications	  were	  made	  to	  the	  Swahili	  version	  and	  the	  process	  was	  repeated	  with	  different	  staff	  members.	  	  The	  sexual	  behaviour	  questionnaire	  was	  further	  reviewed	  by	  the	  International	  Language	  School	  in	  Mwanza[16].	  An	  initial	  pilot	  study	  was	  carried	  out	  using	  only	  the	  enrolment	  questionnaire	  and	  study	  consent	  forms.	  Two	  further	  pilot	  studies	  were	  carried	  out	  to	  check	  all	  study	  procedures,	  including	  the	  consent	  process	  for	  parents/guardians,	  eligibility	  screening	  of	  participants,	  explanation	  and	  procedures	  for	  collecting	  and	  storing	  nurse-­‐assisted	  self-­‐administered	  swabs,	  submission	  of	  dummy	  samples	  to	  the	  laboratory	  for	  logging	  and	  storage,	  and	  submission	  of	  questionnaires	  and	  data	  entry.	  	  
2.3.4 Data	  management	  Questionnaires	  were	  submitted	  weekly	  to	  the	  data	  manager	  at	  MITU,	  and	  entered	  by	  two	  data	  entry	  clerks	  into	  OpenClinica	  LLC	  (Akaza	  Research,	  Waltham,	  MA).	  Data	  checks	  were	  performed	  weekly	  for	  consistency	  (e.g.	  to	  check	  that	  the	  reported	  number	  of	  sex	  partners	  could	  not	  decrease	  over	  time),	  for	  completeness	  (e.g.	  to	  check	  that	  a	  STI	  screen	  was	  completed	  for	  all	  participants	  at	  every	  visit	  if	  they	  had	  reported	  sex	  at	  that	  visit	  or	  an	  earlier	  visit),	  and	  to	  ensure	  that	  numerical	  data	  were	  within	  expected	  ranges.	  Queries	  were	  referred	  to	  the	  research	  team	  on	  printed	  sheets.	  Corrections	  were	  made	  onto	  these	  sheets	  and	  directly	  onto	  the	  questionnaires	  using	  standardized	  procedures	  (e.g.	  dated	  and	  initialed	  corrections	  were	  made	  in	  blue	  ink).	  These	  were	  submitted	  to	  the	  data	  manager	  and	  the	  checks	  were	  re-­‐run	  until	  they	  had	  been	  resolved.	  
2.3.5 Data	  analysis	  Statistical	  methods	  are	  described	  in	  each	  publication	  in	  this	  thesis.	  Overall,	  incidence	  of	  any	  HPV	  was	  considered	  to	  be	  the	  detection	  of	  a	  new	  HPV	  genotype	  during	  follow-­‐up.	  Since	  risk	  of	  acquisition	  of	  another	  HPV	  genotype	  is	  not	  thought	  to	  be	  influenced	  by	  previous	  or	  current	  infection	  with	  a	  different	  HPV	  genotype[17],	  girls	  were	  considered	  to	  be	  continually	  at	  risk	  and	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could	  acquire	  more	  than	  one	  genotype	  during	  follow-­‐up.	  Incidence	  and	  clearance	  of	  individual	  genotypes	  was	  calculated.	  When	  analyzing	  results	  from	  samples	  taken	  every	  3	  months	  (in	  girls	  who	  reported	  sex	  before	  or	  during	  the	  study),	  clearance	  of	  a	  genotype	  was	  considered	  to	  be	  two	  consecutive	  negative	  tests,	  or	  one	  negative	  and	  one	  missing	  sample	  for	  that	  genotype.	  	  For	  the	  calculation	  of	  the	  median	  duration	  of	  infection,	  if	  a	  girl	  tested	  negative	  for	  a	  genotype	  between	  two	  visits	  with	  positive	  samples	  for	  the	  same	  genotype,	  the	  intervening	  negative	  sample	  was	  considered	  a	  false	  negative.	  This	  is	  supported	  by	  studies	  that	  have	  sequenced	  HPV	  genotypes	  to	  determine	  whether	  intervening	  negative	  samples	  between	  two	  positive	  samples	  for	  the	  same	  genotypes	  are	  due	  to	  re-­‐infection	  or	  false	  negative[18,19].	  	  When	  analyzing	  results	  from	  samples	  tested	  every	  6	  months	  (for	  girls	  who	  reported	  never	  having	  had	  sex),	  clearance	  of	  a	  genotype-­‐specific	  infection	  was	  defined	  as	  a	  single	  negative	  sample	  for	  that	  genotype,	  since	  we	  only	  had	  3	  follow-­‐up	  samples	  (6,	  12	  and	  18	  month	  samples),	  For	  duration	  of	  infection	  in	  the	  analysis	  of	  girls	  who	  never	  reported	  previous	  sex,	  two	  positive	  samples	  with	  one	  intervening	  missing	  sample	  (e.g.	  positive	  at	  month-­‐6	  and	  month-­‐18,	  but	  with	  a	  missing	  sample	  at	  month-­‐12),	  was	  considered	  an	  infection	  of	  unknown	  duration,	  and	  the	  individual	  censored	  at	  the	  date	  of	  the	  first	  positive	  sample.	  	  Risk	  factors	  for	  prevalent	  HPV	  were	  evaluated	  using	  logistic	  regression.	  Risk	  factors	  for	  incident	  HPV	  were	  examined	  using	  Poisson	  regression	  in	  order	  that	  girls	  could	  contribute	  more	  than	  one	  incident	  HPV	  genotype	  at	  each	  visit,	  and	  random	  effects	  were	  used	  to	  account	  for	  correlation	  of	  events	  within	  the	  individual.	  Cox	  regression	  was	  used	  to	  analyse	  risk	  factors	  for	  clearance	  since	  this	  allowed	  the	  time	  to	  clearance	  to	  vary	  by	  genotype,	  which	  is	  likely[21].	  The	  assumption	  of	  proportional	  hazards	  (i.e.	  that	  the	  rate	  in	  the	  exposed	  and	  unexposed	  would	  vary	  over	  time	  but	  remain	  proportional	  to	  each	  other)	  was	  tested.	  Risk	  factors	  for	  incident	  HPV	  (in	  those	  reporting	  and	  not	  reporting	  sex)	  and	  clearance	  of	  HPV	  were	  evaluated	  using	  a	  hierachical	  framework	  analysis	  with	  three	  levels,	  with	  age	  included	  throughout	  due	  to	  the	  strong	  association	  between	  age	  and	  HPV[21,23].	  Socioeconomic	  status	  was	  measured	  using	  an	  asset	  index,	  created	  by	  combining	  data	  on	  ownership	  of	  common	  household	  items	  using	  principal	  component	  analysis.	  The	  first	  level	  of	  the	  hierarchical	  framework	  included	  age-­‐adjusted	  sociodemographic	  variables	  measured	  at	  enrolment	  into	  the	  cohort	  study.	  These	  were	  retained	  in	  a	  core	  model	  if	  associated	  with	  HPV	  prevalence	  or	  incidence	  at	  p<0.10.	  At	  the	  second	  level,	  time-­‐varying	  (measured	  at	  each	  follow-­‐up	  visit)	  sociodemographic	  variables	  were	  included	  and	  retained	  if	  associated	  at	  p<0.10	  and	  finally,	  time-­‐varying	  behavioural	  factors	  were	  included	  and	  retained	  if	  associated	  at	  p<0.1.	  Since	  sociodemographic	  factors	  associated	  with	  HPV	  incidence	  or	  clearance	  were	  likely	  to	  directly	  or	  indirectly	  influence	  all	  other	  groups	  of	  risk	  factors	  it	  was	  logical	  that	  these	  were	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included	  first,	  and	  retained	  if	  associated,	  before	  introducing	  behavioural	  risk	  factors	  in	  the	  model.	  Sociodemographic	  variables	  at	  baseline	  were	  also	  likely	  to	  influence	  those	  reported	  during	  follow-­‐up	  and	  should	  therefore	  be	  included	  before	  time-­‐varying	  sociodmographic	  factors	  were	  introduced.	  Behavioural	  factors	  included	  intravaginal	  practices	  (intravaginal	  cleansing	  or	  insertion),	  since	  these	  have	  previously	  been	  described	  in	  the	  Mwanza	  region[32]	  and	  have	  been	  associated	  with	  HPV[33].	  Menstrual	  hygiene	  practices	  were	  also	  included	  since	  disposable	  sanitary	  pads	  or	  tampons	  are	  not	  usually	  available	  or	  affordable	  to	  the	  majority	  of	  adolescent	  girls	  in	  the	  region	  and	  the	  sharing	  or	  re-­‐using	  of	  cloths	  or	  underwear	  for	  menstruation	  might	  theoretically	  increase	  risk	  of	  HPV	  acquisition	  or	  duration	  respectively.	  Sexual	  behaviours	  included	  the	  use	  of	  lubricants	  such	  as	  saliva	  during	  sex	  since	  oral	  HPV	  in	  a	  male	  partner	  may	  be	  a	  source	  of	  vaginal	  infection	  through	  this	  mechanism.	  	  
2.3.6 Clinical	  follow	  up	  	  Prior	  to	  the	  study	  starting,	  study	  nurses	  were	  provided	  with	  accredited	  training	  on	  National	  Tanzanian	  Guidelines	  for	  the	  syndromic	  management	  of	  STI,	  and	  on	  HIV	  Voluntary	  Counselling	  and	  Testing	  (VCT),	  conducted	  by	  a	  regional	  accredited	  trainer	  in	  both.	  	  All	  participants	  who	  reported	  having	  had	  sex	  were	  verbally	  screened	  for	  symptoms	  of	  reproductive	  tract	  infections	  (RTIs)	  during	  the	  study	  visits.	  No	  testing	  for	  RTIs	  other	  than	  HPV	  were	  done	  due	  to	  budget	  constraints.	  Participants	  reporting	  symptoms	  of	  possible	  RTIs	  were	  examined	  by	  one	  of	  the	  study	  nurses	  in	  a	  clinic	  setting,	  either	  in	  the	  Sekou	  Toure	  Hospital	  research	  clinic,	  or	  one	  of	  the	  district	  health	  facilities	  if	  more	  convenient.	  Free	  syndromic	  treatment	  of	  RTIs	  was	  provided	  if	  required	  following	  the	  latest	  National	  Tanzanian	  Guidelines	  (2007)[22].	  	  The	  study	  nurses	  carried	  a	  portable	  box	  containing	  necessary	  equipment	  and	  medications	  to	  diagnose	  and	  treat	  RTIs	  in	  district	  clinics.	  At	  the	  final	  study	  visit,	  VCT	  for	  HIV	  was	  offered	  to	  study	  participants	  who	  reported	  that	  they	  had	  ever	  had	  sex.	  Any	  participant	  testing	  HIV	  positive	  was	  referred	  to	  their	  local	  HIV	  Treatment	  and	  Care	  Centre	  with	  a	  referral	  letter.	  	  HR	  HPV	  has	  a	  median	  duration	  of	  only	  8-­‐9	  months[21,23,24],	  and	  the	  majority	  of	  HPV	  infections	  in	  women	  under	  the	  age	  of	  25	  resolve	  spontaneously[18,24].	  Although	  early	  cytological	  changes	  often	  resolve	  without	  treatment	  in	  young	  women[25,26],	  since	  persistent	  HR	  HPV	  has	  been	  strongly	  associated	  with	  cervical	  cancer	  and	  girls	  in	  this	  study	  population	  may	  not	  be	  able	  to	  get	  screened	  later	  in	  life,	  we	  elected	  to	  offer	  girls	  with	  persistent	  high-­‐risk	  HPV	  referral	  for	  screening	  and	  treatment.	  Participants	  with	  persistent	  HR	  HPV	  diagnosed	  at	  their	  final	  visit	  were	  referred	  to	  the	  regional	  oncologist	  at	  Bugando	  Medical	  Centre,	  a	  tertiary	  referral	  teaching	  hospital	  in	  Mwanza,	  for	  VIA	  and	  cryotherapy	  of	  any	  visible	  lesions.	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Due	  to	  the	  high	  cost	  of	  testing	  an	  individual	  participant’s	  sample	  using	  the	  Linear	  Array	  HPV	  Genotyping	  Test,	  all	  samples	  from	  all	  follow-­‐up	  visits	  from	  every	  participant	  were	  not	  tested.	  	  Since	  we	  did	  not	  test	  samples	  from	  all	  visits	  for	  some	  participants,	  the	  definition	  of	  which	  girls	  required	  referral	  to	  Bugando	  Medical	  Centre	  varied.	  	  All	  enrolment	  samples	  from	  all	  participants	  were	  tested.	  Girls	  who	  reported	  that	  they	  had	  had	  sex	  prior	  to	  enrolment,	  or	  during	  follow-­‐up	  had	  all	  their	  samples	  tested	  (i.e.	  samples	  collected	  at	  month	  3,	  6,	  9,	  12,	  15	  and	  18	  of	  follow-­‐up)	  (Table	  2.2,	  Group	  1).	  Of	  the	  397	  girls	  who	  reported	  never	  having	  had	  sex	  by	  their	  final	  study	  visit,	  120	  were	  randomly	  selected,	  (this	  was	  not	  based	  on	  attendance	  at	  any	  visit),	  and	  samples	  collected	  at	  the	  6,	  12	  and	  18-­‐month	  visits	  were	  tested	  (Table	  2.2,	  Group	  2).	  Finally,	  in	  girls	  who	  did	  not	  report	  sex	  at	  any	  time,	  and	  who	  were	  not	  randomly	  selected	  for	  6-­‐monthly	  sample	  testing	  (Table	  2.2,	  Group	  3)	  but	  who	  had	  high-­‐risk	  HPV	  at	  enrolment,	  the	  sample	  from	  their	  last	  attended	  visit	  was	  tested	  for	  HPV.	  	  Those	  who	  had	  the	  same	  HR	  HPV	  genotype	  detected	  at	  enrolment	  and	  at	  the	  end	  of	  the	  study	  were	  referred	  for	  clinical	  follow-­‐up.	  Clinical	  outcomes	  from	  these	  groups	  are	  summarised	  in	  Annex	  10.	  
Table	  2:2.	  Criteria	  for	  referral	  for	  clinical	  follow	  up	  of	  persistent	  HPV	  at	  study	  completion	  
Participant	  (number)	  
Follow-­‐up	  samples	  which	  were	  
tested	  for	  HPV	  
Criteria	  for	  clinical	  referral	  at	  study	  
completion	  Reported	  sex	  either	  before	  or	  during	  study	  (106).	  
Group	  1.	   All	  samples;	  3,	  6,	  9,	  12,	  15,	  18	  months	  
Three	  consecutive	  positive	  samples	  for	  the	  same	  HR	  HPV	  genotype	  where	  the	  final	  sample	  was	  from	  the	  final	  visit	  attended	  Did	  not	  report	  sex	  either	  before	  or	  during	  the	  study	  but	  randomly	  selected	  (120).	  
Group	  2.	  
6	  month	  samples;	  6,	  12,	  18	  months	   Two	  consecutive	  positive	  samples	  for	  the	  same	  HR	  HPV	  genotype	  where	  the	  final	  sample	  was	  from	  the	  final	  visit	  attended	  Did	  not	  report	  sex	  either	  before	  or	  during	  the	  study	  and	  not	  randomly	  selected	  (277).	  
Group	  3.	  
If	  the	  enrolment	  sample	  was	  positive	  for	  a	  HR	  HPV	  genotype,	  the	  final	  (attended)	  visit	  sample	  was	  tested	  
Sample	  at	  final	  visit	  was	  positive	  for	  the	  same	  HR	  HPV	  genotype	  as	  enrolment	  
	  
2.4 Sample	  size	  Based	  on	  the	  age	  of	  sexual	  debut	  in	  MEMA	  kwa	  Vijana,	  a	  community	  randomised	  trial	  of	  an	  adolescent	  sexual	  and	  reproductive	  health	  intervention	  in	  schools	  in	  the	  Mwanza	  Region,	  it	  was	  estimated	  that	  40%	  (N=200)	  of	  500	  girls	  aged	  15	  and	  16	  years	  who	  reported	  no	  previous	  sex	  at	  enrolment	  would	  pass	  sexual	  debut	  during	  the	  18	  months	  of	  follow-­‐up[27].	  Assuming	  a	  30%	  cumulative	  loss-­‐to-­‐follow	  up,	  158	  participants	  were	  therefore	  expected	  to	  have	  reported	  ever	  having	  had	  sex	  at	  18	  months.	  We	  therefore	  aimed	  to	  enrol	  500	  girls	  who	  reported	  not	  having	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passed	  sexual	  debut,	  of	  whom	  200	  would	  report	  sexual	  debut	  by	  18	  months	  of	  follow	  up,	  and	  of	  whom	  140	  would	  remain	  in	  follow-­‐up.	  Further,	  we	  aimed	  to	  enrol	  26	  who	  reported	  sexual	  debut	  within	  the	  year	  prior	  to	  enrolment,	  of	  whom	  18	  would	  remain	  in	  follow-­‐up	  at	  18	  months.	  There	  are	  no	  data	  from	  sub-­‐Saharan	  Africa	  on	  HPV	  incidence	  after	  initiation	  of	  sexual	  debut.	  A	  study	  in	  Washington,	  USA,	  observed	  a	  cumulative	  incidence	  of	  any	  HPV	  type	  of	  28.5%	  during	  the	  first	  year	  after	  sexual	  debut[28].	  	  Assuming	  a	  similar	  incidence,	  a	  sample	  size	  of	  150	  participants	  reporting	  ever	  having	  had	  sex	  by	  18	  months	  would	  allow	  an	  estimate	  of	  the	  cumulative	  incidence	  of	  any	  HPV	  type	  with	  a	  precision	  of	  ±7.2%.	  	  Further	  analysis	  from	  the	  cohort	  of	  young	  women	  in	  Washington,	  USA,	  identified	  a	  cumulative	  incidence	  of	  HPV16	  and	  HPV18	  of	  10.4%	  and	  4.1%	  respectively[29].	  The	  sample	  size	  of	  150	  participants	  reporting	  sex	  at	  18	  months	  would	  allow	  an	  estimation	  of	  these	  genotype-­‐specific	  incidences	  with	  a	  precision	  of	  ±4.9%	  and	  ±3.2%	  respectively.	  Collection	  of	  behavioural	  data	  was	  planned	  in	  order	  to	  investigate	  risk	  factors	  for	  HPV	  acquisition.	  The	  MEMA	  kwa	  Vijana	  trial	  found	  that	  15%	  of	  girls	  aged	  15-­‐30	  years	  reported	  a	  casual	  partner	  in	  the	  past	  12	  months,	  and	  10%	  had	  more	  than	  1	  partner[27].	  The	  proportion	  using	  a	  condom	  at	  last	  sex	  in	  the	  past	  12	  months	  was	  15%.	  	  With	  a	  sample	  size	  of	  150	  reporting	  sex	  at	  18	  months,	  risk	  factors	  with	  a	  prevalence	  of	  15%	  would	  provide	  77%	  power	  to	  detect	  a	  relative	  risk	  of	  2.75	  or	  above	  (Table	  2.3).	  
Table	  2:3.	  Power	  calculations	  for	  the	  detection	  of	  factors	  associated	  with	  HPV	  among	  
those	  reporting	  sex	  
	  
More than 1 partner
0.95 500 0.30 150 0.285 0.10 2.25 0.07 0.17 0.40
0.95 500 0.30 150 0.285 0.10 2.50 0.07 0.17 0.49
0.95 500 0.30 150 0.285 0.10 2.75 0.07 0.18 0.58
0.95 500 0.40 200 0.285 0.10 2.25 0.07 0.17 0.50
0.95 500 0.40 200 0.285 0.10 2.50 0.07 0.18 0.61
0.95 500 0.40 200 0.285 0.10 2.75 0.07 0.18 0.70
Casual partner in past 12 months
0.95 500 0.30 150 0.285 0.15 2.25 0.11 0.25 0.57
0.95 500 0.30 150 0.285 0.15 2.50 0.10 0.26 0.68
0.95 500 0.30 150 0.285 0.15 2.75 0.10 0.27 0.77
0.95 500 0.40 200 0.285 0.15 2.25 0.11 0.25 0.70
0.95 500 0.40 200 0.285 0.15 2.50 0.11 0.26 0.80
0.95 500 0.40 200 0.285 0.15 2.75 0.10 0.28 0.88
Concurrency 
0.95 500 0.30 150 0.285 0.07 2.25 0.05 0.12 0.29
0.95 500 0.30 150 0.285 0.07 2.50 0.05 0.12 0.36
0.95 500 0.30 150 0.285 0.07 2.75 0.05 0.13 0.42
0.95 500 0.40 200 0.285 0.07 2.25 0.05 0.12 0.36
0.95 500 0.40 200 0.285 0.07 2.50 0.05 0.12 0.45
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2.5 Comparision	  of	  Audio	  Computer	  Assisted	  Self	  Interview	  (ACASI)	  with	  
face-­‐to-­‐face	  interviews	  In	  order	  to	  assess	  alternative	  methods	  of	  sexual	  behaviour	  data	  collection,	  a	  cross-­‐sectional	  comparison	  of	  different	  interview	  methods	  of	  sexual	  behaviour	  data	  collection	  was	  nested	  within	  the	  cohort	  study.	  An	  amendment	  to	  the	  protocol,	  including	  an	  explanation	  of	  this	  comparison,	  was	  submitted	  to	  the	  LSHTM	  and	  MRCC	  ethics	  boards	  and	  was	  approved	  on	  20th	  September	  2012	  by	  LSHTM	  (A354),	  and	  22nd	  January	  2013	  by	  MRCC	  Tanzania	  (NIMR/HQ/R.6c	  vol	  I/241).	  Further	  consent	  was	  not	  considered	  necessary.	  	  Tablet	  computers	  were	  programmed	  with	  the	  assistance	  of	  the	  senior	  data	  manager	  at	  MITU	  and	  allowed	  participants	  to	  listen	  to	  audio	  questions	  in	  Swahili,	  and	  read	  them	  on	  the	  screen.	  The	  questions	  were	  recorded	  by	  an	  interviewer	  not	  employed	  on	  the	  study,	  and	  were	  a	  subset	  of	  those	  included	  in	  the	  standard	  FtF-­‐interview.	  A	  total	  of	  200	  participants	  were	  randomly	  selected	  to	  be	  invited	  to	  complete	  an	  ACASI	  as	  well	  as	  a	  FtF-­‐interview,	  the	  order	  of	  which	  was	  also	  randomly	  allocated	  (FtF-­‐interview	  first	  or	  ACASI	  first).	  The	  random	  selection	  of	  participants	  for	  this	  comparison	  was	  drawn	  from	  those	  who	  had	  attended	  the	  3-­‐month	  visit,	  and	  who	  were	  resident	  in	  one	  of	  the	  two	  districts	  in	  Mwanza	  city	  (Nyamangana	  and	  Ilemela)	  at	  that	  visit.	  Participants	  resident	  in	  the	  district	  of	  Misungwi,	  or	  other	  districts	  but	  were	  travelling	  for	  appointments,	  were	  not	  included	  for	  logistical	  reasons.	  At	  the	  12-­‐month	  visit,	  randomly	  selected	  participants	  were	  invited	  to	  complete	  an	  ACASI	  if	  they	  were	  currently	  (at	  the	  12	  month	  visit)	  resident	  in	  one	  of	  the	  two	  Mwanza	  city	  districts.	  	  Answers	  provided	  by	  the	  participant	  using	  the	  tablet	  computer	  were	  directly	  compared	  to	  those	  obtained	  by	  traditional	  interview.	  An	  initial	  set	  of	  8	  test-­‐questions	  were	  also	  included	  to	  help	  the	  participant	  practice	  using	  the	  tablet	  computer	  and	  which	  were	  used	  as	  a	  final	  competence	  check	  at	  analysis.	  These	  8	  training	  questions,	  delivered	  before	  the	  sexual	  behaviour	  questions,	  covered	  non-­‐sensitive	  topics,	  including	  ever	  having	  made	  a	  trip	  to	  the	  market,	  the	  number	  of	  people	  living	  in	  the	  house,	  and	  the	  person	  the	  respondent	  last	  spoke	  to	  before	  the	  ACASI.	  A	  non-­‐clinical	  research	  assistant	  was	  trained	  to	  assist	  the	  participant	  with	  this	  interview.	  The	  participant	  could	  choose	  to	  repeat	  the	  8	  questions	  any	  number	  of	  times	  before	  commencing	  the	  rest	  of	  the	  interview.	  Questions	  included	  in	  ACASI	  are	  summarised	  in	  Annex	  11.	  An	  example	  of	  a	  study	  participant	  completing	  an	  ACASI	  is	  shown	  in	  Figure	  2.4.	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Figure	  2:4.	  A	  study	  participant	  completing	  an	  ACASI	  (written	  consent	  from	  the	  participant	  for	  this	  photograph	  was	  obtained)	  
2.5.1 ACASI	  sample	  size	  calculations	  A	  randomized	  trial	  of	  ACASI	  in	  15-­‐23	  year-­‐olds	  in	  Zimbabwe,	  showed	  that	  4%,	  6%	  and	  6%	  more	  participants	  using	  ACASI	  reported	  having	  had	  sex,	  had	  kissed	  and	  not	  having	  used	  a	  condom	  at	  last	  sex	  compared	  to	  those	  who	  reported	  these	  using	  informal	  confidential	  voting	  interviews[30].	  	  	  A	  sample	  size	  of	  200	  girls	  undergoing	  two	  interviews	  (ACASI	  and	  FtF-­‐interview)	  would	  allow	  >85%	  power	  to	  detect	  an	  increase	  of	  5%	  in	  the	  disclosure	  of	  sexual	  debut	  (Table	  2.5).	  These	  calculations	  are	  based	  on	  methods	  for	  matched	  case	  control	  studies[31]	  which	  examine	  discordant	  pairs.	  In	  this	  power	  calculation	  assumption,	  1%	  report	  “No”	  to	  an	  answer	  on	  sexual	  behaviour	  in	  ACASI	  but	  “Yes”	  in	  the	  FtF-­‐interviews	  and	  6%	  report	  “Yes”	  in	  ACASI	  and	  “No”	  in	  the	  FtF-­‐interviews.	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Table	  2:4.	  Power	  calculations	  for	  the	  comparison	  of	  disclosure	  in	  ACASI	  and	  face	  to	  face	  
interview	  
Prevalence	  in	  










%	  yes	  in	  
ACASI	  /	  no	  in	  
FTF	  
%	  no	  in	  
ACASI	  /	  yes	  
in	  FTF	  
N=150	   N=200	   N=250	  5%	   7.5%	   5.0%	   2.5%	   0	   -­‐	   27%	   >99%	   >99%	  5%	   7.5%	   4.9%	   2.6%	   0.1%	   26.0	   40%	   69%	   88%	  5%	   7.5%	   4.5%	   3.0%	   0.5%	   6.0	   32%	   46%	   59%	  5%	   7.5%	   4.0%	   3.5%	   1.0%	   3.5	   27%	   36%	   45%	  10%	   15%	   10%	   5%	   0	   -­‐	   >99%	   >99%	   >99%	  10%	   15%	   9%	   6%	   1%	   6.0	   69%	   85%	   93%	  10%	   15%	   8%	   7%	   2%	   3.5	   54%	   68%	   79%	  10%	   15%	   7%	   8%	   3%	   2.7	   45%	   58%	   68%	  20%	   25%	   20%	   5%	   0	   -­‐	   >99%	   >99%	   >99%	  20%	   25%	   19%	   6%	   1%	   6.0	   69%	   85%	   93%	  20%	   25%	   17%	   8%	   3%	   2.7	   45%	   58%	   68%	  20%	   25%	   15%	   10%	   5%	   2.0	   34%	   44%	   53%	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  in	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  sexual	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  factors	  associated	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  baseline	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  infection	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Abstract	  
Background	  	  Human	  papillomavirus	  (HPV)	  vaccines	  are	  recommended	  for	  girls	  prior	  to	  sexual	  debut	  since	  they	  are	  most	  effective	  if	  administered	  before	  girls	  acquire	  HPV.	  Little	  research	  has	  been	  done	  on	  HPV	  prevalence	  in	  girls	  who	  report	  not	  having	  passed	  sexual	  debut	  in	  high	  HPV-­‐prevalence	  countries.	  	  
Methods	  	  Using	  attendance	  registers	  of	  randomly-­‐selected	  primary	  schools	  in	  the	  Mwanza	  region	  of	  Tanzania,	  we	  enrolled	  girls	  aged	  15-­‐16	  years	  who	  reported	  not	  having	  passed	  sexual	  debut.	  A	  face-­‐to-­‐face	  interview	  on	  sexual	  behaviour	  and	  intra-­‐vaginal	  practices,	  and	  a	  nurse-­‐assisted	  self-­‐administered	  vaginal	  swab	  were	  performed.	  Swabs	  were	  tested	  for	  13	  high-­‐risk	  and	  24	  low-­‐risk	  HPV	  genotypes.	  	  
Results	  	  HPV	  was	  detected	  in	  40/474	  (8.4%;95%CI:5.9-­‐11.0)	  girls.	  Ten	  different	  high-­‐risk	  and	  21	  different	  low-­‐risk	  genotypes	  were	  detected.	  High-­‐risk	  genotypes	  were	  detected	  in	  5.3%	  (95%CI:3.5-­‐7.8).	  In	  multivariable	  analysis,	  only	  intra-­‐vaginal	  cleansing	  (practiced	  by	  20.9%)	  was	  associated	  with	  HPV	  detection	  (aOR=2.19,95%CI:1.09–4.39).	  
Conclusion	  	  This	  cohort	  of	  adolescent	  Tanzanian	  girls	  had	  a	  high	  HPV	  prevalence	  prior	  to	  self-­‐reported	  sexual	  debut,	  and	  this	  was	  associated	  with	  intravaginal	  cleansing.	  This	  most	  likely	  reflects	  under-­‐reporting	  of	  sexual	  activity,	  and	  it	  is	  possible	  that	  intravaginal	  cleansing	  is	  a	  marker	  for	  unreported	  sexual	  debut	  or	  non-­‐penetrative	  sexual	  behaviours.	  	  
Key	  words:	  Human	  papillomavirus,	  sub-­‐Saharan	  Africa,	  sexual	  debut,	  prevalence	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Introduction	  Cervical	  cancer	  is	  the	  most	  common	  form	  of	  cancer	  in	  women	  in	  sub-­‐Saharan	  Africa	  and	  the	  highest	  age-­‐standardized	  incidence	  of	  cervical	  cancer	  in	  the	  world	  is	  found	  in	  East	  Africa	  at	  over	  30.0	  per	  100,000	  person-­‐years(1).	  This	  is	  compared	  to	  approximately	  15.0	  per	  100,000	  women	  worldwide,	  and	  6.0	  per	  100,000	  in	  North	  America(1).	  Almost	  all	  cases	  of	  cervical	  cancer	  can	  be	  attributed	  to	  infection	  with	  one	  of	  13	  high-­‐risk	  oncogenic	  genotypes	  of	  the	  human	  papillomavirus	  (HPV)(2).	  Although	  limited	  in	  number,	  studies	  in	  women	  indicate	  that	  East	  Africa	  also	  has	  one	  of	  the	  highest	  global	  prevalences	  of	  HPV	  infection(3,4).	  Worldwide	  data	  consistently	  show	  that	  the	  prevalence	  of	  HPV	  is	  highest	  in	  younger	  women,	  most	  of	  whom	  will	  clear	  the	  infection	  within	  10	  months(5).	  The	  early	  peak	  of	  HPV	  prevalence	  by	  age	  is	  explained	  by	  a	  rapid	  acquisition	  of	  HPV	  around	  the	  time	  of	  first	  sex	  in	  a	  previously	  unexposed,	  or	  immune-­‐naïve	  individual(6,7).	  	  The	  two	  available	  HPV	  vaccines,	  Gardasil®	  (MSD)	  and	  Cervarix®	  (GlaxoSmithKline	  Biologicals),	  cover	  the	  two	  most	  common	  cancer-­‐causing	  HPV	  genotypes	  HPV-­‐16	  and	  -­‐18.	  Additionally,	  Gardasil®	  covers	  HPV-­‐6	  and	  -­‐11,	  which,	  though	  low-­‐risk	  for	  cervical	  cancer,	  are	  common	  causes	  of	  genital	  warts.	  HPV	  vaccination	  is	  most	  effective	  if	  administered	  prior	  to	  acquiring	  infection	  with	  these	  vaccine-­‐related	  genotypes(8).	  Data	  from	  North	  America	  and	  Europe	  support	  the	  assumption	  that	  most	  girls	  and	  women	  are	  HPV	  naïve	  prior	  to	  first	  sex	  and	  that	  HPV	  is	  acquired	  quickly	  after	  sexual	  debut	  and	  with	  changes	  of	  sexual	  partner(7,9).	  However,	  there	  are	  no	  data	  on	  HPV	  prevalence	  in	  young	  women	  prior	  to	  reported	  sexual	  debut	  from	  high	  HPV	  prevalence	  countries	  in	  sub-­‐Saharan	  Africa,	  where	  sexual	  behaviour,	  vaginal	  hygiene	  practices	  and	  rates	  of	  under-­‐reporting	  of	  sexual	  debut	  may	  differ.	  Such	  data	  are	  important	  because	  they	  may	  identify	  modifiable	  risk	  factors	  for	  HPV	  infection,	  and	  because	  any	  planned	  national	  vaccination	  campaign	  will	  target	  young	  girls	  who	  are	  assumed	  to	  be	  HPV	  naïve.	  Further,	  WHO	  has	  recommended	  vaccination	  catch-­‐up	  campaigns	  in	  older	  girls	  if	  a	  significant	  proportion	  can	  be	  assumed	  to	  be	  naïve	  to	  vaccine	  genotypes(10).	  To	  address	  the	  gaps	  in	  knowledge,	  we	  present	  baseline	  cross-­‐sectional	  results	  from	  a	  cohort	  study	  in	  Tanzania	  that	  enrolled	  adolescent	  girls	  who	  reported	  that	  they	  had	  not	  passed	  sexual	  debut,	  and	  who	  were	  tested	  for	  vaginal	  HPV	  DNA.	  This	  study	  is	  the	  first	  to	  describe	  HPV	  prevalence	  in	  girls	  in	  sub-­‐Saharan	  Africa	  who	  report	  no	  previous	  sexual	  intercourse,	  and	  the	  associations	  between	  reported	  sexual	  behaviours,	  vaginal	  practices	  and	  HPV	  infection.	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Cohort	  enrolment	  	  The	  cohort	  was	  enrolled	  between	  January	  and	  August	  2012	  from	  previously-­‐prepared	  attendance	  lists	  of	  randomly-­‐selected	  government	  primary	  schools	  in	  3	  districts	  of	  the	  Mwanza	  Region	  in	  Tanzania.	  These	  lists,	  covering	  all	  primary	  schools	  the	  districts,	  had	  been	  drawn	  up	  in	  2010	  to	  prepare	  for	  a	  trial	  of	  delivery	  methods	  for	  HPV	  vaccine(11).	  The	  lists	  contained	  the	  pupil’s	  name,	  date	  of	  birth	  and	  which	  class	  they	  were	  enrolled	  in.	  Tracing	  information	  had	  also	  been	  collected	  on	  all	  girls.	  We	  enrolled	  eligible	  girls	  who	  had	  attended	  one	  of	  the	  82	  schools	  not	  selected	  to	  receive	  the	  vaccine.	  	  Eligibility	  criteria	  included	  being	  aged	  15	  or	  16	  years	  at	  enrolment;	  enrolled	  in	  class	  6	  in	  2010	  in	  one	  of	  the	  selected	  schools;	  not	  pregnant	  (self-­‐reported);	  planning	  to	  stay	  in	  the	  study	  area	  or	  able	  to	  travel	  to	  appointments;	  self-­‐reporting	  never	  having	  had	  vaginal	  sex;	  and	  being	  willing	  to	  self-­‐administer	  vaginal	  swabs.	  A	  sub-­‐sample	  of	  26	  of	  the	  82	  schools	  were	  randomly	  selected	  and,	  in	  order	  to	  prevent	  stigmatization	  of	  girls	  who	  reported	  sex,	  at	  each	  of	  these	  26	  schools	  the	  first	  girl	  who	  reported	  ever	  having	  had	  sex	  was	  enrolled.	  An	  additional	  eligibility	  requirement	  for	  these	  girls	  was	  having	  passed	  sexual	  debut	  within	  the	  past	  12	  months.	  	  
Ethical	  Issues	  The	  London	  School	  of	  Hygiene	  and	  Tropical	  Medicine	  Ethics	  Committee	  and	  the	  Medical	  Research	  Coordinating	  Committee,	  Tanzania	  approved	  the	  study	  protocol.	  Since	  all	  potential	  participants	  were	  considered	  minors	  in	  Tanzania	  (under	  18	  years	  old),	  written	  informed	  consent	  was	  required	  from	  a	  parent/guardian	  with	  subsequent	  participant	  informed	  assent.	  Consent	  for	  enrolment	  was	  taken	  before	  any	  assessment	  of	  previous	  sexual	  debut.	  The	  consent	  procedure	  involved	  separate	  face-­‐to-­‐face	  explanations	  of	  the	  study	  to	  parents	  and	  daughters	  by	  a	  study	  nurse,	  provision	  of	  written	  information	  and	  time	  to	  ask	  questions.	  Individuals	  unable	  to	  read	  were	  consented	  in	  the	  presence	  of	  an	  independent	  witness	  who	  provided	  an	  additional	  signature.	  Individuals	  unable	  to	  write	  provided	  a	  thumbprint.	  Parents/guardians	  were	  compensated	  for	  their	  time	  with	  Tsh5,000	  (approximately	  $3),	  and	  participants	  were	  provided	  with	  a	  toothbrush	  and	  toothpaste.	  
Study	  procedures	  After	  enrolment,	  girls	  had	  a	  face-­‐to-­‐face	  interview	  with	  a	  female	  study	  nurse.	  Interviews	  were	  carried	  out	  in	  private	  at	  the	  participant’s	  home,	  school	  or	  local	  health	  centre,	  depending	  on	  participant	  preference.	  Interviews	  were	  carried	  out	  in	  Swahili	  using	  a	  structured	  paper	  questionnaire,	  which	  had	  been	  translated	  and	  back-­‐translated	  from	  English.	  Questions	  covered	  demographic	  and	  socio-­‐economic	  details,	  menstrual	  and	  vaginal	  hygiene-­‐practices,	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non-­‐penetrative	  sexual	  behaviours,	  and	  details	  of	  previous	  penetrative-­‐sex	  frequency	  and	  partners.	  Interviews	  included	  colloquial	  terms	  for	  sexual	  behaviours	  that	  had	  been	  collected	  during	  focus	  group	  discussions	  with	  similar-­‐aged	  girls.	  One	  self-­‐administered	  vaginal	  Dacron	  swab	  was	  obtained	  after	  instructions	  from	  a	  study	  nurse,	  who	  remained	  in	  the	  room	  and	  provided	  verbal	  and	  positional	  hand-­‐guidance	  if	  necessary.	  Girls	  are	  being	  followed	  every	  3	  months	  for	  18	  months.	  We	  report	  results	  from	  the	  enrolment	  visit.	  
HPV	  detection	  and	  genotyping	  Immediately	  after	  collection,	  swabs	  were	  stored	  dry	  in	  cryotubes	  and	  placed	  into	  cold	  boxes	  with	  ice-­‐packs.	  They	  were	  submitted	  daily	  to	  the	  reference	  laboratory	  in	  Mwanza	  and	  stored	  at	  -­‐200C	  until	  they	  were	  shipped	  to	  the	  Catalan	  Institute	  of	  Oncology,	  Barcelona,	  Spain.	  HPV	  detection	  and	  genotyping	  were	  performed	  using	  the	  Linear	  Array	  HPV	  genotyping	  assay	  (Roche,	  California,	  USA)	  which	  detects	  37	  HPV	  genotypes	  (HPV-­‐6,-­‐11,-­‐16,-­‐18,-­‐26,-­‐31,-­‐33,-­‐35,-­‐39,-­‐40,-­‐42,-­‐45,-­‐51,-­‐52,-­‐53,-­‐54,-­‐55,-­‐56,-­‐58,-­‐59,-­‐61,-­‐62,-­‐64,-­‐66,-­‐67,-­‐68,-­‐69,-­‐70,-­‐71,-­‐72,-­‐73,-­‐81,-­‐82,-­‐83,-­‐84,	  IS39	  and	  CP6108).	  For	  this	  study,	  13	  HPV	  genotypes	  HPV-­‐16,-­‐18,-­‐31,-­‐33,-­‐35,-­‐39,-­‐45,-­‐51,-­‐52,-­‐56,-­‐58,-­‐59,-­‐68	  were	  classified	  high-­‐risk	  (2).	  Other	  genotypes	  were	  considered	  low-­‐risk.	  Briefly,	  DNA	  was	  extracted	  from	  the	  specimens	  by	  silica-­‐gel	  based	  methods	  (AmpliLute	  Liquid	  Media	  Extraction	  kit,	  Roche).	  Extracted	  material	  was	  amplified	  with	  PGMY	  PCR	  system,	  and	  the	  generated	  amplicons	  were	  detected	  and	  typed	  by	  reverse-­‐line	  blot	  reaction	  (Linear	  Array	  HPV	  Detection	  Kit	  and	  Genotyping	  Test,	  Roche).	  PCR	  reaction	  in	  this	  assay	  is	  based	  on	  a	  multiplex	  system,	  including	  human	  b-­‐globin	  amplification	  primers.	  This	  provides	  an	  internal	  quality	  control	  for	  sample	  material.	  Specimens	  consistently	  negative	  for	  b-­‐globin	  amplification	  were	  excluded	  since	  it	  was	  assumed	  that	  vaginal	  sampling	  was	  unsuccessful.	  All	  protocols	  were	  performed	  according	  to	  manufacturer’s	  instructions:	  each	  step	  was	  performed	  in	  separate	  rooms	  and	  negative	  controls	  were	  used.	  
Data	  management	  and	  statistical	  methods	  Questionnaire	  data	  were	  double-­‐entered	  into	  OpenClinica	  LLC	  (Akaza	  Research,	  MA,	  USA),	  and	  analysed	  using	  STATA	  V12.0	  (StataCorp	  LP,	  Texas,	  USA).	  Baseline	  cohort	  characteristics	  were	  examined,	  and	  the	  prevalence	  of	  any	  HPV	  infection,	  and	  prevalence	  of	  individual	  HPV	  genotypes	  were	  calculated.	  Household	  wealth	  was	  estimated	  using	  a	  score	  based	  on	  the	  number	  of	  possessions	  owned	  by	  the	  head	  of	  the	  household	  in	  which	  the	  participant	  currently	  resided.	  Median	  age	  of	  menarche	  in	  the	  cohort	  was	  calculated	  using	  Kaplan-­‐Meier	  survival	  methods	  to	  account	  for	  those	  who	  had	  not	  reached	  menarche.	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Factors	  associated	  with	  prevalent	  HPV	  infection	  (treated	  as	  a	  binary	  outcome	  for	  any	  HPV	  genotype	  versus	  none)	  were	  identified	  using	  logistic	  regression	  models.	  Age	  was	  considered	  an	  a-­‐priori	  potential	  confounder	  and	  factors	  reaching	  p<0.1	  after	  adjustment	  for	  age	  were	  included	  in	  a	  multivariable	  model.	  Vaginal	  cleansing	  was	  investigated	  as	  a	  binary	  term	  for	  ever	  having	  cleansed,	  and	  as	  frequency	  of	  cleansing	  categorised	  as	  never,	  ≤2	  and	  ≥3	  times	  per	  day.	  All	  p-­‐values	  are	  from	  likelihood	  ratio	  tests.	  	  	  	  Results	  Of	  1,555	  potentially-­‐eligible	  girls	  on	  the	  original	  school	  attendance	  lists,	  1,177	  (76.5%)	  were	  located.	  From	  these,	  801	  (68.1%)	  were	  confirmed	  to	  be	  the	  appropriate	  age,	  and	  628	  (78.4%)	  consented	  to	  be	  screened	  for	  enrolment	  (Figure	  1).	  Of	  those	  screened,	  503	  (80.1%)	  were	  eligible,	  selected	  and	  enrolled,	  of	  whom	  481	  (95.6%)	  reported	  not	  having	  had	  sex.	  Those	  not	  enrolled	  either	  reported	  having	  had	  sex	  and	  were	  not	  randomly	  selected	  for	  inclusion	  (N=102,	  16.2%),	  or	  said	  they	  were	  planning	  to	  move	  out	  of	  the	  study	  area	  (N=23,	  3.7%).	  b-­‐globin	  was	  detected	  in	  495	  (98.8%)	  of	  specimens.	  We	  excluded	  6	  participants	  from	  the	  analysis	  who	  provided	  b-­‐globin	  negative	  vaginal	  swabs,	  and	  one	  who	  did	  not	  provide	  a	  swab.	  We	  present	  HPV	  prevalence	  and	  associated	  factors	  from	  the	  remaining	  474	  girls	  who	  reported	  never	  having	  had	  sex,	  and	  the	  HPV	  prevalence	  in	  girls	  who	  reported	  having	  had	  sex	  within	  the	  past	  year.	  
Cohort	  description	  Of	  the	  474	  participants	  who	  reported	  never	  having	  had	  sex,	  225	  were	  aged	  15	  (47.5%)	  and	  the	  remainder	  (52.5%)	  were	  16	  years	  old	  (Table	  3.1).	  Only	  11	  (2.3%)	  reported	  ever	  having	  kissed,	  and	  34	  (7.2%)	  reported	  allowing	  a	  boy	  to	  touch	  their	  breasts.	  One	  girl	  reported	  touching	  a	  boy’s	  penis,	  and	  another	  reported	  allowing	  a	  boy	  to	  touch	  her	  vagina.	  None	  reported	  oral	  or	  anal	  sex.	  The	  majority	  had	  passed	  menarche	  (N=376,	  79.3%).	  Median	  age	  of	  menarche	  in	  the	  cohort	  was	  15	  years	  (inter-­‐quartile	  range	  14-­‐15).	  One-­‐fifth	  (N=99,	  20.9%)	  reported	  ever	  having	  cleansed	  inside	  their	  vagina;	  78.8%	  (N=78)	  using	  fingers	  and	  the	  remainder	  using	  a	  cloth	  (Table	  3.2).	  	  Approximately	  half	  (53.5%)	  of	  those	  reporting	  cleansing	  used	  soap	  and	  water;	  the	  other	  half	  used	  water	  alone.	  One	  participant	  reported	  inserting	  a	  substance,	  tobacco	  powder,	  into	  her	  vagina.	  	  
HPV	  DNA	  prevalence	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HPV	  DNA	  was	  detected	  from	  vaginal	  swabs	  in	  40	  of	  474	  girls	  who	  reported	  not	  having	  passed	  sexual	  debut,	  giving	  a	  prevalence	  of	  8.4%	  (95%	  confidence	  interval(CI)	  5.9-­‐11.0).	  In	  total,	  24	  (5.1%,	  95%CI	  3.1-­‐7.0)	  girls	  had	  a	  high-­‐risk	  HPV	  genotype.	  Multiple	  genotype	  infections	  were	  detected	  in	  20	  (4.2%,	  95%CI	  2.4-­‐6.0)	  girls,	  comprising	  50.0%	  of	  those	  with	  HPV	  DNA.	  The	  two	  most	  commonly	  detected	  genotypes	  were	  HPV-­‐42	  and	  HPV-­‐58,	  with	  a	  prevalence	  of	  1.9%	  (N=9)	  and	  1.1%	  (N=5),	  respectively	  (Figure	  2).	  	  	  The	  prevalence	  of	  infection	  with	  any	  of	  the	  vaccine	  genotypes	  HPV-­‐6,-­‐11,-­‐16	  or	  -­‐18	  was	  1.6%	  (95%CI	  0.5-­‐2.7).	  A	  total	  of	  22	  eligible	  girls	  who	  reported	  having	  passed	  sexual	  debut	  within	  the	  last	  year	  were	  enrolled	  from	  26	  randomly-­‐selected	  schools.	  HPV	  DNA	  was	  detected	  in	  7	  (31.8%,	  95%CI	  10.7-­‐53.0)	  of	  these	  22	  girls,	  significantly	  higher	  than	  in	  those	  who	  reported	  never	  having	  had	  sex	  (p<0.01),	  and	  high-­‐risk	  HPV	  was	  detected	  in	  22.7%	  (95%CI	  3.7-­‐41.7,	  N=7).	  	  Though	  the	  numbers	  involved	  were	  small,	  their	  demographic	  profile	  was	  similar	  to	  that	  of	  girls	  who	  reported	  no	  previous	  sex	  (data	  not	  shown).	  	  
Associations	  with	  HPV	  In	  univariable	  analyses	  of	  474	  girls	  who	  reported	  never	  having	  had	  sex,	  there	  was	  weak	  evidence	  that	  being	  age	  16	  years	  was	  associated	  with	  HPV	  detection	  (OR	  1.76	  95%CI	  0.89-­‐3.47,	  p=0.10).	  Only	  the	  reporting	  of	  ever	  having	  practiced	  intravaginal	  cleansing	  was	  associated	  with	  HPV	  DNA	  detection	  in	  univariable	  analysis,	  and	  this	  persisted	  after	  adjustment	  for	  age	  (adjusted	  OR(aOR)	  2.19,	  95%CI	  1.09-­‐4.39,	  p=0.03)	  (Table	  3.1).	  Furthermore,	  there	  was	  strong	  evidence	  of	  a	  dose-­‐response	  relationship	  between	  cleansing	  frequency	  and	  HPV	  DNA	  detection	  (per	  unit	  increase	  in	  cleansing	  frequency	  category	  after	  adjustment	  for	  age,	  aOR	  1.54,	  95%CI	  1.17-­‐2.03,	  p=0.002).	  However,	  among	  girls	  who	  reported	  cleansing,	  there	  was	  no	  evidence	  of	  an	  association	  of	  HPV	  detection	  with	  method	  (fingers	  versus	  cloth),	  or	  substance	  used	  (water	  alone	  versus	  soap)(Table	  3.2).	  
	  
Discussion	  In	  the	  first	  study	  to	  examine	  the	  epidemiology	  of	  HPV	  in	  girls	  from	  sub-­‐Saharan	  Africa	  who	  self-­‐reported	  never	  having	  engaged	  in	  vaginal	  sex,	  the	  prevalence	  of	  HPV	  was	  surprisingly	  high	  (8.4%)	  based	  on	  the	  testing	  of	  self-­‐administered	  vaginal	  swabs.	  This	  is	  higher	  than	  in	  two	  previous	  studies	  among	  women	  who	  reported	  no	  previous	  sex:	  one	  study	  of	  130	  Swedish	  women	  aged	  10-­‐25	  years	  reported	  a	  prevalence	  of	  1.5%,	  and	  one	  longitudinal	  study	  of	  American	  women	  aged	  18-­‐20	  years	  reported	  that	  1.7%	  of	  specimens	  were	  found	  to	  have	  HPV	  DNA(7,9).	  	  A	  further	  three	  small	  studies	  in	  Sweden,	  Denmark	  and	  Australia	  found	  no	  HPV	  DNA	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in	  cervical	  or	  vaginal	  specimens	  from	  15,	  30	  and	  55	  women	  respectively,	  aged	  between	  13	  and	  41	  years,	  who	  reported	  no	  previous	  sex(12–14).	  	  Previous	  studies	  have	  confirmed	  vaginal	  sex	  as	  the	  predominant	  method	  for	  acquisition	  of	  cervical	  HPV	  infection	  in	  women,	  as	  demonstrated	  by	  rapid	  HPV	  acquisition	  after	  reported	  sexual	  debut,	  and	  a	  significant	  increase	  in	  the	  risk	  of	  HPV	  infection	  with	  increased	  number	  of	  partners	  and	  with	  high-­‐risk	  partners(13,15).	  Lack	  of	  disclosure	  of	  previous	  sex	  is,	  therefore,	  the	  most	  likely	  explanation	  for	  the	  relatively	  high	  HPV	  prevalence	  observed	  in	  our	  study.	  Previous	  research	  in	  adolescents	  in	  different	  world	  regions	  consistently	  illustrates	  under-­‐reporting	  of	  sexual	  behaviours(16,17)	  and	  studies	  conducted	  in	  the	  same	  geographical	  area	  of	  Tanzania	  as	  this	  study	  have	  demonstrated	  under-­‐reporting	  of	  sex	  in	  girls	  of	  similar	  ages,	  and	  in	  older,	  sexually-­‐active	  women(16,18).	  In	  young	  females	  in	  this	  region	  of	  Tanzania,	  in	  which	  the	  median	  age	  of	  reported	  sexual	  debut	  is	  16(19),	  potential	  consequences	  of	  disclosure	  of	  sex	  under	  the	  age	  of	  16	  include	  expulsion	  from	  school,	  physical	  punishment,	  and	  social	  exclusion(20).	  However,	  irrespective	  of	  reporting	  errors,	  finding	  HPV	  in	  specimens	  collected	  from	  girls	  who	  report	  no	  previous	  vaginal	  sex	  remains	  important.	  Vaccine	  efficacy	  is	  highest	  in	  those	  who	  have	  not	  previously	  been	  exposed	  to	  the	  vaccine-­‐related	  HPV	  genotypes,	  and	  age	  of	  vaccination	  is	  based	  on	  the	  assumption	  that	  girls	  are	  HPV	  negative	  prior	  to	  self-­‐reported	  sexual	  debut(21).	  Our	  data	  reinforce	  WHO	  recommendations	  that	  vaccination	  should	  be	  targeted	  at	  younger	  girls(10)	  and	  suggest	  that	  the	  vaccination	  target	  age	  should	  be	  several	  years	  before	  the	  median	  age	  of	  self-­‐reported	  sexual	  debut	  in	  the	  population.	  
Alternative	  explanations	  for	  the	  presence	  of	  vaginal	  HPV	  DNA	  in	  girls	  and	  women	  who	  report	  no	  previous	  sex	  include	  mother-­‐to-­‐child	  transmission	  (MTCT)	  of	  HPV,	  non-­‐penetrative	  sex	  practices,	  or	  transmission	  via	  fomites(22).	  MTCT	  is	  the	  primary	  mechanism	  for	  HPV	  acquisition	  in	  cases	  of	  respiratory	  papillomatosis	  in	  children.	  However,	  in	  well-­‐conducted	  prospective	  studies,	  MTCT	  of	  genital	  HPV	  types	  was	  infrequent	  and	  most	  often	  transient(23,24).	  Transmission	  through	  non-­‐penetrative	  sex	  practices	  such	  as	  hand-­‐genital	  or	  oro-­‐genital	  contact	  has	  been	  described	  in	  exclusively	  homosexual	  women	  in	  the	  USA	  who	  report	  never	  having	  had	  sex	  with	  a	  man	  (4/21	  women,	  19%)(25).	  However,	  only	  two	  participants	  in	  our	  sample	  reported	  these	  practices,	  and	  neither	  had	  detectable	  vaginal	  HPV	  DNA.	  	  In	  the	  age-­‐adjusted	  analysis	  in	  our	  study,	  disclosure	  of	  ever	  having	  practiced	  intravaginal	  cleansing	  was	  associated	  with	  more	  than	  doubled	  odds	  of	  prevalent	  HPV.	  Furthermore,	  a	  positive	  dose-­‐response	  relationship	  was	  seen	  with	  increasing	  frequency	  of	  vaginal	  cleansing.	  Commonly,	  women	  use	  intravaginal	  practices	  (IVP)	  to	  manage	  menstruation,	  as	  part	  of	  their	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sexual	  practice	  (altering	  vaginal	  lubrication	  or	  tightness),	  and	  to	  improve	  genital	  hygiene.	  IVP	  includes	  both	  cleansing	  inside	  the	  vagina	  with	  water,	  soap	  or	  other	  products,	  and	  the	  insertion	  of	  products	  into	  the	  vagina	  (e.g.	  pulverized	  herbs)(26).	  IVP	  is	  a	  common	  practice	  in	  many	  parts	  of	  sub-­‐Saharan	  Africa(27),	  and	  has	  been	  reported	  in	  96%	  of	  women	  working	  in	  bars	  and	  guesthouses	  in	  Tanzania(26).	  In	  that	  population,	  many	  women	  reported	  initiating	  IVP	  at	  the	  time	  of	  menarche	  or	  when	  they	  were	  given	  instruction	  about	  sex	  or	  marriage(28),	  and	  in	  our	  study,	  20.9%	  of	  girls	  reported	  intravaginal	  cleansing.	  IVP	  has	  been	  associated	  with	  increased	  risk	  of	  HIV	  acquisition	  in	  sex	  workers	  in	  Kenya,	  and	  with	  a	  doubled	  risk	  of	  acquisition	  of	  a	  new	  sexually	  transmitted	  infection	  (STI)	  in	  a	  prospective	  study	  of	  adolescent	  girls	  in	  the	  USA(29,30).	  With	  specific	  relevance	  to	  HPV,	  a	  cross-­‐sectional	  study	  of	  312	  adolescent	  girls	  in	  the	  USA	  found	  that	  vaginal	  cleansing	  in	  the	  past	  90	  days	  was	  associated	  with	  a	  doubling	  of	  the	  odds	  of	  cervical	  HPV	  infection(31).	  	  HPV	  has	  been	  detected	  in	  fingernail	  and	  fingertip	  specimens	  of	  young	  sexually	  active	  women	  in	  the	  USA,	  as	  well	  as	  on	  toilet	  seats	  in	  several	  European	  airports,	  and	  on	  surfaces	  in	  a	  sexual	  health	  clinic	  in	  the	  UK(32,33).	  HPV’s	  viability	  to	  cause	  infection	  of	  animal	  cells	  after	  desiccation	  has	  been	  demonstrated	  in	  a	  UK	  laboratory	  setting(34).	  In	  East	  Africa,	  HPV	  infection	  in	  women	  is	  highly	  prevalent(3,35,36)	  and	  therefore	  an	  adolescent	  girl	  who	  performs	  intravaginal	  cleansing	  may	  theoretically	  self-­‐infect	  with	  HPV	  either	  from	  her	  own	  external	  or	  extra-­‐genital	  sites,	  or	  from	  objects	  such	  as	  cloth,	  taps	  or	  water	  buckets	  contaminated	  from	  other	  household	  members.	  Acquisition	  of	  HPV	  from	  household	  members	  may	  be	  direct,	  via	  the	  insertion	  of	  shared	  cloths,	  or	  indirect	  via	  contaminated	  fingers.	  A	  similar	  explanation	  has	  been	  postulated	  for	  the	  presence	  of	  vaginal	  Trichomonas	  vaginalis	  in	  Zambian	  girls	  aged	  13-­‐16	  who	  reported	  no	  previous	  sexual	  contact(37).	  Intravaginal	  cleansing	  may	  additionally	  increase	  the	  risk	  of	  HPV	  infection	  through	  vaginal	  mucosal	  abrasions,	  allowing	  HPV	  to	  access	  target	  basal	  membrane	  cells,	  or	  through	  alteration	  of	  the	  vaginal	  microbiome,	  which	  has	  been	  associated	  with	  increased	  risk	  of	  other	  viral	  STIs	  including	  HIV(38).	  	  An	  important	  and	  likely	  explanation	  for	  the	  observed	  association	  between	  intravaginal	  cleansing	  and	  HPV	  is	  that	  intravaginal	  cleansing	  may	  be	  a	  marker	  of	  unreported	  sexual	  debut	  or	  non-­‐penetrative	  sex	  behaviours.	  Girls	  may	  be	  more	  likely	  to	  start	  vaginal	  cleansing	  after	  sexual	  debut	  because	  they	  believe	  that	  this	  may	  prevent	  pregnancy	  or	  STIs,	  relieve	  STI-­‐related	  symptoms,	  or	  because	  they	  have	  been	  taught	  that	  this	  practice	  is	  appropriate	  for	  sexually-­‐active	  women(27).	  Increased	  frequency	  of	  cleansing	  has	  been	  associated	  with	  higher	  number	  of	  sex	  acts	  and/or	  partners(26),	  as	  has	  HPV	  acquisition(7),	  which	  may	  explain	  the	  dose-­‐response	  relationship	  between	  intravaginal	  cleansing	  and	  HPV	  infection	  seen	  in	  our	  study.	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Multiple	  HPV-­‐genotype	  infections	  were	  as	  common	  as	  single	  genotype	  infections	  in	  this	  study,	  consistent	  with	  observations	  in	  adolescent	  girls	  in	  previous	  studies	  in	  the	  USA(31,39).	  More	  than	  half	  of	  the	  girls	  with	  HPV	  were	  found	  to	  have	  a	  high-­‐risk	  genotype,	  also	  consistent	  with	  the	  literature	  on	  sexually	  active	  adolescent	  girls	  or	  young	  women	  in	  Denmark,	  Canada	  and	  Tanzania(13,35,40).	  Of	  the	  40	  girls	  who	  had	  HPV,	  only	  6	  (15.0%)	  had	  one	  of	  the	  four	  HPV	  genotypes	  included	  the	  currently-­‐licensed	  vaccines,	  and	  only	  4	  (10.0%)	  had	  one	  or	  both	  of	  the	  two	  high-­‐risk	  genotypes	  in	  the	  vaccine.	  	  Major	  strengths	  of	  this	  study	  include	  the	  interview	  method,	  in	  which	  the	  questionnaire	  included	  local	  age-­‐specific	  colloquial	  terms	  for	  sexual	  practices,	  and	  was	  administered	  by	  trained	  nurses	  experienced	  in	  adolescent	  sexual	  behaviour	  research.	  In	  addition,	  vaginal	  swabs	  were	  self-­‐administered	  but	  collection	  was	  directly	  observed	  by	  nurses.	  Self-­‐administered	  vaginal	  swabs	  in	  a	  previous	  local	  study	  (median	  age	  17)	  demonstrated	  collection	  of	  epithelial	  cells	  in	  233/244(95%)	  of	  swabs	  (41),	  and	  99%	  of	  our	  specimens	  contained	  b-­‐globin,	  indicating	  successful	  sampling.	  Studies	  have	  shown	  a	  strong	  correlation	  for	  HPV	  detection	  between	  clinician-­‐collected	  and	  self-­‐administered	  vaginal	  swabs(42,43).	  Finally,	  the	  method	  used	  for	  HPV	  detection	  and	  genotyping,	  Roche	  Linear	  Array,	  has	  been	  proven	  in	  large	  studies	  to	  be	  highly	  sensitive(44,45).	  	  One	  of	  the	  limitations	  of	  this	  study	  is	  that	  the	  enrolment	  list	  came	  from	  primary	  schools.	  Although	  primary	  school	  attendance	  is	  a	  legal	  requirement	  in	  Tanzania,	  and	  has	  been	  reported	  as	  97%(46),	  it	  may	  be	  lower	  in	  rural	  populations	  and	  in	  upper	  primary	  school	  years	  (from	  which	  this	  sample	  was	  drawn),	  and	  may	  have	  affected	  the	  representativeness	  of	  the	  sample.	  Similarly,	  the	  refusal	  rate	  was	  22%,	  which	  may	  have	  also	  affected	  sample	  representativeness,	  and	  the	  small	  sample	  size	  resulted	  in	  limited	  statistical	  power	  to	  detect	  associations.	  During	  screening	  for	  study	  enrolment	  a	  higher	  than	  expected	  proportion	  (80.3%)	  reported	  no	  previous	  sex.	  This	  may	  reflect	  under-­‐reporting,	  and	  could	  relate	  to	  parental	  involvement	  in	  consent	  procedures.	  Biological	  markers	  would	  have	  allowed	  us	  to	  detect	  previous	  sex	  and	  mitigated	  some	  of	  the	  bias	  from	  relying	  on	  self-­‐report.	  Unfortunately,	  currently	  available	  markers	  in	  vaginal	  fluids	  (Y-­‐chromosome,	  semenogelin,	  prostate-­‐specific	  antigen)	  do	  not	  reliably	  detect	  previous	  sex	  which	  occurred	  over	  14	  days	  prior	  to	  sample	  collection(47).	  A	  serological	  marker	  of	  sexual	  exposure,	  such	  as	  herpes	  simplex	  virus	  type-­‐2(HSV-­‐2)	  antibody(48)	  was	  not	  measured	  because	  of	  	  budget	  constraints,	  concerns	  that	  drawing	  a	  blood	  sample	  may	  have	  increased	  refusal	  rate,	  and	  because	  HSV-­‐2	  is	  not	  a	  gold	  standard	  for	  the	  detection	  of	  sexual	  debut(49).	  	  Finally,	  self-­‐administered	  vaginal	  swabs	  were	  collected	  rather	  than	  physician-­‐collected	  endo-­‐cervical	  specimens.	  The	  HPV	  genotypes	  detected	  therefore	  may	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not	  reflect	  cervical	  HPV	  genotypes(50).	  However	  it	  has	  been	  argued	  that	  vulvo-­‐vaginal	  HPV	  infections	  may	  ascend	  to	  the	  cervix(7).	  The	  proposed	  HPV	  vaccination	  programme	  in	  Tanzania	  will	  target	  girls	  in	  primary	  school	  class	  4,	  where	  the	  median	  age	  is	  10	  years,	  and	  a	  catch-­‐up	  campaign	  in	  older	  girls	  has	  not	  thus-­‐far	  been	  proposed.	  This	  study	  provides	  useful	  evidence	  for	  policy	  makers	  in	  relation	  to	  the	  likely	  effectiveness	  of	  such	  a	  campaign.	  Overall,	  80.3%	  of	  15-­‐16	  year	  old	  girls	  reported	  no	  previous	  sex,	  99.2%	  of	  whom	  did	  not	  have	  infection	  with	  either	  of	  the	  two	  high-­‐risk	  HPV	  genotypes	  included	  in	  current	  HPV	  vaccines	  (HPV-­‐16/18).	  	  The	  WHO	  recommend	  including	  older	  girls	  in	  catch-­‐up	  campaigns	  if	  a	  significant	  proportion	  of	  girls	  are	  naïve	  to	  HPV	  vaccine	  types(10):	  our	  findings	  suggest	  that	  such	  a	  campaign	  in	  older	  girls	  may	  be	  efficacious	  in	  preventing	  infection	  with	  these	  HPV	  types.	  	  The	  data	  we	  present	  strongly	  link	  prevalent	  HPV	  infection	  with	  reported	  intravaginal	  cleansing.	  Intravaginal	  cleansing	  may	  be	  a	  marker	  for	  undisclosed	  sexual	  activity	  in	  our	  population	  but	  could	  alternatively	  be	  a	  novel	  mechanism	  for	  the	  non-­‐sexual	  transmission	  of	  HPV.	  If	  this	  is	  the	  case,	  the	  identification	  of	  this	  potentially	  modifiable	  risk	  factor	  would	  be	  highly	  relevant	  for	  a	  country	  with	  one	  of	  the	  highest	  rates	  of	  cervical	  cancer	  in	  the	  world.	  Further	  research	  to	  confirm	  and	  understand	  the	  link	  between	  intravaginal	  cleansing	  and	  HPV	  is	  required	  and	  is	  currently	  underway	  in	  Mwanza.	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Table	  3:1	  Analysis	  of	  factors	  associated	  with	  detection	  of	  HPV	  in	  adolescent	  girls	  who	  reported	  never	  having	  had	  sex	  (n=474)	  
Characteristic	   No.	  (%)	   HPV-­‐positive	  No.	  (%)	   Age-­‐adjusted	  analysis	   Multivariable	  analysis	  OR	  (95%	  CI)	  a	   p	  b	   aOR	  (95%	  CI)	  c	   p	  b	  Overall	  	   	  	   474	   40	  (8.4)	   	  	   	  	   	  	   	  	  Socio-­‐demographic	  Age	  (years)	   15	   225	  (47.5)	   14	  (6.2)	   1	   0.10	   1	   0.10	  	  	   16	   249	  (52.5)	   26	  (10.4)	   1.76	  (0.89-­‐3.47)	   	   1.74	  (0.88-­‐3.43)	   	  Current	  residence	   Urban	   233	  (49.2)	   16	  (6.9)	   1	   	  0.13	   1	   	  0.29	  Rural	   241	  (50.8)	   24	  (10.0)	   1.47	  (0.76-­‐2.84)	   	   1.43	  (0.74-­‐2.79)	   	  Lives	  with	   One	  or	  both	  parents	   359	  (75.7)	   31	  (8.6)	   1	   	  0.23	   1	   0.63	  	   Other	  relatives	  or	  friends	   115	  (24.3)	   9	  (7.8)	   0.84	  (0.39-­‐1.84)	   	   0.83	  (0.38-­‐1.81)	   	  	  	   Husband	   0	   	  	   -­‐	   	  	   	  	   	  	  Composite	  measure	  of	  household	  wealth	   High	   113	  (23.8)	   11	  (8.3)	   1	   0.40	   1	   0.91	  Medium	   228	  (48.1)	   18	  (7.9)	   0.84	  (0.38-­‐1.85)	   	   0.78	  (0.35-­‐1.73)	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Low	   133	  (28.1)	   11	  (9.7)	   0.91	  (0.37-­‐2.19)	   0.87	  (0.36-­‐2.11)	  Current	  occupation	   Schooling	  or	  vocational	  training	   329	  (50.4)	   25	  (7.6)	   1	   	  0.15	   1	   	  0.33	  Working	   6	  (0.8)	   0	   -­‐	   	   -­‐	   	  	  	   	  Not	  working,	  not	  schooling	   139	  (29.3)	   15	  (10.8)	   1.44	  (0.73-­‐2.82)	   	   1.40	  (0.71-­‐2.77)	   	  Religion	   Christian	   417	  (88.0)	   35	  (8.4)	   1	   	  0.21	   1	   	  0.30	  	   Muslim	   43	  (9.1)	   3	  (7.0)	   0.85	  (0.25-­‐2.88)	   	   0.76	  (0.22-­‐2.63)	   	  	   Other	  religion	   8	  (1.7)	   2	  (25.0)	   3.28	  (0.63-­‐17.06)	   	   4.15	  (0.79-­‐21.96)	   	  	  	  	   None	   6	  (1.3)	   0	   -­‐	   	  	   -­‐	   	  	  Alcohol,	  drugs	  or	  cigarettes	  (ever)	   No	   473	  (99.8)	   40	  (8.5)	   -­‐	   	   -­‐	   	  Yes	   1	  (0.2)	   0	   	   	   	   	  Sexual	  Behaviour	  	  Kissed,	  ever	   No	   463	  (97.5)	   40	  (8.6)	   -­‐	   -­‐	   -­‐	   -­‐	  	  	   Yes	   11	  (2.3)	   0	   	  	   	  	   	  	   	  	  Breast	  touching,	  ever	   No	   440	  (92.8)	   38	  (8.6)	   1	   0.53	   1	   0.63	  	   Yes	   34	  (7.2)	   2	  (5.9)	   0.62	  (0.11-­‐2.72)	   	   0.71	  (0.16-­‐3.10)	   	  Hand-­‐genital	  contact	  with	  a	  boy,	  ever	   No	   472	  (99.6)	   40	  (8.5)	   -­‐	   -­‐	   -­‐	   -­‐	  Yes	   2	  (0.4)	   0	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  a	  ORs	  adjusted	  for	  age	  as	  a-­‐priori	  confounder.	  	  	  b	  p-­‐value	  from	  likelihood	  ratio	  (LR)	  test.	  	  	  c	  ORs	  adjusted	  for	  age	  and	  ever	  cleansed.	  d	  Of	  those	  passed	  menarche	  	  	  	  	  
Oral	  sex,	  ever	   No	   474	  (100)	   40	  (8.4)	   -­‐	   -­‐	   -­‐	   -­‐	  	   Yes	   0	   0	   	   	   	   	  Menstruation	  Passed	  menarche	   No	   98	  (20.7)	   7	  (7.1)	   1	   0.24	   1	   0.84	  	  	   Yes	   376	  (79.3)	   33	  (8.8)	   1.73	  (0.88-­‐3.43)	   	   1.09	  (0.46-­‐2.58)	   	  Sanitary	  item	  used	  during	  menstruation	  d	   Cloth	  or	  paper	   171	  (36.1)	   11	  (6.4)	   1	   0.33	   1	   0.34	  Underwear	   77	  (16.2)	   8	  (10.4)	   1.67	  (0.64-­‐4.33)	   	   1.69	  (0.65-­‐4.41)	   	  	   Sanitary	  napkin	   128	  (27.0)	   14	  (11.0)	   1.90	  (0.83-­‐4.84)	   	   1.78	  (0.77-­‐4.13)	   	  Intra-­‐vaginal	  practices	   	  Ever	  cleansed	   No	   375	  (79.1)	   26	  (6.9)	   1	   0.03	   1	   0.03	  	  	   Yes	   99	  (20.9)	   14	  (14.1)	   2.19	  (1.09-­‐4.39)	   	   2.19	  (1.09-­‐4.39)	   	  Ever	  inserted	   No	   473	  (99.8)	   40	  (8.5)	   -­‐	   -­‐	   -­‐	   -­‐	  	   Yes	   1	  (0.2)	   0	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Figure	  3:1	  Flow	  diagram	  of	  cohort	  enrolment	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Table	  3:2.	  Intravaginal	  cleansing	  and	  HPV	  prevalence	  
Characteristic	   No.	  (%)	   HPV	  positive	  No.	  (%)	   aOR	  (95%	  CI)b	   pa	  
	   	  	   	  	   	  	   	  	   	  	  Frequency	  of	  cleansing	   Never	   375	  (79.1)	   26	  (6.9)	   1	   0.01	  	   ≤2	  per	  day	   61	  (12.9)	   5	  (8.3)	   1.21	  (0.44-­‐3.28)	   p	  trend	  =0.002	  	  	   ≥3	  per	  day	   38	  (8.0)	   9	  (23.7)	   4.03	  (1.72-­‐9.45)	   	  Cleansed	  with	  	   Water	   46	  (46.5)	   5	  (10.9)	   1	   0.39	  	  	   Soap	  +	  water	   53	  (53.5)	   9	  (17.0)	   1.67	  (0.51-­‐5.39)	   	  Cleansed	  using	   Fingers	   78	  (78.8)	   13	  (16.7)	   1	   0.13	  	   Cloth	   21	  (21.2)	   1	  (4.7)	   	  0.25	  (0.03-­‐2.04)	   	  
	  	  	  	  a	  	  p-­‐value	  from	  likelihood	  ratio	  (LR)	  test.	  	  b	  adjusted	  for	  age	  as	  a-­‐priori	  confounder.	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Figure	  3:2.	  HPV	  genotypes	  detected	  in	  girls	  reporting	  never	  having	  had	  sex	  (n=474)	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4.1 Preamble	  This	  manuscript	  describes	  the	  genotype-­‐specific	  and	  overall;	  rate,	  duration	  and	  clearance	  of	  HPV	  infection	  in	  girls	  before	  reported	  sexual	  debut,	  and	  factors	  associated	  with	  the	  rate	  of	  HPV	  before	  sexual	  debut.	  These	  address	  part	  of	  objectives	  2	  and	  3	  which	  are:	  
• Identify	  the	  rate	  of	  HPV	  infection,	  clearance	  of	  genotype-­‐specific	  HPV,	  the	  duration	  of	  infection	  after	  initiation	  of	  sexual	  activity,	  and	  the	  rate	  of	  infection	  in	  those	  who	  do	  not	  report	  initiation	  of	  sexual	  activity.	  
• Evaluate	  sexual	  behaviour,	  vaginal	  practice	  and	  demographic	  factors	  associated	  with	  the	  incidence	  of	  genotype-­‐specific	  HPV	  infection	  in	  those	  who	  report	  and	  do	  not	  report	  the	  initiation	  of	  sexual	  activity.	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Abstract:	  
Purpose:	  Acquisition	  of	  human	  papillomavirus	  (HPV)	  in	  women	  occurs	  predominantly	  through	  vaginal	  sex.	  However,	  HPV	  has	  been	  detected	  in	  girls	  who	  report	  no	  previous	  sex.	  We	  aimed	  to	  determine	  incidence	  and	  risk	  factors	  for	  HPV	  acquisition	  in	  girls	  who	  report	  no	  previous	  sex	  in	  Tanzania,	  a	  country	  with	  high	  HPV	  prevalence	  and	  cervical	  cancer	  incidence.	  	  
Methods	  We	  followed	  503	  adolescent	  girls	  aged	  15-­‐16	  years	  in	  Mwanza,	  Tanzania	  with	  face-­‐to-­‐face	  interviews	  and	  self-­‐administered	  vaginal	  swabs	  every	  3	  months	  for	  18	  months;	  397	  girls	  reported	  no	  sex	  before	  enrolment	  or	  during	  follow-­‐up,	  of	  whom	  120	  were	  randomly	  selected.	  Samples	  from	  enrolment,	  6,	  12	  and	  18-­‐month	  visits	  were	  tested	  for	  37	  HPV	  genotypes.	  Incidence,	  clearance,	  point	  prevalence	  and	  duration	  of	  any	  HPV	  and	  genotype-­‐specific	  infections	  were	  calculated	  and	  associated	  factors	  evaluated.	  	  
Results	  Of	  120	  girls	  who	  reported	  no	  previous	  sex,	  119	  were	  included,	  contributing	  438	  samples.	  HPV	  was	  detected	  in	  51(11.6%)	  samples.	  The	  overall	  incidence	  of	  new	  HPV	  infections	  was	  29.4/100	  person	  years(pys)(95%CI:15.9-­‐54.2).	  The	  point	  prevalence	  of	  vaccine	  types	  HPV6,-­‐11,-­‐16	  and	  -­‐18	  was	  0.9%,	  0.9%,	  2.0%	  and	  0%,	  respectively.	  Spending	  a	  night	  away	  from	  home	  and	  using	  the	  internet	  were	  associated	  with	  incident	  HPV,	  and	  reporting	  having	  seen	  a	  pornographic	  movie	  was	  inversely	  associated	  with	  HPV	  incidence.	  	  
	  
Conclusion	  Incident	  HPV	  infections	  were	  detected	  frequently	  in	  adolescent	  girls	  who	  reported	  no	  previous	  sex	  over	  18	  months.	  This	  is	  likely	  to	  reflect	  under-­‐reporting	  of	  sex.	  A	  low	  point	  prevalence	  of	  HPV	  genotypes	  in	  licensed	  vaccines	  was	  seen,	  indicating	  that	  vaccination	  of	  these	  girls	  might	  still	  be	  effective.	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Introduction	  	  
	  Human	  papillomavirus	  (HPV)	  infects	  the	  mucosal	  surfaces	  of	  the	  female	  and	  male	  ano-­‐genital	  tract[1].	  The	  predominant	  mechanism	  of	  HPV	  acquisition	  in	  women	  is	  thought	  to	  be	  through	  penetrative	  vaginal	  sex.	  Historically,	  HPV	  has	  only	  detected	  in	  a	  small	  proportion	  of	  girls	  and	  women	  who	  report	  no	  previous	  sex[2,3],	  and	  HPV	  incidence	  and	  prevalence	  have	  been	  shown	  to	  increase	  rapidly	  in	  women	  after	  reported	  first	  sex[4].	  Risk	  factors	  for	  incident	  HPV	  infection,	  identified	  in	  longitudinal	  data,	  include	  having	  a	  higher	  number	  of	  sex	  partners[5,6].	  In	  addition,	  HPV	  genotypes	  have	  been	  shown	  to	  be	  concordant	  between	  couples	  in	  sexual	  relationships[7].	  High-­‐risk	  (HR)	  or	  oncogenic	  HPV	  genotypes	  have	  been	  associated	  with	  cervical	  cancer[8,9].	  Vaccination	  against	  these	  HR	  HPV	  genotypes	  is	  recommended	  before	  first	  sex	  since	  the	  vaccine	  offers	  less	  protection	  once	  an	  HPV	  genotype	  has	  been	  acquired[10].	  	  	  	  Tanzania	  has	  one	  of	  the	  highest	  rates	  of	  cervical	  cancer	  in	  the	  world	  and,	  to	  date,	  no	  national	  HPV	  vaccination	  programme[11]	  although	  the	  country	  is	  conducting	  a	  GAVI	  supported	  HPV	  vaccine	  demonstration	  project.	  In	  a	  previous	  cross-­‐sectional	  analysis	  at	  enrolment	  of	  a	  cohort	  of	  adolescent	  girls	  in	  Tanzania,	  we	  identified	  a	  high	  prevalence	  (8.4%)	  of	  HPV	  in	  girls	  who	  reported	  no	  previous	  sex[12].	  HPV	  detection	  was	  associated	  with	  reporting	  having	  cleaned	  inside	  the	  vagina,	  which	  may	  have	  been	  a	  marker	  for	  undisclosed	  sexual	  activity[13].	  To	  further	  investigate	  the	  detection	  of	  vaginal	  HPV	  in	  girls	  who	  stated	  that	  they	  had	  not	  passed	  sexual	  debut,	  we	  present	  results	  from	  longitudinal	  follow-­‐up	  of	  these	  girls	  in	  Mwanza,	  Tanzania.	  This	  study	  is	  the	  first	  to	  report	  the	  incidence	  of	  HPV	  in	  girls	  who	  report	  no	  previous	  sex	  in	  sub-­‐Saharan	  Africa	  (SSA).	  	  
Methods	  	  	  	  Study	  procedures	  The	  cohort	  was	  enrolled	  between	  January	  and	  August	  2012,	  as	  described	  previously[12].	  Briefly,	  we	  enrolled	  eligible	  girls	  attending	  government	  primary	  schools	  in	  three	  districts	  in	  the	  Mwanza	  region	  of	  Tanzania	  that	  had	  been	  randomly	  selected	  in	  preparation	  for	  an	  HPV	  vaccine	  trial[14].	  Eligibility	  criteria	  included	  having	  been	  in	  class	  6	  in	  2010	  in	  one	  of	  the	  non-­‐vaccine	  schools,	  reporting	  never	  having	  previously	  had	  sex,	  being	  willing	  to	  undergo	  study	  procedures,	  able	  to	  attend	  appointments,	  and	  being	  15	  or	  16	  years	  old	  at	  the	  time	  of	  enrolment.	  	  During	  the	  study,	  samples	  were	  collected	  every	  3	  months	  for	  18	  months	  as	  described	  previously[12].	  	  At	  enrolment	  and	  each	  follow-­‐up	  visit,	  girls	  underwent	  a	  face-­‐to-­‐face	  interview	  in	  Swahili	  using	  a	  structured	  questionnaire,	  which	  included	  questions	  on	  sexual	  behaviour	  and	  intravaginal	  practices.	  Girls	  were	  additionally	  asked	  to	  provide	  one	  self-­‐administered	  vaginal	  swab	  under	  the	  supervision	  of	  a	  trained	  research	  nurse.	  	  In	  this	  paper,	  we	  present	  data	  from	  a	  randomly	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selected	  sub-­‐group	  of	  girls	  who	  reported	  never	  having	  had	  sex	  before	  the	  study	  or	  during	  study	  follow-­‐up.	  	  Ethical	  Considerations	  Permissions	  The	  study	  protocol	  was	  approved	  by	  the	  Medical	  Research	  Coordinating	  Committee,	  Tanzania	  (Ref:	  NIMR/HQ/R.8a/Vol.	  IX/1249),	  and	  the	  London	  School	  of	  Hygiene	  and	  Tropical	  Medicine	  Ethics	  Committee	  (Ref:	  6040).	  Since	  participants	  were	  under	  the	  age	  of	  legal	  consent,	  written	  informed	  consent	  was	  required	  from	  a	  parent/guardian	  before	  written	  assent	  was	  requested	  from	  the	  participant.	  Girls	  with	  persistent	  HR	  HPV	  at	  study	  completion	  (defined	  as	  the	  same	  HR	  HPV	  genotype	  detected	  at	  two	  consecutive	  6-­‐month	  visits)	  were	  referred	  for	  follow-­‐up	  with	  the	  national	  cervical	  screening	  programme.	  	  HPV	  detection	  and	  genotyping	  Dry	  vaginal	  swabs	  were	  stored	  in	  cryotubes	  immediately	  after	  collection	  and	  transported	  in	  cold-­‐boxes	  with	  ice-­‐packs	  before	  submission	  to	  the	  Mwanza	  Intervention	  Trials	  Unit	  Laboratory	  in	  Mwanza,	  where	  they	  were	  stored	  at	  -­‐20oC	  until	  they	  were	  shipped	  to	  the	  Catalan	  Institute	  of	  Oncology	  in	  Barcelona.	  Samples	  from	  enrolment,	  month-­‐6,	  month-­‐12	  and	  month-­‐18	  visits	  for	  girls	  included	  in	  this	  sub-­‐study	  were	  tested	  using	  the	  Linear	  Array	  HPV	  genotyping	  assay	  (Roche,	  California,	  USA)	  which	  detects	  13	  HR	  and	  24	  LR	  genotypes[15].	  We	  considered	  HPV	  genotypes	  categorised	  by	  the	  International	  Agency	  for	  Research	  on	  Cancer	  (IARC)	  as	  associated	  with	  cancer	  (group	  I)	  and	  probably	  associated	  with	  cancer	  (group	  IIa)	  as	  HR	  HPV	  genotypes[16].	  All	  other	  genotypes	  (group	  IIb:	  possibly	  associated	  with	  cancer,	  and	  III,	  not	  associated	  with	  cancer)	  were	  considered	  LR	  types.	  Samples	  negative	  for	  β-­‐globin	  were	  classified	  as	  inadequate	  samples	  for	  HPV	  genotyping.	  	  	  Data	  management	  and	  statistical	  methods	  	  Data	  were	  double-­‐entered	  into	  OpenClinica	  LLC	  (Akaza	  Research,	  Waltham,	  MA,	  USA)	  and	  analysis	  performed	  using	  STATA	  V10.3	  (Statacorp	  LP,	  College	  Station,	  Texas,	  USA.	  	  	  	  	  	  	  	  Reported	  sexual	  behaviours	  at	  enrolment	  and	  over	  follow-­‐up	  were	  tabulated	  in	  all	  girls	  who	  reported	  not	  having	  had	  sex,	  and	  in	  those	  girls	  whose	  samples	  were	  tested	  for	  the	  current	  study.	  Genotype-­‐specific	  incidence	  was	  calculated	  using	  person-­‐time	  at	  risk	  from	  the	  date	  of	  enrolment.	  	  A	  new	  (i.e.	  incident)	  infection	  was	  defined	  as	  a	  first	  positive	  test	  for	  the	  specific	  HPV	  type	  among	  those	  not	  infected	  with	  that	  genotype	  at	  enrolment.	  Where	  there	  were	  missed	  visits	  or	  missing	  HPV	  results	  leading	  to	  a	  gap	  in	  the	  observations,	  girls	  were	  censored	  at	  the	  last	  available	  result	  before	  the	  gap.	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  The	  duration	  of	  infection	  was	  calculated	  using	  person-­‐time	  from	  the	  date	  of	  infection	  to	  the	  date	  of	  clearance,	  assumed	  midway	  between	  the	  last	  positive	  and	  first	  negative	  sample	  for	  that	  genotype.	  	  Clearance	  of	  a	  genotype-­‐specific	  infection	  was	  defined	  as	  a	  single	  negative	  sample	  for	  that	  genotype.	  	  Infections	  that	  were	  not	  cleared	  were	  censored	  at	  the	  date	  of	  the	  last	  positive	  sample.	  	  If	  there	  were	  two	  positive	  samples	  with	  one	  intervening	  missing	  sample	  (e.g.	  positive	  at	  month-­‐6	  and	  month-­‐18,	  but	  with	  a	  missing	  sample	  at	  month-­‐12),	  duration	  was	  considered	  unknown	  and	  censored	  at	  the	  date	  of	  the	  first	  positive	  sample.	  	  The	  overall	  incidence	  of	  all	  HPV	  infections	  (Tables	  2	  &	  3)	  was	  calculated	  as	  the	  number	  of	  new	  infections	  (allowing	  multiple	  events	  at	  each	  time	  point)	  over	  person-­‐years	  at	  risk,	  and	  girls	  were	  assumed	  continuously	  at	  risk.	  Gaps	  (explained	  above)	  where	  a	  visit	  was	  missed	  were	  removed,	  but	  girls	  were	  assumed	  at	  risk	  again	  after	  a	  gap.	  The	  overall	  incidence	  rate	  was	  estimated	  using	  Poisson	  regression	  with	  random	  effects	  to	  account	  for	  clustering	  of	  infections	  within	  the	  same	  girl.	  The	  HPV	  genotype-­‐specific	  point	  prevalence	  was	  estimated	  as	  the	  number	  of	  visits	  where	  the	  genotype	  was	  detected,	  divided	  by	  the	  total	  number	  of	  visits,	  including	  the	  enrolment	  visit	  	  Poisson	  regression	  with	  random	  effects	  was	  used	  to	  estimate	  rate	  ratios	  for	  factors	  associated	  with	  HPV	  incidence.	  A	  conceptual	  framework	  was	  used	  to	  examine	  risk	  factors,	  and	  age	  was	  considered	  an	  a	  priori	  confounder	  and	  included	  in	  all	  models.	  Socio-­‐economic	  status	  was	  determined	  by	  an	  asset	  index	  which	  was	  created	  by	  combining	  data	  collected	  at	  enrolment	  from	  the	  entire	  cohort	  (i.e.	  including	  those	  who	  did	  and	  did	  not	  report	  sex	  during	  the	  study)	  using	  principal	  components	  analysis.	  	  
Results	  A	  total	  of	  1,555	  listed	  school	  attendees	  were	  potentially	  eligible	  based	  on	  age	  criteria	  (Figure	  4.1).	  Of	  those,	  1,177	  (75.7%)	  were	  located,	  and	  503	  met	  eligibility	  criteria	  and	  were	  enrolled,	  481	  (95.4%)	  of	  whom	  reported	  never	  having	  had	  sex.	  Of	  those,	  397	  (82.5%)	  reported	  never	  having	  had	  sex	  during	  the	  study,	  and	  at	  the	  final	  study	  visit	  confirmed	  that	  they	  had	  never	  had	  sex.	  We	  randomly	  selected	  120	  (30.2%)	  of	  these	  girls.	  One	  girl	  spontaneously	  reported	  that	  she	  had	  been	  HIV-­‐positive	  from	  birth	  (girls	  were	  not	  explicitly	  asked	  this)	  and	  was	  excluded	  from	  the	  analysis.	  Table	  4.1	  summarises	  reported	  sexual	  behaviour,	  cigarette	  smoking,	  alcohol	  consumption	  and	  drug	  use	  in	  all	  396	  girls	  in	  the	  cohort	  who	  reported	  no	  previous	  sex,	  and	  in	  the	  randomly	  selected	  119	  girls,	  who	  did	  not	  report	  being	  HIV-­‐positive.	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At	  enrolment,	  61	  of	  the	  119	  (51.3%)	  girls	  were	  aged	  16	  years,	  and	  the	  remainder	  were	  aged	  15	  years.	  Approximately	  half	  (52.9%)	  lived	  in	  urban	  areas,	  92.4%	  were	  Christian,	  79.0%	  were	  in	  school,	  and	  19.3%	  were	  neither	  working	  nor	  in	  school.	  The	  final	  visit	  of	  the	  study	  (18	  months)	  was	  attended	  by	  90.8%	  of	  girls.	  At	  this	  visit,	  girls	  were	  asked	  if	  they	  were	  circumcised	  (i.e.	  had	  experienced	  genital	  cutting),	  and	  of	  the	  108	  girls	  who	  were	  asked,	  none	  reported	  this.	  	  Girls	  contributed	  438	  valid	  specimens.	  	  	  Overall,	  10	  of	  the	  119	  girls	  (8.5%)	  who	  never	  reported	  having	  had	  sex	  had	  HPV	  detected	  at	  enrolment.	  The	  119	  girls	  contributed	  a	  total	  of	  152.8	  person-­‐years(pys)	  of	  follow-­‐up,	  during	  which	  44	  new	  HPV	  infections	  were	  detected.	  The	  overall	  incidence	  of	  new	  HPV	  infections	  in	  girls	  who	  reported	  never	  having	  had	  sex	  was	  29.4	  per	  100pys	  (95%	  Confidence	  Interval	  (CI):15.9-­‐54.2),	  and	  for	  new	  HR	  HPV	  infections	  was	  11.3/100pys	  (95%CI:5.8-­‐22.1)	  (Table	  4.3).	  Infection	  with	  at	  least	  one	  HPV	  genotype	  was	  detected	  at	  11.6%	  of	  visits,	  and	  infection	  with	  at	  least	  one	  HR	  HPV	  genotype	  was	  detected	  at	  6.6%	  of	  visits.	  	  	  	  	  	  	  The	  HPV	  genotype	  with	  the	  highest	  incidence	  was	  HPV66	  (2.7/100pys),	  followed	  by	  HPV59	  (2.6/100pys),	  and	  HPV16,-­‐51,-­‐52	  and	  -­‐6	  (2.0/100pys	  for	  each)	  (Table	  4.1).	  The	  genotypes	  with	  the	  highest	  point	  prevalence	  were	  HPV16	  (2.1%),	  HPV42	  (1.8%),	  HPV61	  (1.6%)	  (Figure	  4.2).	  	  	  The	  mean	  duration	  of	  any	  new	  HPV	  infection	  was	  7.0	  months;	  8.1	  for	  any	  HR	  HPV	  infection,	  and	  6.6	  for	  any	  LR	  infection	  (Table	  4.2).	  The	  rate	  of	  clearance	  of	  LR	  HPV	  infections	  was	  more	  than	  three	  times	  that	  of	  HR	  HPV	  infections	  (103.3	  versus	  28.8/100pys).	  	  In	  the	  unadjusted	  analysis,	  there	  was	  some	  evidence	  of	  an	  association	  between	  new	  HPV	  infections	  and	  living	  in	  an	  urban	  compared	  to	  a	  rural	  area,	  having	  spent	  a	  night	  away	  from	  home	  in	  the	  last	  6	  months	  and	  having	  cleansed	  inside	  the	  vagina	  in	  the	  last	  6	  months	  (Table	  4.4).	  In	  the	  adjusted	  analysis,	  there	  was	  strong	  evidence	  that	  having	  spent	  a	  night	  away	  from	  home	  in	  the	  last	  6	  months	  (adjusted	  risk	  ratio	  (aRR)	  5.47	  (95%CI:1.72-­‐17.4.),	  or	  having	  used	  the	  internet	  (aRR	  3.90	  (95%CI:1.05-­‐14.50)	  were	  associated	  with	  new	  HPV	  infection.	  There	  was	  some	  evidence	  that	  having	  watched	  a	  pornographic	  movie	  was	  associated	  with	  a	  lower	  risk	  of	  HPV	  acquisition	  (aRR	  0.18	  (95%CI:0.03-­‐1.03)).	  There	  was	  weak	  evidence	  that	  having	  cleansed	  inside	  the	  vagina	  with	  soap	  in	  the	  past	  6	  months,	  compared	  to	  not	  having	  cleansed	  inside	  the	  vagina	  in	  the	  last	  6	  months	  was	  associated	  with	  a	  new	  HPV	  infection	  (aRR	  2.64	  (95%CI:0.75-­‐9.31)).	  	  
Discussion	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  We	  followed	  a	  cohort	  of	  119	  adolescent	  girls	  who	  reported	  never	  having	  sex	  for	  18	  months	  in	  Tanzania,	  a	  country	  with	  a	  high	  HPV	  prevalence	  and	  the	  world’s	  highest	  cervical	  cancer	  incidence.	  We	  found	  that	  11%	  of	  the	  samples	  provided	  during	  this	  period	  showed	  evidence	  of	  vaginal	  HPV	  infection,	  which	  likely	  reflects	  under-­‐reporting	  of	  sex	  or,	  less	  likely,	  acquisition	  of	  HPV	  through	  non-­‐penetrative	  sex	  or	  vaginal	  cleansing.	  Studies	  have	  compared	  self-­‐reporting	  of	  sex	  with	  biomarkers	  of	  recent	  sex[17],	  compared	  different	  methods	  of	  interview[18,19],	  or	  carried	  out	  repeat	  surveys[20]	  in	  East	  Africa,	  and	  have	  shown	  that	  under-­‐reporting	  of	  sex	  is	  common.	  	  	  A	  number	  of	  cross-­‐sectional	  studies	  have	  found	  that	  cervical	  or	  vaginal	  HPV	  was	  detected	  in	  0-­‐1.5%	  of	  self-­‐reported	  virgins	  in	  Europe,	  Australia	  and	  USA[2,3,21,22].	  Longitudinal	  studies,	  which	  sampled	  girls	  who	  consistently	  reported	  no	  previous	  sex	  at	  multiple	  time	  points	  during	  follow-­‐up,	  have	  detected	  higher	  rates	  of	  HPV.	  One	  study	  in	  girls	  in	  the	  USA	  with	  a	  median	  age	  of	  19	  years	  detected	  HPV	  in	  7.8%	  of	  girls	  who	  were	  followed	  for	  24	  months	  and	  consistently	  reported	  that	  they	  had	  never	  had	  sex[4].	  Another	  study	  in	  the	  USA	  followed	  14-­‐17	  year	  old	  girls	  every	  3	  months	  for	  a	  median	  of	  5.2	  years,	  and	  found	  HPV	  in	  10	  of	  22	  (45.5%)	  who	  reported	  never	  having	  had	  sex[23].	  	  Both	  of	  these	  studies	  identified	  an	  association	  between	  non-­‐penetrative	  sexual	  behaviours	  and	  HPV	  detection	  in	  girls.	  Non-­‐penetrative	  sex	  practices	  including	  hand-­‐genital	  contact	  and	  oral-­‐genital	  sex	  have	  been	  identified	  as	  risk	  factors	  for	  HPV	  acquisition	  in	  heterosexual	  women[4,24],	  and	  in	  homosexual	  women	  who	  report	  never	  having	  had	  penile-­‐vaginal	  sex[25].	  In	  our	  study	  population,	  oral-­‐genital	  sex	  is	  infrequently	  reported	  in	  adolescents[26,27];	  oral-­‐genital	  sex	  was	  not	  reported	  by	  any	  of	  our	  participants	  and	  hand-­‐genital	  contact	  was	  only	  reported	  by	  2	  participants.	  	  	  Use	  of	  smart	  phones	  and	  access	  to	  the	  internet	  is	  increasing	  in	  Tanzania	  [28],	  and	  increasing	  access	  to	  pornography	  may	  influence	  sexual	  attitudes	  and	  behaviours[29].	  New	  HPV	  infection	  was	  associated	  with	  reporting	  having	  accessed	  the	  internet,	  but	  inversely	  associated	  with	  reporting	  having	  seen	  a	  pornographic	  movie.	  	  Reasons	  for	  the	  latter	  observation	  are	  unclear	  and	  this	  may	  be	  a	  chance	  finding.	  It	  may	  be	  possible	  that	  having	  seen	  a	  pornographic	  movie	  is	  associated	  with	  risky	  sex	  (i.e.	  without	  a	  condom),	  but	  is	  under-­‐reported	  by	  those	  at	  increased	  risk.	  Reporting	  not	  having	  seen	  pornography	  may	  therefore	  be	  a	  marker	  for	  risky	  sex	  and	  consequently	  HPV	  risk.	  	  	  	  	  	  Intravaginal	  cleansing	  was	  associated	  with	  prevalent	  HPV	  in	  girls	  who	  reported	  never	  having	  had	  sex	  at	  the	  time	  of	  enrolment	  into	  our	  cohort[12].	  We	  have	  suggested	  that	  intravaginal	  cleansing	  was	  most	  likely	  to	  have	  been	  a	  marker	  for	  un-­‐reported	  sex,	  but	  additionally	  commented	  that	  the	  practice	  of	  intravaginal	  cleansing,	  which	  involves	  inserting	  fingers	  or	  a	  cloth	  inside	  the	  vagina,	  may	  introduce	  HPV	  from	  external	  genitalia	  or	  fomites.	  In	  this	  current	  study,	  there	  was	  no	  strong	  evidence	  that	  recent	  intravaginal	  cleansing	  was	  associated	  with	  new	  HPV	  infection	  during	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longitudinal	  follow-­‐up,	  but	  there	  was	  weak	  evidence	  of	  an	  association	  with	  reported	  cleansing	  with	  soap	  compared	  to	  not	  cleansing	  in	  the	  past	  6	  months.	  Again,	  this	  is	  most	  likely	  to	  be	  a	  marker	  of	  unreported	  sex,	  since	  girls	  may	  be	  more	  likely	  to	  perform	  intravaginal	  cleansing	  if	  they	  believe	  this	  practice	  is	  appropriate	  or	  desirable	  before	  or	  after	  sex,	  or	  that	  it	  is	  effective	  in	  reducing	  the	  risk	  of	  STI	  or	  pregnancy[13].	  	  However,	  since	  intravaginal	  cleansing	  has	  been	  associated	  with	  HPV	  in	  cross-­‐sectional	  studies[30]	  and	  the	  acquisition	  of	  other	  STIs	  in	  longitudinal	  studies[31,32],	  and	  since	  HPV	  has	  been	  detected	  on	  fingers	  of	  women	  with	  genital	  warts	  and	  on	  surfaces	  in	  sexual	  health	  clinics	  in	  the	  UK[33,34],	  self-­‐infection	  remains	  a	  theoretical	  possibility	  which	  should	  be	  further	  investigated.	  	  We	  also	  observed	  a	  strong	  association	  between	  spending	  a	  night	  away	  from	  home	  in	  the	  past	  6	  months	  and	  HPV	  acquisition.	  Traveling	  or	  short	  time	  migration	  have	  been	  associated	  with	  HIV	  infection	  in	  previous	  studies	  in	  SSA[35,36],	  but	  not	  with	  HPV.	  It	  is	  likely	  that	  spending	  a	  night	  away	  from	  home	  is	  a	  marker	  for	  unreported	  sex	  and	  therefore	  HPV	  risk.	  	  One	  of	  the	  limitations	  of	  this	  study	  was	  that	  we	  only	  tested	  samples	  from	  girls	  every	  6	  months	  rather	  than	  testing	  samples	  from	  3-­‐monthly	  visits	  and,	  as	  a	  result,	  it	  is	  likely	  that	  the	  incidence	  of	  HPV	  was	  underestimated	  since	  some	  short-­‐lived	  infections	  may	  have	  cleared	  quickly	  between	  the	  6-­‐month	  visits.	  This	  may	  have	  been	  partially	  mitigated	  by	  using	  the	  highly	  sensitive	  HPV	  Roche	  Linear	  Array,	  reducing	  the	  risk	  of	  false	  negative	  tests.	  A	  further	  limitation	  is	  the	  relatively	  small	  number	  of	  events	  in	  the	  risk	  factor	  analysis,	  which	  will	  have	  resulted	  in	  imprecise	  effect	  estimates.	  The	  major	  strength	  of	  this	  study	  was	  the	  face-­‐to-­‐face	  interviews.	  These	  included	  current	  colloquial	  terms	  for	  sexual	  behaviours.	  The	  interviewers	  were	  experienced	  in	  sexual	  behaviour	  research	  with	  adolescents,	  and	  attempted	  to	  meet	  the	  same	  participant	  at	  every	  visit,	  establishing	  a	  trusting	  relationship	  and	  potentially	  reducing	  under-­‐reporting.	  We	  nested	  a	  study	  of	  alternative	  interview	  methods	  within	  our	  cohort	  and	  found	  no	  increase	  in	  reporting	  of	  sex	  when	  comparing	  audio-­‐computer	  assisted	  self-­‐interview.	  Unfortunately,	  the	  interviews	  did	  not	  include	  questions	  about	  masturbation,	  which	  has	  previously	  been	  reported	  by	  adolescent	  girls	  in	  Tanzania[26],	  and	  which	  could	  potentially	  lead	  to	  transmission	  via	  fingers.	  Similarly,	  HPV	  could	  be	  acquired	  through	  fomite	  transmission	  during	  female	  genital	  cutting	  via	  unsterilized	  equipment	  or	  the	  fingers	  of	  the	  practitioner.	  Although	  only	  1	  participant	  in	  our	  cohort	  reported	  having	  undergone	  genital	  cutting	  this	  may	  have	  been	  an	  underestimate.	  In	  a	  study	  of	  girls	  and	  women	  aged	  15-­‐44	  years	  in	  a	  different	  area	  of	  Tanzania,	  73%	  had	  evidence	  of	  genital	  cutting,	  and	  only	  one-­‐fifth	  of	  those	  with	  evidence	  of	  this	  on	  examination	  had	  reported	  it[37].	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Our	  results	  demonstrate	  that	  some	  Tanzanian	  adolescent	  girls	  who	  report	  never	  having	  had	  sex	  have	  a	  relatively	  high	  incidence	  of	  vaginal	  HPV.	  HPV16	  and	  HPV	  18	  are	  responsible	  for	  over	  70%	  of	  cervical	  cancers	  and	  currently	  available	  HPV	  vaccines	  offer	  a	  high	  level	  of	  protection	  from	  these	  genotypes[38,39].	  In	  our	  study,	  HPV16	  was	  the	  most	  frequently	  detected	  genotype.	  However,	  98%	  of	  these	  girls	  had	  no	  evidence	  of	  HPV16	  or	  -­‐18,	  suggesting	  that	  catch-­‐up	  vaccination	  campaigns	  in	  girls	  older	  than	  the	  current	  target	  population	  recommended	  by	  WHO	  (9-­‐13	  years	  old	  [40])	  may	  be	  effective	  at	  reducing	  cervical	  cancer.	  	  This	  may	  be	  particularly	  relevant	  since	  the	  Tanzania	  vaccination	  programme	  has	  proposed	  primarily	  targeting	  girls	  in	  standard	  (class)	  4	  if	  they	  are	  in	  school,	  or	  9-­‐year-­‐old	  girls	  if	  out	  of	  school.	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Table	  4:1.	  Prevalence	  of	  reported	  behaviours	  among	  all	  girls	  in	  the	  study	  who	  did	  not	  
report	  sex	  at	  enrolment	  or	  during	  follow-­‐up	  (n=396),	  and	  among	  those	  randomly	  
selected	  for	  the	  HPV	  incidence	  study	  (n=119)	  	   Number	  of	  girls	  reporting	  
the	  behaviour	  among	  all	  
(n=396)	  who	  did	  not	  
report	  sex1	  (%)	  
Number	  of	  girls	  reporting	  
behaviour	  among	  
(n=119)	  who	  did	  not	  
report	  sex1	  and	  who	  have	  
HPV	  results	  (%)	  
At	  enrolment	   	   	  Ever	  drank	  alcohol	   	   	  Yes	   1	  (0.3%)	   0	  (0%)	  Ever	  smoked	   	   	  Yes	   0	  (0%)	   0	  (0%)	  Ever	  took	  drugs	   	   	  Yes	   0	  (0%)	   0	  (0%)	  Ever	  cleansed	  vagina	   	   	  Yes	   68	  (17.2%)	   20	  (16.8%)	  Ever	  kissed	  a	  boy	  	   	   	  Yes	   0	  (0%)	   0	  (0%)	  Boy	  ever	  touched	  breasts	  	   	   	  Yes	   22	  (5.6%)	   8	  (6.7%)	  Ever	  touched	  boy’s	  genitals	  or	  boy	  touched	  girl’s	  genitals	   	  Yes	   2	  (0.5%)	   0	  (0%)	  Ever	  had	  oral	  sex	   	   	  Yes	   0	  (0%)	   0	  (0%)	  
During	  follow-­‐up2	   	   	  Spent	  a	  night	  away	  since	  last	  visit	   	   	  Yes	   272	  (68.7%)	   86	  (72.3%)	  Used	  internet	  ever3	   	   	  Yes	   95	  (24.0%)	   35	  (29.4%)	  Ever	  watched	  a	  pornographic	  movie3	   	   	  Yes	   62	  (15.7%)	   17	  (14.3%)	  Drank	  alcohol	  since	  last	  visit	   	   	  Yes	   4	  (1.0%)	   1	  (0.8%)	  Practiced	  vaginal	  cleansing	  since	  last	  visit	  	   	  Yes	   141	  (35.6%)	   42	  (35.3%)	  Kissed	  a	  boy	  since	  last	  visit	   	   	  Yes	   6	  (1.5%)	   3	  (2.5%)	  Boy	  touched	  breasts	  since	  last	  visit	   	   	  Yes	   12	  (3.0%)	   3	  (2.5%)	  Touched	  boy’s	  genitals/boy	  touched	  girl’s	  genitals	  since	  last	  visit	   	  Yes	   2	  (0.5%)	   1	  (0.8%)	  1Girls	  who	  did	  not	  report	  sex	  at	  enrolment	  or	  during	  the	  study	  up	  to	  and	  including	  the	  final	  visit	  (18	  months)	  2Girls	  were	  asked	  at	  every	  visit	  whether	  they	  had	  experienced	  any	  of	  these	  behaviours	  since	  they	  were	  last	  seen	  in	  the	  study	  3Girls	  were	  asked	  during	  follow-­‐up	  if	  they	  had	  ever	  used	  the	  internet	  or	  seen	  a	  pornographic	  movie,	  but	  they	  were	  not	  asked	  when	  they	  had	  done	  that.	  	  After	  a	  girl	  reported	  ever	  having	  used	  the	  internet	  or	  having	  seen	  a	  pornographic	  movie,	  all	  subsequent	  visits	  are	  counted	  as	  ‘yes’.	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Table	  4:2.	  HPV	  genotype	  prevalence,	  incidence,	  duration	  and	  clearance	  among	  119	  girls	  


























High	  risk	  genotypes	  HPV16	   1	  (1%)	   3	  /	  149.7	  (2.0)	   0	   0/	  1.7	  	  (0)	   9.2*	  (†)	  HPV18	   0	   0	  /	  152.8	  (0)	   –	   –	   –	  HPV31	   0	   1	  /	  152.6	  (0.7)	   0	   0/	  0.3	  	  (0)	   ‡	  HPV33	   0	   0	  /	  152.8	  (0)	   –	   –	   –	  HPV35	   1	  (1%)	   0	  /	  151.4	  (0)	   –	   –	   –	  HPV39	   0	   1	  /	  152.1	  (0.7)	   0	   0/	  0.7	  	  (0)	   ‡	  HPV45	   0	   0	  /	  152.8	  (0)	   –	   –	   –	  HPV51	   1	  (1%)	   3	  /	  150.6	  (2.0)	   2	  (67%)	   2/	  1.3	  	  (159.0)	   5.9	  	  (5.8)	  HPV52	   1	  (1%)	   3	  /	  150.6	  (2.0)	   0	   0/	  0.8	  	  (0)	   3.2*	  (†)	  HPV56	   1	  (1%)	   1	  /	  152.1	  (0.7)	   0	   0/	  0.3	  	  (0)	   ‡	  HPV58	   2	  (2%)	   1	  /	  151.1	  (0.7)	   0	   0/	  0.2	  	  (0)	   ‡	  HPV59	   1	  (1%)	   4	  /	  151.3	  (2.6)	   0	   0/	  1.0	  	  (0)	   3.1*	  (†)	  HPV68	   0	   1	  /	  152.2	  (0.7)	   0	   0/	  0.7	  	  (0)	   ‡	  
All	  HR	  
infections5	   8	   18	   2	  (11%)	  
2	  /	  6.9	  
(28.8)	   8.1*	  (†)	  
Low	  risk	  genotypes	  HPV6	   0	   3	  /	  151.1	  (2.0)	   1	  (33%)	   1/	  1.5	  	  (67.3)	   7.5*	  (6.0)	  HPV11	   1	  (1%)	   1	  /	  150.2	  (0.7)	   1	  (100%)	   1/	  0.5	  	  (194.3)	   ‡	  HPV26	   0	   2	  /	  151.4	  (1.3)	   1	  (50%)	   1/	  0.7	  	  (135.0)	   5.8	  (5.8)	  HPV40	   0	   0	  /	  152.8	  (0)	   –	   –	   –	  HPV42	   2	  (2%)	   1	  /	  150.1	  (0.7)	   0	   0/	  0.3	  	  (0)	   ‡	  HPV53	   0	   0	  /	  152.8	  (0)	   –	   –	   –	  HPV54	   0	   0	  /	  152.8	  (0)	   –	   –	   –	  HPV55	   0	   1	  /	  152.1	  (0.7)	   0	   0/	  0.8	  	  (0)	   ‡	  HPV61	   1	  (1%)	   2	  /	  150.4	  (1.3)	   1	  (50%)	   1/	  0.7	  	  (136.5)	   5.8	  (5.8)	  HPV62	   1	  (1%)	   1	  /	  150.7	  (0.7)	   1	  (100%)	   1/	  0.5	  	  (207.5)	   ‡	  HPV64	   0	   2	  /	  151.9	  (1.3)	   1	  (50%)	   1/	  0.7	  	  (137.6)	   5.8	  (5.8)	  HPV66	   0	   4	  /	  150.9	  (2.7)	   1	  (25%)	   1/	  1.7	  	  (58.0)	   7.5*	  (5.8)	  HPV67	   0	   2	  /	  150.9	  (1.3)	   2	  (100%)	   2/	  1.0	  	  (207.5)	   5.8	  (5.8)	  HPV69	   0	   0	  /	  152.8	  (0)	   –	   –	   –	  HPV70	   0	   1	  /	  152.6	  (0.7)	   0	   0/	  0.3	  	  (0)	   ‡	  HPV71	   0	   0	  /	  152.8	  (0)	   –	   –	   –	  HPV72	   0	   0	  /	  152.8	  (0)	   –	   –	   –	  HPV73	   0	   1	  /	  152.6	  (0.7)	   0	   0/	  0.2	  	  (0)	   ‡	  HPV81	   1	  (1%)	   0	  /	  151.4	  (0)	   –	   –	   –	  HPV82	   1	  (1%)	   1	  /	  152.1	  (0.7)	   0	   0/	  0.3	  	  (0)	   ‡	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HPV83	   0	   0	  /	  152.8	  (0)	   –	   –	   –	  HPV84	   1	  (1%)	   2	  /	  150.3	  (1.3)	   1	  (50%)	   1/	  0.7	  	  (135.3)	   6.0	  (6.0	  )	  HPV	  CP-­‐108	   0	   1	  /	  152.6	  (0.7)	   0	   0/	  0.2	  	  (0)	   ‡	  HPV	  IS-­‐39	   0	   1	  /	  152.1	  (0.7)	   1	  (100%)	   1/	  0.5	  	  (208.1)	   ‡	  
All	  LR	  
infections5	   8	   26	   11	  (42%)	  
11	  /	  10.6	  
(103.3)	  	   6.6*	  (5.8)	  
All	  HPV	  
infections	   16	   44	   13	  (30%)	  
13	  /	  17.6	  
(73.9)	   7.0*	  (6.0)	  1Positive	   for	   that	  genotype	  at	   the	  enrolment	  visit.	   2New	   infection	  defined	  as	   first	  positive	   test	   for	   the	   specific	  HPV	  type,	   among	   those	   not	   infected	   at	   enrolment.	   	   3Clearance	   defined	   as	   a	   negative	   sample	   for	   the	   specific	   genotype;	  denominator	   is	   total	   genotype-­‐specific	   new	   infections.	   	   4Mean	   duration	   of	   new	   infections	   estimated	   using	   Kaplan	  Meier	  methods	  restricted	  by	  the	  longest	  follow-­‐up	  time	  (i.e.	  duration).	  	  *Mean	  duration	  of	  infection	  for	  the	  genotype	  is	  underestimated	  because	  the	  individual	  with	  the	  longest	  observed	  duration	  was	  censored.	  †Median	  duration	  could	  not	   be	   estimated	   because	   survival	   curve	   does	   not	   drop	   below	   50%.	   	   ‡One	   infection	   only,	   Kaplan-­‐Meier	   survival	  function	  not	  estimated.	  5Total	  number	  of	  group	  (HR	  or	  LR)-­‐specific	  infections	  among	  119	  girls.	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Table	  4:3.	  Incidence	  and	  point	  prevalence	  in	  adolescent	  girls	  who	  did	  not	  report	  sex	  at	  
enrolment	  or	  during	  18	  months	  follow-­‐up	  
Outcome	   All	  girls	  (N=119)	  1	  
Negative	  for	  all	  HPV	  genotypes	  at	  
enrolment	  	  
(HPV	  naïve)	  (N=109)	  2	  
Incidence	  
	   New	  infections	  /	  person-­‐years	  (rate	  /	  100	  person-­‐years,	  95%	  CI)	  3	  All	  HPV	   44	  /	  152.8	  (29.4;	  15.9–54.2	  )	   40	  /	  140.6	  (27.9;	  14.7–53.0)	  All	  HR	  HPV	   18	  /	  152.8	  (11.3;	  5.8–22.1)	   18	  /	  140.6	  (12.4;	  6.4–24.0)	  All	  LR	  HPV	   26	  /	  152.8	  (18.1;	  9.3–35.1)	   22	  /	  140.6	  (15.8;	  7.9–31.7)	  
Prevalence	   	   	  	   Total	  infections	  (number	  of	  visits	  with	  at	  least	  one	  infection	  /	  all	  visits;	  %	  of	  all	  visits)	  4	  All	  HPV	   87	  (51	  /	  438;	  11.6%)	   50	  (24	  /	  402;	  6.0%)	  All	  HR	  HPV	   38	  (29	  /	  438;	  6.6%)	   23	  (16	  /	  402;	  4.0%)	  All	  LR	  HPV	   49	  (36	  /	  438;	  8.2%)	   27	  (17	  /	  402;	  4.2%)	  1HPV	  incidence	  among	  all	  girls	  who	  did	  not	  report	  passing	  sexual	  debut	  during	  the	  study;	  includes	  10	  girls	  in	  whom	  prevalent	  HPV	  was	  detected	  at	  enrolment.	  	  	  2HPV	  incidence	  among	  girls	  who	  did	  not	  report	  passing	  sexual	  debut	  during	  the	  study	  and	  no	  HPV	  was	  detected	  at	  enrolment.	  	  3Rate	  estimated	  from	  random	  effects	  Poisson	  regression:	  point	  estimates	  and	  95%	  CI	  take	  into	  account	  correlation	  of	  repeated	  events	  within	  girls.	  	  Girls	  assumed	  to	  be	  continually	  at	  risk	  and	  can	  acquire	  >1	  infection	  at	  each	  visit.	  	  4Total	  number	  of	  genotype-­‐specific	  infections	  and	  number	  of	  visits	  where	  at	  least	  one	  genotype	  was	  detected,	  at	  all	  visits	  including	  enrolment	  visit.	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Table	  4:4.	  Selected	  risk	  factors	  for	  any	  new	  HPV	  infection	  among	  119	  girls	  who	  did	  not	  
report	  sex	  at	  enrolment	  or	  during	  18	  months	  follow-­‐up	  	   Number	  of	  
infections	  /	  
person-­‐years	  
(rate/	  100	  pys)	  
Crude	  RR	  (95%	  CI)	   Adjusted	  RR	  (95%	  CI)1	  
Sociodemographic	  (enrolment)	   	   	  Age	  at	  enrolment	   	   P=0.40	   	  15	  years	   29	  /	  73.9	  (36.9)	   1	   	  16	  years	   15	  /	  78.9	  (21.7)	   0.59	  	  (0.17	  -­‐1.99)	   	  Religion	   	   P=0.78	   P=0.85	  Christian	   37	  /	  141.5	  (27.2)	   1	   1	  Muslim	   5	  /	  8.9	  	  (50.0)	   1.84	  	  (0.17	  -­‐	  19.81)	   1.70	  	  (0.16	  -­‐	  18.03)	  Other	   2	  /	  2.4	  	  (69.9)	   2.57	  	  (0.04	  -­‐	  176.57)	   2.08	  	  (0.03	  -­‐	  137.78)	  SES	  score	  (tertiles)2	   	   P=0.56	   P=0.76	  Low	   9	  /	  47.1	  (19.3)	   1	   1	  Middle	   12	  /	  52.4	  (25.0)	   1.30	  	  (0.27	  -­‐	  6.13)	   1.21	  	  (0.24	  -­‐	  6.02)	  High	   23	  /	  53.4	  (42.4)	   2.20	  	  (0.49	  -­‐	  9.81)	   1.89	  	  (0.32	  -­‐	  11.12)	  
Sociodemographic	  (time	  varying)	   	   	  Current	  residence	   	   P=0.07	   P=0.34	  Urban	   34	  /	  84.7	  (40.3)	   1	   1	  Rural	   10	  /	  68.1	  (15.9)	   0.39	  	  (0.14	  -­‐	  1.10)	   0.57	  	  (0.18	  -­‐	  1.80)	  Current	  occupation	   	   P=0.24	   P=0.41	  School	   1	  /	  7.8	  	  (7.2)	   0.27	  	  (0.02	  -­‐	  2.89)	   0.70	  	  (0.05	  -­‐	  9.11)	  Work/vocational	  training	   28	  /	  117.5	  (27.2)	   1	   1	  Not	  working	   15	  /	  27.6	  (43.9)	   1.61	  	  (0.65	  -­‐	  4.02)	   1.83	  	  (0.73	  -­‐	  4.61)	  Spent	  a	  night	  away	  since	  last	  seen	   P<0.001	   P<0.001	  No	   26	  /	  112.0	  (20.0)	   1	   1	  Yes	   18	  /	  40.8	  (109.6)	   5.47	  	  (1.72	  -­‐	  17.4)	   5.63	  	  (1.81	  -­‐	  17.49)	  
Behavioural	  (time	  varying)	   	   	   	  Current	  menstrual	  hygiene	   	   P=0.12	   P=0.12	  Cloth	   10	  /	  58.6	  (22.5)	   1	   1	  Underwear	   8	  /	  21.6	  (21.8)	   0.97	  	  (0.23	  -­‐	  4.10)	   0.41	  	  (0.07	  -­‐	  2.58)	  Sanitary	  pad	   26	  /	  60.3	  (45.3)	   2.02	  	  (0.55	  -­‐	  7.34)	   1.18	  (0.25	  -­‐	  5.64)	  Pre	  menarche	   0	  /	  12.4	  (0)	   –	   –	  Used	  internet3	   	   P=0.12	   P=0.03	  No	   34	  /	  132.7	  (25.9)	   1	   1	  Yes	   10	  /	  20.1	  (58.0)	   2.24	  	  (0.79	  -­‐	  6.36)	   3.90	  	  (1.05	  -­‐14.50)	  Watched	  a	  pornographic	  movie3	   P=0.20	   P=0.03	  No	   42	  /	  137.9	  (31.6)	   1	   1	  Yes	   2	  /	  15.0	  (11.5)	   0.36	  	  (0.07	  -­‐	  1.92)	   0.18	  	  (0.03	  -­‐	  1.03)	  Cleansed	  vagina	  in	  last	  6	  months4	   P=0.03	   P=0.32	  No	   24	  /	  118.4	  (21.2)	   1	   1	  Yes	   20	  /	  34.4	  (59.2)	   2.79	  	  (1.08	  -­‐	  7.17)	   1.79	  	  (0.57	  -­‐	  5.59)	  Substance	  used	  for	  vaginal	  cleansing	  	   P=0.01	   P=0.12	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Did	  not	  cleanse	   30	  /	  126.8	  (25.5)	   1	   1	  Soap	  or	  soap	  and	  water	   14	  /	  19.1	  (103.4)	   4.05	  	  (1.30	  -­‐	  12.6)	   2.64	  	  (0.75	  -­‐	  9.31)	  Water	  only	   0	  /	  6.9	  	  (0)	   –	   –	  Kissed	  a	  boy	  in	  the	  last	  6	  months	   P=0.56	   P=0.34	  No	   43	  /	  151.4	  (28.6)	   1	   1	  Yes	   1	  /	  1.5	  	  (87.1)	   3.05	  	  (0.06	  -­‐	  155.9)	   6.59	  	  (0.09	  -­‐	  481.3)	  Boy	  touched	  participant’s	  breasts	  in	  last	  6	  months	   	   	  No	   44	  /	  151.9	  (29.6)	   –	   –	  Yes	   0	  /	  1.0	  	  (0)	   –	   –	  Boy	  touched	  participant’s	  genitals	  or	  participant	  touched	  boy’s	  genitals	  in	  the	  last	  6months	  No	   44	  /	  152.4	  (29.4)	   –	   –	  Yes	   0	  /	  0.5	  	  (0)	   –	   –	  	  1	  Potential	  risk/protective	  factors	  were	  examined	  using	  a	  conceptual	  framework	  with	  three	  levels;	  age	  was	  considered	  an	  a	  priori	  confounder	  and	  included	  in	  all	  models.	  Age-­‐adjusted	  sociodemographic	  factors	  at	  enrolment	  were	  retained	  in	  a	  core	  model	  if	  associated	  with	  HPV	  infection	  at	  p<0.10.	  Time	  varying	  sociodemographic	  factors	  were	  sequentially	  added	  and	  retained	  at	  p<0.10.	  	  Variables	  not	  presented	  include	  enrolment	  variables	  (tribe,	  who	  the	  girl	  lived	  with,	  reporting	  of	  ever	  having	  kissed,	  had	  a	  partner	  touch	  her	  breasts	  or	  genitals	  or	  whether	  she	  had	  touched	  a	  partner’s	  genitals	  and	  whether	  she	  had	  cleansed	  inside	  the	  vagina)	  since	  none	  of	  these	  were	  associated	  in	  the	  unadjusted	  or	  adjusted	  analysis.).	  	  2SES:	  socio-­‐economic	  status.	  This	  was	  determined	  using	  an	  asset	  index	  created	  by	  combining	  data	  collected	  from	  the	  entire	  cohort	  at	  enrolment,	  separated	  into	  tertiles.	  3Girls	  were	  asked	  during	  follow-­‐up	  if	  they	  had	  ever	  used	  the	  internet	  or	  seen	  a	  pornographic	  movie,	  but	  they	  were	  not	  asked	  when	  they	  had	  done	  that.	  	  After	  a	  girl	  reported	  ever	  having	  used	  the	  internet	  or	  having	  seen	  a	  pornographic	  movie,	  all	  subsequent	  visits	  are	  counted	  as	  ‘yes’.	  4Vaginal	  cleansing	  is	  cleaning	  inside	  the	  vagina	  with	  water,	  soap	  or	  other	  products	  using	  fingers	  or	  a	  cloth.	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Figure	  4:1.	  Enrolment	  of	  study	  participants	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Figure	  4:2.	  HPV	  genotype	  point	  prevalence	  (95%	  confidence	  interval),	  and	  number	  of	  
infections	  at	  all	  visits	  including	  enrolment	  among	  119	  girls	  who	  did	  not	  report	  sex	  at	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5.1 Preamble	  This	  manuscript	  describes	  the	  genotype-­‐specific	  and	  overall;	  rate,	  duration	  and	  clearance	  of	  HPV	  infection	  in	  girls	  after	  reported	  sexual	  debut,	  and	  factors	  associated	  with	  the	  incidence	  and	  clearance	  of	  HPV.	  These	  address	  part	  of	  objectives	  2,	  3	  and	  4	  which	  are:	  
• Identify	  the	  rate	  of	  HPV	  infection,	  clearance	  of	  genotype-­‐specific	  HPV,	  the	  duration	  of	  infection	  after	  initiation	  of	  sexual	  activity,	  and	  the	  rate	  of	  infection	  in	  those	  who	  do	  not	  report	  initiation	  of	  sexual	  activity.	  
• Evaluate	  sexual	  behaviour,	  vaginal	  practice	  and	  demographic	  factors	  associated	  with	  the	  incidence	  of	  genotype-­‐specific	  HPV	  infection	  in	  those	  who	  report	  and	  do	  not	  report	  the	  initiation	  of	  sexual	  activity.	  
• Identify	  risk	  factors	  associated	  with	  HPV	  genotype-­‐specific	  clearance.	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Abstract	  
Background	  	  No	  reports	  exist	  on	  genotype-­‐specific	  human	  papillomavirus	  (HPV)	  acquisition	  in	  girls	  after	  first	  sex	  in	  sub-­‐Saharan	  Africa,	  despite	  high	  HPV-­‐prevalence	  and	  cervical	  cancer	  incidence.	  
Methods	  We	  followed	  503	  girls	  aged	  15-­‐16	  years	  in	  Mwanza,	  Tanzania,	  3-­‐monthly	  for	  18	  months	  with	  face-­‐to-­‐face	  interviews	  and	  self-­‐administered	  vaginal	  swabs.	  Swabs	  were	  tested	  for	  13	  high-­‐risk	  and	  24	  low-­‐risk	  HPV	  genotypes.	  Incidence,	  clearance	  and	  duration	  of	  overall	  HPV	  and	  genotype-­‐specific	  infections	  were	  calculated	  and	  associated	  factors	  evaluated.	  	  
Results	  	  106	  participants	  reported	  first	  sex	  prior	  to	  enrolment	  (N=29)	  or	  during	  follow-­‐up	  (N=77).	  One	  was	  HIV-­‐positive	  at	  the	  final	  visit.	  The	  other	  105	  girls	  contributed	  323	  adequate	  specimens.	  Incidence	  of	  any	  new	  HPV	  genotype	  was	  225/100	  person-­‐years(pys),	  and	  incidence	  of	  vaccine	  types	  HPV6,-­‐11,-­‐16	  and	  -­‐18	  were;	  12,	  2,	  2	  and	  7/100pys,	  respectively.	  Reporting	  sex	  in	  the	  past	  3	  months,	  and	  knowing	  the	  most	  recent	  sexual	  partner	  for	  a	  longer	  period	  before	  sex	  were	  associated	  with	  new	  HPV	  acquisition.	  	  Median	  time	  from	  reported	  sexual	  debut	  to	  first	  HPV	  infection	  was	  5	  months,	  and	  infection	  duration,	  6	  months.	  
Conclusion	  HPV	  incidence	  was	  very	  high,	  including	  of	  some	  vaccine	  genotypes,	  in	  Tanzanian	  adolescent	  girls	  after	  first	  sex,	  and	  infection	  duration	  was	  short,	  highlighting	  the	  importance	  of	  vaccinating	  girls	  before	  sexual	  debut.	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Introduction	  A	  number	  of	  closely	  related	  human	  papillomavirus	  (HPV)	  genotypes	  are	  classified	  by	  the	  International	  Agency	  for	  Research	  on	  Cancers	  (IARC)	  as	  oncogenic	  (Group	  I)	  or	  probably	  oncogenic	  (Group	  IIA)[1],	  and	  are	  commonly	  referred	  to	  as	  ‘high-­‐risk’	  (HR)	  HPVs.	  Persistent	  infection	  (repeated	  detection	  over	  at	  least	  6	  months)	  with	  HR	  HPV,	  is	  associated	  with	  ano-­‐genital	  cancers	  in	  men	  and	  women[2,3].	  Infection	  with	  HR	  HPV	  genotypes	  is	  the	  primary	  cause	  of	  cervical	  cancer[4],	  and	  the	  highest	  age-­‐standardised	  cervical	  cancer	  incidence	  and	  mortality	  worldwide	  are	  seen	  in	  sub-­‐Saharan	  Africa	  (SSA),	  along	  with	  some	  of	  the	  highest	  HPV	  prevalences[5,6].	  Worldwide	  data	  describing	  HPV	  prevalence	  by	  age	  show	  that	  the	  highest	  prevalence	  is	  in	  women	  under	  25	  years	  old[6].	  From	  limited	  studies	  which	  have	  tested	  girls	  for	  HPV	  before	  and	  after	  fist	  sex,	  prevalence	  is	  high	  following	  sexual	  debut[7–9].	  	  Current	  HPV	  vaccines	  are	  prophylactic,	  not	  therapeutic,	  and	  should	  be	  given	  before	  HPV	  acquisition[10].	  Knowledge	  of	  the	  rates	  and	  timing	  of	  HPV	  acquisition	  is	  thus	  essential	  to	  inform	  HPV	  vaccination	  policy.	  To	  date,	  no	  studies	  have	  documented	  genotype-­‐specific	  HPV	  incidence	  or	  overall	  HPV	  incidence	  in	  girls	  in	  SSA	  around	  the	  time	  of	  sexual	  debut.	  A	  national	  HPV	  vaccination	  programme	  for	  Tanzania,	  although	  in	  the	  planning	  stages,	  has	  not	  yet	  commenced.	  In	  order	  to	  examine	  initial	  HPV	  infection	  and	  natural	  history,	  we	  enrolled	  unvaccinated	  adolescent	  girls	  aged	  15	  and	  16	  years	  old	  and	  followed	  them	  every	  3	  months	  for	  18	  months	  in	  Mwanza,	  Tanzania.	  	  	  
Methods	  Cohort	  enrolment	  The	  cohort	  was	  enrolled	  as	  described	  previously[11].	  Briefly,	  for	  preparation	  for	  an	  HPV	  vaccination	  trial,	  registration	  lists	  of	  girls	  enrolled	  in	  government	  primary	  schools	  in	  3	  districts	  of	  Mwanza	  region,	  northern	  Tanzania,	  were	  collected	  in	  2010[12].	  	  We	  enrolled	  girls	  who	  had	  been	  in	  class	  6	  in	  2010	  in	  one	  of	  the	  82	  government	  schools	  not	  randomly	  selected	  for	  vaccination.	  	  Additional	  enrolment	  eligibility	  criteria	  included:	  being	  aged	  15	  or	  16	  years,	  self-­‐reporting	  never	  having	  had	  sex	  and	  currently	  not	  pregnant,	  being	  able	  to	  attend	  appointments,	  and	  being	  willing	  to	  self-­‐administer	  a	  vaginal	  swab.	  In	  order	  to	  prevent	  stigmatization	  of	  girls	  enrolled	  or	  not	  enrolled,	  we	  randomly	  selected	  26	  schools	  from	  which	  we	  enrolled	  the	  first	  girl	  who	  reported	  ever	  having	  had	  sex,	  if	  her	  reported	  first	  sex	  was	  within	  the	  past	  year.	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  Ethical	  permissions	  The	  London	  School	  of	  Hygiene	  and	  Tropical	  Medicine	  Ethics	  Committee	  and	  the	  Medical	  Research	  Coordinating	  Committee,	  Tanzania	  approved	  the	  study	  protocol	  in	  2011.	  Since	  participants	  were	  under	  18	  years	  old	  at	  enrolment,	  written	  informed	  consent	  was	  required	  from	  a	  parent/guardian	  with	  subsequent	  informed	  assent	  from	  participants.	  Further	  consent	  procedures	  have	  been	  described	  previously[11].	  Study	  procedures	  Girls	  were	  enrolled	  between	  January	  and	  August	  2012,	  and	  followed	  three-­‐monthly	  for	  18	  months.	  At	  each	  visit,	  girls	  had	  a	  face-­‐to-­‐face	  interview	  with	  a	  female	  study	  nurse.	  All	  interviews	  were	  carried	  out	  in	  Swahili	  using	  a	  structured	  paper	  questionnaire.	  Enrolment	  questions	  and	  interview	  locations	  have	  been	  described	  previously[11].	  Follow-­‐up	  questions	  included	  sexual	  behaviour,	  vaginal	  practices	  and	  marriage	  since	  the	  last	  visit,	  and	  their	  current	  occupation.	  At	  each	  visit,	  one	  nurse-­‐assisted,	  self-­‐administered	  vaginal	  Dacron	  swab	  was	  obtained,	  irrespective	  of	  reported	  sex.	  	  At	  each	  follow-­‐up	  visit,	  girls	  who	  reported	  previous	  sex	  (at	  any	  time)	  were	  offered	  a	  pregnancy	  test	  and	  asked	  about	  symptoms	  of	  reproductive	  tract	  infections.	  Those	  reporting	  symptoms	  were	  examined	  in	  the	  research	  clinic	  and	  offered	  syndromic	  treatment	  according	  to	  Tanzanian	  guidelines.	  	  At	  study	  completion,	  girls	  were	  offered	  a	  rapid	  test	  for	  HIV	  with	  appropriate	  referral	  if	  positive.	  	  In	  this	  paper,	  we	  present	  data	  from	  girls	  who	  reported	  having	  had	  sex	  prior	  to	  enrolment,	  or	  who	  passed	  sexual	  debut	  during	  follow-­‐up.	  HPV	  detection	  and	  genotyping	  Swabs	  were	  placed	  dry	  into	  cryotubes	  immediately	  after	  collection,	  stored	  in	  cold	  boxes	  with	  ice-­‐packs	  in	  the	  field,	  submitted	  daily	  to	  the	  laboratory	  in	  Mwanza	  and	  stored	  at	  -­‐200C.	  They	  were	  shipped	  to	  the	  Catalan	  Institute	  of	  Oncology,	  Barcelona,	  Spain	  where	  HPV	  detection	  and	  genotyping	  were	  performed	  using	  the	  Linear	  Array	  HPV	  genotyping	  assay	  (Roche,	  California,	  USA).	  This	  test	  detects	  37	  HPV	  genotypes	  (HPV6,-­‐11,-­‐16,-­‐18,-­‐26,-­‐31,-­‐33,-­‐35,-­‐39,-­‐40,-­‐42,-­‐45,-­‐51,-­‐52,-­‐53,-­‐54,-­‐55,-­‐56,-­‐58,-­‐59,-­‐61,-­‐62,-­‐64,-­‐66,-­‐67,-­‐68,-­‐69,-­‐70,-­‐71,-­‐72,-­‐73,-­‐81,-­‐82,-­‐83,-­‐84,	  IS39	  and	  CP6108).	  For	  this	  study,	  we	  classified	  HPV	  genotypes	  which	  were	  in	  IARC	  groups	  I	  (termed	  carcinogenic)	  and	  IIa	  (termed	  probably	  carcinogenic)	  as	  HR;	  these	  were;	  HPV-­‐16,-­‐18,-­‐31,-­‐33,-­‐35,-­‐39,-­‐45,-­‐51,-­‐52,-­‐56,-­‐58,-­‐59,-­‐68.	  We	  classified	  all	  remaining	  genotypes	  (group	  IIb,	  termed	  possibly	  carcinogenic	  and	  group	  III,	  no	  evidence	  of	  association	  with	  cancer)	  as	  LR[1].	  Methods	  for	  DNA	  extraction,	  amplification	  and	  genotype	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detection	  were	  described	  previously[11].	  Specimens	  negative	  for	  β-­‐globin	  amplification	  were	  excluded	  since	  vaginal	  sampling	  was	  assumed	  to	  be	  unsuccessful.	  Data	  management	  and	  statistical	  methods	  Questionnaire	  data	  were	  double-­‐entered	  into	  OpenClinica	  LLC	  (Akaza	  Research,	  Waltham,	  MA,	  USA),	  and	  analyzed	  using	  STATA	  V13.0	  (StataCorp	  LP,	  College	  Station,	  Texas,	  USA).	  	  Analyses	  were	  restricted	  to	  girls	  whose	  reported	  sexual	  debut	  was	  before	  enrolment	  or	  during	  follow-­‐up	  ('sexually	  active').	  	  Girls	  who	  were	  HIV-­‐positive	  were	  excluded	  from	  all	  analyses.	  	  	  	  	  For	  each	  HPV	  genotype,	  the	  number	  of	  prevalent	  infections	  (present	  at	  enrolment	  among	  those	  sexually	  active	  at	  entry),	  new	  infections	  (genotype	  not	  detected	  at	  enrolment	  or	  before	  reported	  sexual	  debut)	  and	  cleared	  infections	  (a	  new	  genotype	  infection	  that	  is	  no	  longer	  detected)	  were	  tabulated	  among	  all	  sexually	  active	  girls.	  The	  genotype-­‐specific	  prevalence	  was	  estimated	  as	  the	  number	  of	  visits	  where	  the	  genotype	  was	  detected,	  divided	  by	  the	  number	  of	  sexually	  active	  visits.	  	  Genotype-­‐specific	  incidence	  was	  calculated;	  person-­‐years	  (pys)	  at	  risk	  were	  calculated	  from	  enrolment	  (among	  girls	  whose	  reported	  sexual	  debut	  was	  before	  enrolment)	  or	  date	  of	  sexual	  debut	  (among	  girls	  who	  reported	  sexual	  debut	  during	  follow-­‐up).	  	  Date	  of	  infection	  was	  defined	  as	  the	  midpoint	  between	  the	  last	  negative	  and	  first	  positive	  sample	  for	  that	  genotype.	  Since	  the	  incidence	  rate	  was	  high	  and	  infection	  duration	  short,	  girls	  with	  intervals	  of	  missing	  HPV	  results	  over	  180	  days	  were	  censored	  at	  the	  last	  available	  HPV	  result	  before	  the	  gap.	  Kaplan	  Meier	  methods	  were	  used	  to	  estimate	  time	  from	  sexual	  debut	  to	  first	  HPV	  infection	  among	  girls	  who	  reported	  sexual	  debut	  during	  follow-­‐up	  and	  who	  were	  HPV-­‐DNA	  negative	  at	  all	  visits	  before	  reported	  sexual	  debut	  ('HPV	  naïve').	  	  The	  overall	  incidence	  of	  all	  new	  HPV,	  new	  HR	  HPV,	  and	  new	  LR	  HPV	  infections	  were	  calculated	  among:	  1)	  all	  sexually	  active	  girls;	  2)	  girls	  who	  reported	  sexual	  debut	  during	  follow-­‐up;	  and	  3)	  HPV-­‐naïve	  girls	  who	  reported	  sexual	  debut	  during	  follow-­‐up.	  	  In	  these	  analyses,	  girls	  were	  assumed	  to	  be	  continually	  at	  risk	  of	  infection	  with	  a	  new	  genotype,	  and	  could	  acquire	  more	  than	  one	  new	  infection	  at	  each	  visit.	  Periods	  longer	  than	  180	  days	  with	  missing	  HPV	  results	  were	  removed	  from	  the	  analysis;	  however,	  observation	  time	  after	  this	  gap	  contributed	  to	  the	  analysis.	  The	  overall	  incidence	  rate	  and	  95%	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confidence	  interval	  (CI)	  were	  estimated	  using	  random	  effects	  Poisson	  regression	  to	  account	  for	  clustering	  of	  multiple	  infections	  within	  the	  same	  girl.	  	  	  	  Rate	  ratios	  (RR)	  for	  factors	  associated	  with	  HPV	  incidence	  among	  all	  sexually	  active	  girls	  were	  estimated	  using	  random	  effects	  Poisson	  regression.	  Potential	  risk	  factors	  were	  examined	  using	  a	  conceptual	  framework	  with	  three	  levels;	  age	  was	  considered	  an	  a	  priori	  confounder	  and	  was	  included	  in	  all	  models.	  Socioeconomic	  status	  was	  measured	  using	  an	  asset	  index,	  created	  by	  combining	  data	  on	  ownership	  of	  common	  household	  items	  in	  the	  entire	  cohort	  (i.e.	  including	  non-­‐sexually	  active	  participants)	  using	  principal	  component	  analysis.	  	  	  The	  genotype-­‐specific	  clearance	  rate	  was	  calculated	  among	  all	  sexually	  active	  girls	  who	  had	  acquired	  a	  new	  genotype;	  pys	  at	  risk	  were	  calculated	  from	  the	  date	  of	  infection	  (midway	  between	  the	  last	  negative	  and	  first	  positive	  sample	  for	  the	  genotype).	  Clearance	  was	  defined	  as	  two	  consecutive	  negative	  samples,	  or	  one	  negative	  and	  one	  missing	  sample,	  for	  the	  genotype.	  	  When	  a	  girl	  tested	  negative	  for	  a	  genotype	  between	  two	  visits	  with	  positive	  samples	  for	  the	  same	  genotype,	  the	  intervening	  negative	  sample	  was	  considered	  a	  false	  negative.	  If	  that	  sample	  was	  missing,	  it	  was	  considered	  positive	  for	  the	  same	  genotype.	  The	  date	  of	  clearance	  was	  defined	  as	  the	  midpoint	  between	  the	  last	  positive	  and	  first	  negative	  sample.	  	  Girls	  who	  did	  not	  clear	  an	  infection	  were	  censored	  at	  the	  last	  sample	  date.	  	  Kaplan-­‐Meier	  methods	  were	  used	  to	  estimate	  the	  median	  and	  mean	  genotype-­‐specific	  duration,	  and	  the	  proportion	  cleared	  at	  12	  months.	  	  	  Factors	  associated	  with	  clearance	  of	  new	  HPV	  infection	  were	  examined	  using	  methods	  for	  multiple	  failure-­‐time	  data.	  	  HPV	  was	  the	  unit	  of	  analysis;	  therefore,	  girls	  infected	  with	  multiple	  genotypes	  could	  clear	  more	  than	  one	  infection.	  Failure	  (i.e.	  clearance)	  events	  were	  assumed	  to	  be	  unordered,	  so	  genotype-­‐specific	  clearance	  was	  considered	  to	  be	  independent	  of	  clearing	  other	  genotypes.	  	  Cox	  regression	  was	  used	  to	  examine	  risk	  factors	  for	  clearance.	  	  The	  Cox	  model	  was	  stratified	  by	  HPV	  genotype	  and	  robust	  standard	  errors	  were	  used	  to	  adjust	  for	  correlation	  of	  repeated	  events	  among	  girls.	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We	  located	  1,177	  (75.7%)	  of	  1,555	  potentially-­‐eligible	  girls	  on	  the	  original	  school	  attendance	  lists.	  Of	  these,	  801	  (68.1%)	  met	  the	  age	  criteria,	  of	  whom	  628	  (78.4%)	  consented	  to	  be	  screened	  (Figure	  5.1).	  Of	  those	  screened,	  503	  (80.1%)	  were	  eligible	  and	  enrolled,	  and	  416	  (82.7%)	  attended	  the	  final	  visit.	  Overall,	  106	  (21.1%)	  participants	  reported	  sex,	  either	  at	  enrolment	  (N=29)	  or	  during	  follow-­‐up	  (N=77).	  	  Among	  29	  girls	  whose	  reported	  date	  of	  first	  sex	  was	  before	  enrolment,	  median	  time	  from	  sexual	  debut	  to	  enrolment	  was	  4.2	  months	  (range	  0.1-­‐12.4).	  	  Among	  106	  girls	  reporting	  sex,	  91	  (85.8%)	  attended	  the	  final	  visit	  (18	  months),	  and	  the	  median	  (IQR)	  follow-­‐up	  time	  was	  17.8	  (17.4-­‐17.9)	  months.	  At	  the	  final	  visit,	  49	  of	  91	  (53.8%)	  participants	  accepted	  HIV	  testing;	  one	  (1.1%)	  was	  positive	  and	  excluded	  from	  the	  analyses.	  	  The	  remaining	  105	  girls	  contributed	  437	  “sexually-­‐active	  visits”	  (visits	  after	  the	  reported	  date	  of	  sexual	  debut,	  including	  the	  enrolment	  visit)	  to	  the	  analysis;	  vaginal	  swabs	  were	  provided	  at	  353	  of	  these	  visits	  (80.8%)	  of	  which	  323	  (91.5%)	  were	  adequate	  specimens	  and	  were	  genotyped.	  	  At	  enrolment,	  71/105	  (67.6%)	  participants	  were	  aged	  16	  years	  and	  the	  others	  were	  aged	  15.	  	  Nearly	  two-­‐thirds	  lived	  in	  rural	  areas	  (68,	  64.8%),	  92	  (87.6%)	  were	  Christian,	  7	  (6.7%)	  were	  in	  school,	  and	  over	  half	  were	  neither	  working	  nor	  schooling	  (60,	  57.1%).	  	  During	  the	  study,	  71	  (67.6%)	  reported	  ever	  having	  cleansed	  inside	  their	  vagina,	  and	  one	  (1.0%)	  reported	  ever	  having	  inserted	  a	  substance	  into	  the	  vagina.	  Only	  one	  girl	  reported	  that	  she	  was	  circumcised.	  	  	  HPV	  prevalence	  and	  incidence	  Of	  the	  29	  girls	  who	  reported	  ever	  having	  had	  sex	  at	  enrolment,	  7	  (24.1%)	  had	  at	  least	  one	  prevalent	  HPV	  infection	  at	  enrolment	  (Table	  5.1).	  	  A	  total	  of	  28	  new	  HR	  infections	  and	  57	  new	  LR	  infections	  were	  detected	  during	  follow	  up	  (Table	  5.1).	  	  During	  the	  study,	  the	  most	  common	  HR	  genotypes	  were	  HPV51	  (5.0%	  of	  visits),	  HPV58	  (4.6%),	  HPV56	  (4.0%)	  and	  HPV59	  (4.0%)	  (Figure	  5.2).	  	  The	  most	  common	  LR	  types	  were	  HPV84	  (9.0%	  of	  visits),	  HPV83	  (7.4%),	  HPV61	  (5.3%),	  HPV66	  (5.3%)	  and	  CP-­‐108	  (5.3%).	  Genotype-­‐specific	  incidence	  ranged	  from	  2.2/100	  person-­‐years	  (pys)	  to	  14.2/100	  pys	  for	  each	  of	  the	  HR	  genotypes,	  and	  0	  to	  24.1/100	  pys	  for	  each	  of	  the	  LR	  genotypes	  (Table	  5.1).	  	  The	  highest	  incidence	  rates	  (per	  100	  pys)	  of	  HR	  types	  were	  for	  HPV58	  (14.2),	  HPV51	  (9.6)	  and	  HPV18	  (6.7).	  	  The	  highest	  incidence	  rates	  of	  LR	  types	  were	  for	  HPV84	  (24.1),	  CP-­‐108	  (16.1),	  HPV66	  (14.4),	  and	  HPV6	  (12.2).	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  Among	  the	  76	  girls	  who	  reported	  first	  sex	  during	  follow-­‐up,	  35	  (46.1%)	  had	  at	  least	  one	  HPV	  infection	  detected	  before	  the	  reported	  date	  of	  first	  sex.	  	  Among	  HPV-­‐naïve	  girls,	  median	  time	  from	  reported	  sexual	  debut	  to	  HPV	  infection	  was	  4.9	  months	  (Figure	  5.3),	  and	  to	  first	  HR-­‐HPV,	  9.3	  months.	  Cumulative	  incidence	  of	  any	  HPV	  infection	  at	  6	  months	  was	  52.8%;	  35.8%	  for	  HR	  and	  34.7%	  for	  LR	  genotypes.	  The	  overall	  incidence	  rate	  (per	  100	  pys)	  of	  new	  HPV	  infections	  in	  sexually	  active	  girls	  (Table	  5.2)	  was	  225	  (95%CI:166–305);	  HR-­‐HPV	  incidence	  was	  66	  (95%CI:45–95)	  and	  LR-­‐HPV	  was	  157	  (95%CI:111-­‐222).	  Among	  girls	  who	  reported	  sexual	  debut	  during	  follow-­‐up,	  the	  incidence	  rate	  for	  new	  HPV	  infections	  and	  for	  new	  HR-­‐HPV	  infections	  were	  209	  (95%CI:146–299)	  and	  63	  (95%CI:40–99),	  respectively.	  	  Restricting	  to	  HPV-­‐naïve	  girls,	  the	  incidence	  rate	  for	  new	  HPV	  infections	  was	  193	  (95%CI:118–316)	  and	  for	  new	  HR-­‐HPV	  infections	  was	  72	  (95%CI:42–122).	  	  Overall,	  HPV	  was	  detected	  at	  46%	  of	  “sexually	  active	  visits”	  in	  all	  girls	  (Table	  5.2).	  Risk	  factors	  for	  incidence	  of	  new	  HPV	  infection	  In	  the	  adjusted	  analysis,	  there	  was	  evidence	  of	  an	  association	  with	  occupation	  (adjusted	  (a)RR=1.95,	  95%CI:1.1-­‐3.42	  comparing	  those	  not	  working	  with	  those	  in	  work	  or	  vocational	  training)(Table	  5.3).	  There	  was	  strong	  evidence	  of	  an	  association	  with	  the	  reporting	  of	  recent	  sex	  (aRR	  2.48,	  95%CI:1.40-­‐4.37,	  comparing	  girls	  who	  reported	  sex	  once	  with	  those	  who	  reported	  no	  sex	  in	  the	  past	  3	  months).	  	  There	  was	  also	  evidence	  of	  a	  higher	  rate	  of	  new	  HPV	  infections	  among	  girls	  who	  had	  known	  their	  most	  recent	  partner	  for	  longer	  (aRR	  3.15,	  95%CI:1.32–7.50,	  comparing	  those	  who	  knew	  their	  partner	  for	  at	  least	  6	  months	  with	  those	  who	  knew	  the	  partner	  for	  <1	  month).	  	  	  There	  was	  weak	  evidence	  of	  a	  higher	  rate	  of	  new	  HPV	  infections	  among	  girls	  reporting	  3	  or	  more	  partners	  compared	  with	  only	  1	  partner.	  	  There	  was	  also	  weak	  evidence	  of	  a	  lower	  rate	  among	  girls	  who	  reported	  vaginal	  cleansing	  (aRR	  0.69,	  95%CI:0.43–1.10).	  	  HPV	  duration	  and	  clearance	  Overall,	  33	  girls	  had	  at	  least	  one	  new	  HPV	  genotype	  during	  follow-­‐up	  and	  contributed	  85	  new	  infections	  to	  analysis	  of	  HPV	  genotype-­‐specific	  duration	  and	  clearance.	  	  In	  total,	  26	  of	  85	  (30.6%)	  new	  infections	  were	  cleared	  during	  follow-­‐up.	  	  Median	  duration	  of	  new	  HPV	  genotype-­‐specific	  infections	  was	  6.1	  months,	  and	  for	  new	  HR	  and	  new	  LR	  HPV	  genotypes	  6.0	  and	  6.1	  months,	  respectively.	  	  The	  overall	  rate	  of	  clearance	  (per	  100	  pys)	  was	  90.4	  for	  any	  HPV	  genotype,	  106.7	  for	  HR	  and	  82.6	  for	  LR	  genotypes.	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  In	  the	  unadjusted	  analysis,	  clearance	  of	  any	  HPV	  was	  associated	  with	  younger	  age	  of	  the	  girl,	  the	  most	  recent	  male	  partner	  being	  reported	  to	  have	  been	  circumcised,	  and	  the	  girl	  reporting	  that	  she	  had	  not	  practised	  vaginal	  cleansing	  in	  the	  past	  3	  months	  (Table	  5.4).	  	  After	  adjusting	  for	  age,	  there	  was	  no	  evidence	  of	  a	  significant	  association	  with	  any	  of	  the	  factors	  examined.	  	  	  	  	  
Discussion	  In	  this	  study,	  we	  demonstrated	  an	  extremely	  high	  incidence	  of	  vaginal	  HPV	  infection	  after	  first	  sex	  in	  adolescent	  Tanzanian	  girls.	  Acquisition	  was	  rapid	  in	  the	  initial	  months	  after	  first	  reported	  sex,	  and	  over	  half	  of	  the	  girls	  were	  positive	  for	  any	  HPV	  DNA	  in	  the	  first	  6	  months	  after	  reported	  sexual	  debut.	  These	  findings	  support	  current	  recommendations	  that	  adolescent	  girls	  should	  ideally	  be	  vaccinated	  before	  first	  sex[13].	  	  	  Few	  studies	  have	  examined	  HPV	  incidence	  in	  young	  women	  after	  sexual	  debut.	  First	  acquisition	  of	  HPV	  (which	  predominantly	  occurs	  in	  the	  months	  after	  first	  penetrative	  sex)	  is	  a	  unique	  opportunity	  to	  document	  HPV	  genotypes	  to	  which	  young	  women	  are	  exposed	  and	  which	  may	  then	  become	  latent	  (and	  therefore	  un-­‐detectable)	  until	  reactivation	  later	  in	  life.	  Current	  molecular	  testing	  cannot	  differentiate	  reactivation	  from	  first	  acquisition	  or	  reinfection	  and	  therefore	  all	  studies	  of	  HPV	  incidence	  in	  sexually	  active	  women	  can	  only	  record	  presumed	  incidence	  of	  HPV	  infections,	  since	  some	  apparent	  new	  infections	  may	  actually	  be	  reactivations.	  	  HPV84,-­‐83,-­‐61,-­‐66	  and	  CP-­‐108	  were	  the	  most	  common	  genotypes	  seen	  in	  our	  study.	  This	  is	  in	  contrast	  to	  global	  prevalence	  data	  in	  cytologically	  normal	  women	  that	  have	  reported	  HPV16,-­‐18,-­‐52,-­‐31	  and	  -­‐58	  as	  the	  most	  prevalent	  genotypes[6].	  In	  our	  study	  the	  incidence	  rate	  of	  HPV	  vaccine	  genotypes	  was	  low;	  ranging	  between	  2.4	  and	  13.6	  per	  100pys	  for	  each	  of	  the	  HPV	  types	  covered	  by	  the	  quadrivalent	  vaccine	  (HPV6,-­‐11,-­‐16	  and	  18);	  and	  between	  1.3	  and	  13.6	  per	  100pys	  for	  each	  of	  the	  HPV	  types	  covered	  by	  the	  new	  nonavalent	  vaccine	  (HPV6,-­‐11,-­‐16,-­‐18,-­‐31,-­‐33,-­‐45,-­‐52,-­‐58).	  	  Incidence	  rates	  of	  HPV16	  (2.3/100pys)	  and	  HPV18	  (6.7/100pys)	  were	  lower	  relative	  to	  other	  genotypes.	  Our	  data	  could	  be	  used	  in	  modelling	  studies	  to	  explore	  whether	  catch-­‐up	  vaccination	  campaigns	  in	  older	  girls	  (for	  example	  up	  to	  age	  17	  years)	  have	  additional	  impact	  on	  cervical	  cancer	  incidence.	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The	  overall	  HPV	  incidence	  in	  our	  study	  (225/100	  person-­‐years;	  187/1000	  person-­‐months)	  was	  far	  higher	  than	  that	  reported	  in	  already	  sexually	  active	  women.	  A	  cohort	  study	  of	  sexually	  active	  women	  in	  Brazil,	  median	  age	  33	  years,	  reported	  an	  incidence	  of	  13.4/1000	  person-­‐months[14],	  and	  a	  study	  in	  women	  in	  Canada,	  median	  age	  21,	  reported	  an	  incidence	  of	  19/1000	  person-­‐months[15].	  Cumulative	  incidence	  has	  been	  reported	  as	  39-­‐44%	  at	  24	  to	  36	  months	  after	  first	  sex	  in	  Brazil	  and	  the	  USA	  [7,8,14],	  lower	  than	  the	  53%	  at	  the	  much	  shorter	  follow-­‐up	  period	  of	  6	  months	  in	  our	  study.	  Young	  women	  are	  known	  to	  have	  a	  high	  incidence	  of	  infection	  but	  the	  particularly	  high	  incidence	  in	  our	  study	  may	  additionally	  be	  driven	  by	  a	  high	  HPV	  prevalence	  of	  infection	  in	  the	  male	  partners	  of	  these	  young	  women[6,7,16–18].	  However,	  the	  incidence	  in	  our	  cohort	  is	  higher	  than	  other	  studies	  in	  young	  women	  in	  East	  Africa.	  A	  cohort	  study	  of	  sexually	  active	  women	  in	  Uganda	  (median	  age	  20	  years)	  found	  an	  HPV	  incidence	  of	  30.5/100pys[19],	  and	  a	  previous	  study	  in	  Mwanza,	  Tanzania	  (median	  age	  18)	  reported	  an	  incidence	  of	  74/100pys[17].	  Comparing	  the	  incidence	  of	  individual	  genotypes	  in	  our	  Tanzanian	  study	  with	  a	  study	  which	  reported	  incidence	  of	  HPV6,-­‐11,-­‐16	  and	  -­‐18	  in	  women	  in	  the	  USA[20];	  in	  our	  participants,	  the	  incidence	  of	  HPV6,-­‐11	  and	  -­‐18	  were	  three	  fold	  higher,	  but	  a	  lower	  rate	  was	  seen	  for	  HPV16	  in	  our	  Tanzanian	  study	  (2.3/100pys	  vs	  5.4/100pys	  in	  the	  study	  in	  the	  USA).	  This	  is	  in	  keeping	  with	  findings	  that	  HPV16	  is	  less	  common	  in	  SSA	  than	  in	  other	  regions	  including	  the	  USA[6,21].	  	  Not	  working	  was	  associated	  with	  increased	  incident	  HPV	  risk	  compared	  to	  being	  employed	  or	  in	  vocational	  training.	  Girls	  who	  are	  not	  working	  may	  be	  at	  increased	  risk	  of	  engaging	  in	  sex	  in	  exchange	  for	  gifts	  or	  money	  or	  forced	  sex,	  which	  are	  risk	  factors	  for	  HIV	  and	  other	  STIs[22],	  but	  have	  not	  clearly	  been	  identified	  as	  risk	  factors	  for	  HPV[23,24].	  	  These	  behaviours	  were	  infrequently	  reported	  in	  our	  study,	  although	  they	  have	  been	  described	  in	  other	  studies	  in	  older	  women	  in	  the	  region[25].	  Reporting	  sex	  once	  in	  the	  past	  3	  months	  was	  associated	  with	  increased	  risk	  of	  incident	  HPV	  compared	  to	  not	  reporting	  sex.	  A	  single	  episode	  of	  sex	  may	  be	  more	  likely	  to	  occur	  outside	  of	  the	  context	  of	  a	  stable	  relationship	  (although	  information	  on	  the	  nature	  of	  the	  sexual	  partner	  was	  not	  collected	  in	  our	  study).	  Knowing	  a	  partner	  for	  6	  or	  more	  months	  before	  sex	  was	  associated	  with	  a	  more	  than	  three-­‐fold	  risk	  of	  incident	  HPV	  compared	  to	  knowing	  a	  partner	  for	  under	  one	  month.	  Girls	  may	  be	  more	  likely	  to	  be	  involved	  in	  risky	  sex	  (i.e.	  without	  a	  condom)	  and	  therefore	  be	  at	  increased	  risk	  of	  HPV[26],	  if	  a	  partner	  is	  well	  known	  to	  them.	  Contrary	  to	  that,	  however,	  reported	  condom	  use	  at	  last	  sex	  was	  not	  associated	  with	  lower	  HPV	  incidence,	  although	  numbers	  were	  small.	  Reported	  male	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partner	  circumcision	  was	  similarly	  not	  associated	  with	  incident	  HPV,	  in	  contrast	  to	  a	  large	  study	  in	  Uganda[27].	  However,	  girls	  in	  our	  study	  may	  not	  have	  always	  known	  whether	  their	  partners	  were	  or	  were	  not	  circumcised.	  Limitations	  of	  our	  study	  include	  the	  use	  of	  self-­‐administered	  swabs	  rather	  than	  clinician-­‐collected	  cervical	  swabs.	  We	  used	  these	  since	  we	  anticipated	  that	  most	  girls	  would	  not	  have	  passed	  sexual	  debut	  at	  enrolment	  and	  therefore	  speculum	  examination	  was	  considered	  undesirable.	  	  Over	  90%	  were	  β-­‐globin	  positive,	  indicating	  adequate	  sampling[28].	  Also,	  a	  previous	  study	  in	  Uganda	  had	  demonstrated	  good	  HPV-­‐genotype	  correlation	  in	  self-­‐administered	  and	  clinician-­‐administered	  swabs[29].	  	  We	  chose	  to	  remove	  un-­‐observed	  intervals	  (without	  vaginal	  swab	  results)	  of	  over	  180	  days	  from	  the	  analysis.	  	  However,	  sensitivity	  analyses,	  where	  we	  assumed	  girls	  to	  be	  uninfected	  with	  a	  new	  genotype	  during	  those	  intervals,	  gave	  similar	  results	  (incidence	  among	  all	  “sexually	  active”	  girls	  was	  158/100pys,	  (95%CI:123–203)).	  Samples	  that	  were	  negative	  or	  missing	  for	  a	  given	  genotype	  but	  had	  been	  taken	  between	  two	  samples	  that	  were	  positive	  for	  that	  genotype	  were	  classified	  as	  positive	  because	  studies	  demonstrating	  long-­‐term	  persistence	  have	  shown	  that	  sporadic	  detection	  of	  the	  same	  genotype	  early	  in	  the	  course	  of	  the	  persistent	  infection	  is	  common[30].	  We	  excluded	  one	  girl	  who	  was	  HIV	  positive	  at	  study	  completion,	  since	  HPV	  incidence	  is	  higher	  with	  HIV	  infection[31,32].	  Only	  46%	  of	  participants	  who	  attended	  the	  final	  visit	  accepted	  an	  HIV	  test	  and	  therefore	  we	  may	  have	  unknowingly	  included	  HIV	  positive	  girls	  in	  the	  analysis,	  although	  national	  estimates	  are	  that	  there	  is	  a	  very	  low	  HIV	  prevalence	  in	  15-­‐19	  year	  old	  girls	  in	  Tanzania	  (1.3%)[33].	  In	  our	  study,	  median	  time	  from	  first	  reported	  sex	  to	  acquisition	  of	  any	  HPV	  was	  5	  months.	  This	  is	  longer	  than	  the	  2.4	  months	  reported	  in	  college	  students	  in	  the	  USA	  who	  were	  tested	  every	  three	  months[34].	  Differences	  in	  the	  types	  of	  relationships	  formed	  (marriage	  versus	  casual	  sex	  partner),	  recent	  sex	  and	  condom	  use	  may	  explain	  these	  differences	  since	  some	  of	  these	  have	  been	  identified	  as	  risk	  factors	  for	  acquisition	  in	  our	  or	  other	  studies[26,35].	  Reporting	  bias	  may	  have	  influenced	  accurate	  assessment	  of	  these	  risks:	  participants	  in	  our	  study	  may	  have	  been	  less	  willing	  to	  report	  sex	  and	  had	  less	  accurate	  recall	  of	  dates	  of	  sex	  compared	  to	  the	  women	  in	  the	  USA	  study.	  The	  median	  duration	  of	  infection	  in	  our	  study	  was	  shorter	  (6	  months)	  than	  in	  previous	  studies	  (reported	  range	  8-­‐31	  months[14,15,36]).	  This	  may	  be	  an	  underestimate	  since	  the	  duration	  of	  follow-­‐up	  was	  limited	  depending	  on	  the	  point	  at	  which	  girls	  reported	  sexual	  debut.	  A	  short	  duration	  of	  infection	  could	  also	  be	  due	  to	  cervico-­‐vaginal	  immune	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activation	  in	  Tanzanian	  girls,	  which	  has	  been	  shown	  to	  be	  higher	  in	  STI	  and	  HIV-­‐uninfected	  young	  women	  in	  Kenya	  compared	  to	  the	  USA[37].	  High	  levels	  of	  endo-­‐cervical	  T-­‐lymphocytes	  identified	  in	  the	  women	  studied	  in	  Kenya	  could	  have	  mediated	  HPV	  clearance[37].	  Finally,	  higher	  cervical	  HPV	  viral	  load,	  age	  over	  30	  years,	  being	  HIV	  positive	  and	  having	  a	  high	  number	  of	  sex	  partners	  were	  associated	  with	  lower	  HPV	  clearance	  in	  women	  in	  Uganda[32].	  We	  identified	  no	  associations	  with	  HPV	  clearance,	  potentially	  because	  our	  cohort	  displayed	  little	  variation	  in	  age	  or	  number	  of	  sex	  partners,	  and	  all	  those	  included	  in	  the	  estimates	  of	  the	  clearance	  rate	  were	  either	  HIV-­‐negative	  or	  had	  unknown	  HIV	  status.	  	  We	  report	  a	  rapid	  acquisition	  of	  HPV	  infection,	  extremely	  high	  incidence,	  and	  rapid	  clearance	  in	  young	  women	  after	  their	  first	  reported	  sex.	  This	  study	  was	  carried	  out	  in	  a	  region	  with	  one	  of	  the	  highest	  incidences	  of	  cervical	  cancer	  in	  the	  world,	  and	  our	  findings	  may	  help	  to	  explain	  these	  high	  rates	  of	  cervical	  cancer	  and	  the	  high	  HPV	  prevalence	  observed	  in	  East	  Africa[6]	  and	  support	  the	  current	  recommendation	  that	  HPV	  vaccination	  should	  be	  given	  to	  girls	  before	  their	  first	  sex[38].	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Table	  5:1.	  HPV	  genotype	  prevalence,	  incidence,	  duration	  and	  clearance	  among	  105	  
sexually	  active	  girls	  during	  follow-­‐up	  
HPV	  type	   Prevalent	  (%)1	  
New	  
infections/pys	  









High	  risk	  genotypes	  HPV16	   0	  	   1	  /	  44.0	  (2.3)	   0	  	   0/	  0.1	  	  (0)	   ‡	  HPV18	   0	  	   3	  /	  44.6	  (6.7)	   1	  (33%)	   1/	  0.5	  	  (211.7)	   2.7	  (2.7)	  HPV31	   0	  	   2	  /	  43.6	  (4.6)	   1	  (50%)	   1/	  0.9	  	  (113.8)	   6.1	  (6.1)	  HPV33	   0	  	   2	  /	  44.5	  (4.5)	   1	  (50%)	   1/	  0.4	  	  (268.6)	   3.0	  (3.0)	  HPV35	   0	  	   2	  /	  44.5	  (4.5)	   1	  (50%)	   1/	  1.0	  	  (99.5)	   6.0*	  (4.9)	  HPV39	   1	  (3%)	   2	  /	  44.3	  (4.5)	   0	  	   0/	  1.2	  	  (0)	   13.5*	  (†)	  HPV45	   0	  	   1	  /	  43.1	  (2.3)	   1	  (100%)	   1/	  0.2	  	  (403.6)	   ‡	  HPV51	   2	  (7%)	   4	  /	  41.7	  (9.6)	   3	  (75%)	   3/	  1.9	  	  (158.7)	   6.1	  (6.1)	  HPV52	   0	  	   1	  /	  44.3	  (2.3)	   1	  (100%)	   1/	  0.5	  	  (198.5)	   ‡	  HPV56	   0	  	   1	  /	  44.1	  (2.3)	   0	  	   0/	  0.4	  	  (0)	   ‡	  HPV58	   1	  (3%)	   6	  /	  42.1	  (14.2)	   0	  	   0/	  1.8	  	  (0)	   13.2*	  (†)	  HPV59	   3	  (10%)	   2	  /	  42.7	  (4.7)	   1	  (50%)	   1/	  0.3	  	  (289.9)	   2.7	  (2.7)	  HPV68	   0	  	   1	  /	  44.9	  (2.2)	   0	  	   0/	  0.1	  	  (0)	   ‡	  
All	  HR	  infections5	   7	   28	   10	  (36%)	   10	  /	  9.4	  (106.7)	   6.9*	  (6.0)	  
Low	  risk	  genotypes	  HPV6	   1	  (3%)	   5	  /	  41.0	  (12.2)	   2	  (40%)	   2/	  1.4	  	  (146.8)	   5.0	  (6.1)	  HPV11	   0	  	   1	  /	  45.1	  (2.2)	   0	  	   0/	  0.2	  	  (0)	   ‡	  HPV26	   0	  	   0	  /	  45.5	  (0)	   –	   –	   –	  HPV40	   0	  	   2	  /	  43.8	  (4.6)	   0	  	   0/	  0.3	  	  (0)	   1.7*	  (†)	  HPV42	   0	  	   3	  /	  41.9	  (7.2)	   1	  (33%)	   1/	  0.8	  	  (133.3)	   6.1	  (6.1)	  HPV53	   0	  	   2	  /	  42.7	  (4.7)	   1	  (50%)	   1/	  0.6	  	  (180.4)	   3.3*	  (3.0)	  HPV54	   1	  (3%)	   4	  /	  41.8	  (9.6)	   1	  (25%)	   1/	  1.4	  	  (73.6)	   6.1*	  (†)	  HPV55	   0	  	   4	  /	  43.8	  (9.1)	   1	  (25%)	   1/	  1.3	  	  (78.4)	   6.2*	  (4.9)	  HPV61	   1	  (3%)	   0	  /	  45.0	  (0.0)	   –	   –	   –	  HPV62	   0	  	   3	  /	  43.6	  (6.9)	   1	  (33%)	   1/	  1.7	  	  (59.2)	   9.4*	  (2.7)	  HPV64	   0	  	   1	  /	  45.4	  (2.2)	   0	  (0	  %)	   0/	  0.1	  	  (0)	   ‡	  HPV66	   1	  (3%)	   6	  /	  41.5	  (14.4)	   2	  (33%)	   2/	  3.2	  	  (62.5)	   11.3*	  (11.8)	  HPV67	   1	  (3%)	   1	  /	  44.6	  (2.2)	   1	  (100%)	   1/	  0.3	  	  (299.4)	   ‡	  HPV69	   0	  	   0	  /	  44.8	  (0)	   –	   –	   –	  HPV70	   0	  	   0	  /	  44.5	  (0)	   –	   –	   –	  HPV71	   0	  	   1	  /	  45.1	  (2.2)	   0	  	   0/	  0.4	  	  (0)	   ‡	  HPV72	   0	  	   0	  /	  45.5	  (0)	   –	   –	   –	  HPV73	   1	  (3%)	   4	  /	  43.1	  (9.3)	   1	  (25%)	   1/	  0.9	  	  (117.6)	   3.5*	  (2.7)	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HPV81	   0	  	   1	  /	  45.0	  (2.2)	   0	  	   0/	  0.1	  	  (0)	   ‡	  HPV82	   0	  	   0	  /	  45.4	  (0)	   –	   –	   –	  HPV83	   0	  	   3	  /	  40.7	  (7.4)	   1	  (33%)	   1/	  2.0	  	  (50.6)	   11.9*	  (†)	  HPV84	   2	  (7%)	   9	  /	  37.3	  (24.1)	   3	  (33%)	   3/	  3.1	  	  (97.5)	   6.0*	  (6.0)	  HPV	  CP-­‐108	   0	  	   7	  /	  43.6	  (16.1)	   1	  (14%)	   1/	  1.8	  	  (55.6)	   7.0*	  (4.9)	  HPV	  IS39	   0	   0	  /	  45.5	  (0)	   –	   –	   –	  
All	  LR	  infections5	   8	   57	   16	  (28%)	   16	  /	  19.4	  (82.6)	  	   8.9*	  (6.1)	  
All	  HPV	  infections	   15±	   85	   26	  (31%)	   26	  /	  28.8	  (90.4)	   8.4*	  (6.1)	  1Positive	   for	   that	   genotype	   at	   the	   enrolment	   visit,	   amongst	   29	   girls	   who	   were	   sexually	   active	   at	   enrolment.	   2New	  infection	   defined	   as	   first	   positive	   test	   for	   the	   specific	   HPV	   type,	   among	   those	   not	   infected	   at	   enrolment	   or	   before	  reported	  sexual	  debut.	  Girls	  with	  gaps	  >180	  days	  in	  observation	  time	  are	  censored	  at	  the	  last	  available	  HPV	  result	  before	  the	  gap	  3Clearance	  defined	  as	  ≥2	  consecutive	  samples	  negative	  for	  the	  specific	  genotype;	  denominator	  is	  total	  genotype-­‐specific	   new	   infections.	   	   4Mean	   duration	   of	   new	   infections	   estimated	   using	   Kaplan	   Meier	   methods	   restricted	   by	   the	  longest	   follow-­‐up	   time	   (i.e.	   duration)	   5Total	   number	  of	   group	   (HR	  or	   LR)-­‐specific	   infections	   among	  105	   girls.	   	   *Mean	  duration	  of	  infection	  for	  the	  genotype	  is	  underestimated	  because	  the	  individual	  with	  the	  longest	  observed	  duration	  was	  censored.	  †Median	  duration	  could	  not	  be	  estimated	  because	  survival	  curve	  does	  not	  drop	  below	  50%.	   	  ‡One	  infection	  only,	  Kaplan-­‐Meier	  survival	  function	  not	  estimated	  ±15	  infections	  within	  7	  girls.	  5	  had	  at	  least	  one	  HR	  HPV	  genotype	  at	  enrolment,	  5	  had	  at	  least	  one	  LR	  HPV	  genotype	  at	  enrolment,	  7	  had	  any	  genotype	  at	  enrolment.	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Table	  5:2.	  Incidence	  and	  point	  prevalence	  of	  HPV	  in	  adolescent	  girls	  who	  reported	  sex	  
Outcome	  
All	  girls	  who	  reported	  
sexual	  debut	  before	  or	  
during	  the	  study	  
(N=105)	  
All	  girls	  who	  reported	  
sexual	  debut	  during	  
study	  (N=76)	  1	  
Girls	  who	  reported	  
sexual	  debut	  during	  
study	  and	  were	  HPV	  
naïve	  (N=41)	  2	  
Reported	  sexual	  debut	  
prior	  to	  enrolment	  
(N=29)	  
Incidence	  
	   New	  infections	  /	  person-­‐years	  (rate	  /	  100	  person-­‐years,	  95%	  CI)	  3	  
All	  HPV	   119	  /	  56.4	  	  (225;	  166–305)	   62	  /	  30.1	  	  (209;	  146–299)	   40	  /	  19.5	  	  	  (193;	  118–316)	   57	  /	  26.3	  	  (248;	  144–425)	  All	  HR	  HPV	   37	  /	  56.4	  (66;	  45–95)	   19	  /	  30.1	  (63;	  40–99)	   14	  /	  19.5	  (72;	  42–122)	   18	  /	  26.3	  	  (71;	  37–135)	  All	  LR	  HPV	   82	  /	  56.4	  (157;	  111–222)	   43	  /	  30.1	  (146;	  97–218)	   26	  /	  19.5	  (127;	  66–246)	   39	  /	  26.3	  (176;	  95–327)	  
Point	  prevalence	   	   	   	  	   Total	  infections	  (number	  of	  visits	  with	  at	  least	  one	  infection	  /	  sexually	  active	  visits;	  %	  of	  all	  visits)	  4	  All	  HPV	   323	  (148	  /	  323;	  45.8%)	   186	  (87	  /	  172;	  50.6%)	   91	  (40	  /	  106;	  37.7%)	   137	  (61	  /	  151;	  40.4%)	  All	  HR	  HPV	   108	  (87	  /	  323;	  26.9%)	   57	  (49	  /	  172;	  28.5%)	   32	  (26	  /	  106;	  24.5%)	   51	  (38	  /	  151;	  25.2%)	  All	  LR	  HPV	   215	  (118	  /	  323;	  36.5%)	   129	  (70	  /	  172;	  40.7%)	   59	  (29	  /	  106;	  27.4%)	   86	  (48	  /	  151;	  31.8%)	  
1HPV	  incidence	  among	  all	  girls	  who	  reported	  passing	  sexual	  debut	  during	  the	  study;	  includes	  35	  girls	  in	  whom	  HPV	  was	  detected	  before	  reported	  sexual	  debut	  (infections	  before	  reported	  sexual	  debut	  do	  not	  contribute	  to	  the	  incidence	  estimate	  in	  this	  column,	  but	  girls	  are	  not	  excluded	  from	  the	  analysis).	  	  	  2HPV	  incidence	  among	  41	  girls	  who	  reported	  passing	  sexual	  debut	  during	  the	  study	  and	  no	  HPV	  was	  detected	  before	  reported	  sexual	  debut.	  3Rate	  estimated	  from	  random	  effects	  Poisson	  regression:	  point	  estimates	  and	  95%	  CI	  take	  into	  account	  correlation	  of	  repeated	  infections	  within	  girls.	  Girls	  assumed	  to	  be	  continually	  at	  risk	  and	  can	  acquire	  >1	  infection	  at	  each	  visit.	  	  Observation	  time	  after	  gaps	  >180	  days	  contribute	  to	  the	  analysis	  therefore	  total	  number	  of	  infections	  is	  different	  from	  that	  in	  Table	  1.	  4Total	  number	  of	  genotype-­‐specific	  infections	  and	  number	  of	  visits	  where	  at	  least	  one	  genotype	  was	  detected	  at	  all	  visits	  after	  reported	  date	  of	  sexual	  debut,	  including	  enrolment	  visit.	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Table	  5:3.	  Association	  of	  selected	  potential	  risk/protective	  factors1	  with	  any	  new	  HPV	  
infection	  among	  105	  adolescent	  girls	  who	  reported	  previous	  sex	  
	   Number	  of	  infections2	  /	  
person-­‐years	  (rate/	  
100	  pys)	  
Crude	  RR	  (95%	  CI)	   Adjusted	  RR	  (95%	  CI)3	  
Sociodemographic	  (enrolment)	   	   	   	  Age	  at	  enrolment	   	   P=0.45	   	  15	  years	   32	  /	  19.1	  (189)	   1	   	  16	  years	   87	  /	  37.3	  (244)	   1.29	  	  (0.67–2.47	  )	   	  Religion	   	   P=0.83	   P=0.83	  Christian	   99	  /	  49.2	  (213)	   1	   1	  Muslim	   16	  /	  5.5	  	  (333)	   1.56	  	  (0.59–4.12	  )	   1.57	  	  (0.60–4.16	  )	  Other	  	   4	  /	  1.7	  	  (219)	   1.16	  	  (0.11–12.30)	   1.07	  	  (0.10–11.30)	  Socio-­‐economic	  status	  score	  (tertiles)	   P=0.57	   P=0.63	  Low	   58	  /	  25.5	  (246)	   1	   1	  Middle	   33	  /	  20.3	  (174)	   0.70	  	  (0.35–1.43	  )	   0.72	  	  (0.36–1.48	  )	  High	   28	  /	  10.6	  (256)	   1.04	  	  (0.48–2.23	  )	   1.03	  	  (0.48–2.21	  )	  
Sociodemographic	  (time	  varying)	   	   	   	  Current	  residence	   	   P=0.80	   P=0.53	  Urban	   50	  /	  20.7	  (235)	   1	   1	  Rural	   65	  /	  34.6	  (217)	   0.92	  	  (0.49–1.72	  )	   0.82	  	  (0.44–1.53	  )	  Current	  occupation	   	   P=0.05	   P=0.06	  School	   5	  /	  2.9	  	  (164)	   1.13	  	  (0.30–4.26)	   1.15	  	  (0.30–4.36)	  Work|vocational	  training	   29	  /	  23.1	  (144)	   1	   1	  Not	  working	   85	  /	  30.4	  (283)	   1.96	  	  (1.12–3.43)	   1.95	  	  (1.11–3.42)	  Currently	  married?	   	   P=0.66	   P=0.79	  No	   90	  /	  43.9	  (217)	   1	   1	  Yes	   29	  /	  12.5	  (248)	   1.14	  	  (0.63–2.09	  )	   0.92	  	  (0.50–1.70	  )	  Alcohol	  since	  last	  visit	   	   P=0.42	   P=0.48	  No	   116	  /	  55.2	  (228)	   1	   1	  Yes	   3	  /	  1.2	  	  (134)	   0.59	  	  (0.16–2.22	  )	   0.62	  	  (0.16–2.40	  )	  
Behavioural	  (time	  varying)	   	   	   	  Total	  partners	  ever	   	   P=0.09	   P=0.09	  1	   86	  /	  43.1	  (225)	   1	   1	  2	   16	  /	  10.0	  (155)	   0.69	  	  (0.35–1.34	  )	   0.77	  	  (0.38–1.54	  )	  3+	   16	  /	  2.5	  	  (509)	   2.26	  	  (0.83–6.17	  )	   2.76	  	  (0.95–8.04	  )	  Number	  of	  times	  had	  sex	  in	  past	  3months	   P=0.005	   P=0.008	  0	   49	  /	  31.4	  (159)	   1	   1	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1	   30	  /	  9.3	  	  (400)	   2.52	  	  (1.44–4.42	  )	   2.48	  	  (1.40–4.37	  )	  2+	   39	  /	  15.5	  (257)	   1.62	  	  (0.95–2.77	  )	   1.52	  	  (0.88–2.63	  )	  Most	  recent	  male	  sexual	  partner	  circumcised	   P=0.22	   P=0.23	  No	   33	  /	  16.1	  (182)	   1	   1	  Yes	   80	  /	  31.5	  (263)	   1.47	  	  (0.79–2.72	  )	   1.48	  	  (0.77–2.85	  )	  Don't	  know4	   5	  /	  8.0	  	  (109)	   –	   –	  Most	  recent	  sexual	  partner	  was	  in	  a	  concurrent	  relationship	   P=0.06	   P=0.25	  No	   53	  /	  31.1	  (171)	   1	   1	  Yes	   12	  /	  2.7	  	  (402)	   2.37	  	  (0.99–5.68	  )	   1.83	  	  (0.66–5.07	  )	  Don't	  know4	   53	  /	  21.7	  (287)	   –	   –	  Age	  difference	  of	  most	  recent	  partner	   P=0.11	   P=0.10	  ≤2	  years	   8	  /	  8.9	  (82)	   1	   1	  3–5	  years	   26	  /	  11.0	  	  (215)	   2.65	  	  (1.03–6.83	  )	   2.58	  	  (1.04–6.45	  )	  >5	  years	   35	  /	  13.1	  	  (237)	   2.64	  	  (1.04–6.73	  )	   2.33	  	  (0.94–5.77	  )	  Don't	  know4	   49	  /	  22.6	  (316)	   –	   –	  Used	  condom	  at	  last	  sex	   	   P=0.93	   P=0.90	  No	   105	  /	  46.5	  (226)	   1	   1	  Yes	   13	  /	  9.1	  	  (235)	   1.04	  	  (0.45–2.40	  )	   0.95	  	  (0.41–2.20	  )	  Does	  partner	  put	  saliva	  on	  penis	   	   P=0.58	   P=0.26	  No	   78	  /	  33.5	  (229)	   1	   1	  Yes	   7	  /	  1.7	  	  (309)	   1.34	  	  (0.48–3.75	  )	   1.87	  	  (0.64–5.48	  )	  Don't	  know4	   2	  /	  0.5	  	  (292)	   –	   –	  Does	  partner	  use	  vaseline	  for	  sex	   P=0.007	   P=0.17	  No	   77	  /	  35.7	  (208)	   1	   1	  Yes	   10	  /	  1.1	  	  (717)	   3.44	  	  (1.47–8.04	  )	   2.06	  	  (0.76–5.63	  )	  Time	  had	  known	  most	  recent	  partner	  before	  first	  sex	  (with	  that	  partner)	   P=0.14	   P=0.03	  <1m	   26	  /	  16.1	  (143)	   1	   1	  1-­‐6m	   64	  /	  28.0	  (252)	   1.76	  	  (0.89–3.47	  )	   1.76	  	  (0.90–3.46	  )	  6+m	   28	  /	  11.0	  (314)	   2.19	  	  (0.92–5.20	  )	   3.15	  	  (1.32–7.50	  )	  Cleansed	  vagina	  in	  past	  3months5	   	   P=0.02	   P=0.11	  No	   68	  /	  29.8	  (300)	   1	   1	  Yes	   51	  /	  26.6	  (169)	   0.56	  	  (0.35–0.90	  )	   0.69	  	  (0.43–1.10	  )	  1Potential	  risk/protective	  factors	  were	  examined	  using	  a	  conceptual	  framework	  with	  three	  levels;	  age	  was	  considered	  an	  a	  priori	  confounder	  and	  included	  in	  all	  models.	  Age-­‐adjusted	  sociodemographic	  factors	  at	  enrolment	  were	  retained	  in	  a	  core	  model	  if	  associated	  with	  HPV	  infection	  at	  p<0.10.	  	  Time-­‐varying	  sociodemographic	  factors	  were	  added	  sequentially	  and	  retained	  if	  associated	  at	  p<0.10.	  Time-­‐varying	  behavioural	  factors	  were	  then	  added	  sequentially,	  and	  retained	  at	  p<0.10.	  All	  p-­‐values	  presented	  in	  the	  table	  are	  from	  the	  likelihood	  ratio	  test.	  	  2Girls	  are	  assumed	  to	  be	  continually	  at	  risk	  and	  can	  acquire	  >1	  infection	  at	  each	  visit.	  Observation	  time	  after	  gaps	  >180	  days	  contribute	  to	  the	  analysis;	  therefore,	  the	  total	  number	  of	  infections	  (119)	  is	  different	  from	  that	  in	  Table	  1.	  3Sociodemographic	  factors	  at	  enrolment	  adjusted	  for	  age	  (a	  priori).	  Time-­‐varying	  sociodemographic	  factors	  adjusted	  for	  age	  (a	  priori)	  and	  all	  independent	  sociodemographic	  predictors	  of	  HPV	  infection	  (at	  p<0.1)	  (occupation).	  	  Behavioural	  factors	  adjusted	  for	  age,	  occupation	  and	  all	  independent	  behavioural	  predictors	  of	  HPV	  infection	  (number	  of	  times	  had	  sex	  in	  past	  3	  
119	  	  
months	  and	  time	  knew	  most	  recent	  partner	  before	  sex	  (variables	  in	  bold)).	  	  4Don’t	  know’	  responses	  considered	  missing	  data	  and	  not	  included	  in	  analysis.	  	  5Vaginal	  cleansing	  is	  cleaning	  inside	  the	  vagina	  with	  water,	  soap	  or	  other	  products	  using	  fingers	  or	  a	  cloth.	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Table	  5:4.	  Clearance	  of	  new	  HPV	  infections	  and	  associated	  factors	  among	  girls	  who	  
reported	  having	  had	  sex	  at	  any	  time	  during	  follow-­‐up	  (unit	  of	  analysis	  is	  the	  infection)	  	   Number	  cleared	  /	  
person-­‐years	  (rate/	  
100	  pys)	  
Crude	  HR	  (95%	  CI)	   Adjusted	  HR	  (95%	  CI)	  
Sociodemographic	  (enrolment)	   	   	   	  Age	  at	  enrolment	   	   P=0.03	   	  15	  years	   8	  /	  6.1	  	  (132.2)	   1	   	  16	  years	   18	  /	  22.7	  (79.3)	   0.09	  	  (0.01–0.74)	   	  Religion	   	   P=0.08	   P=0.21	  Christian	   25	  /	  23.1	  (108.3)	   1	   1	  Muslim	   1	  /	  4.8	  	  (20.8)	   0.39	  	  (0.13–1.13)	   0.53	  	  (0.20–1.43)	  Other	   0	  /	  0.9	  	  (0.0)	   –	   –	  Socio-­‐economic	  status	  score	  (tertiles)	   P=0.10	   P=0.12	  Low	   16	  /	  15.3	  (104.6)	   1	   1	  Middle	   7	  /	  8.0	  	  (87.6)	   0.81	  	  (0.22–3.02)	   0.73	  	  (0.37–1.45)	  High	   3	  /	  5.5	  	  (54.9)	   0.35	  	  (0.13–0.93)	   0.40	  	  (0.14–1.09)	  
Sociodemographic	  (time	  varying)	   	   	   	  Current	  residence	   	   P=0.10	   P=0.24	  Urban	   13	  /	  15.2	  (85.4)	   1	   1	  Rural	   13	  /	  12.9	  (101.0)	   2.23	  	  (0.85–5.85)	   0.44	  	  (0.11–1.71)	  Current	  occupation	   	   P=0.88	   P=0.56	  School	   6	  /	  7.8	  	  (77.0)	   1	   1	  Work|vocational	  training	   0	  /	  0.1	  	  (0.0)	   –	   –	  Not	  working	   20	  /	  20.8	  (96.0)	   0.90	  	  (0.24–3.38)	   1.55	  	  (0.34–7.09)	  Currently	  married	   	   P=0.25	   P=0.46	  No	   21	  /	  23.8	  (88.3)	   1	   1	  Yes	   5	  /	  5.0	  	  (100.3)	   0.44	  	  (0.11–1.78)	   0.60	  	  (0.15–2.33)	  Alcohol	  since	  last	  visit	   	   P=0.35	   P=0.35	  No	   24	  /	  27.5	  (87.2)	   1	   1	  Yes	   2	  /	  1.2	  	  (164.0)	   2.45	  	  (0.37–16.28)	   2.45	  	  (0.37–16.28)	  
Behavioural	  (time	  varying)	   	   	   	  Total	  partners	  ever	   	   P=0.58	   P=0.16	  1	   18	  /	  17.6	  (102.6)	   1	   1	  2	   4	  /	  5.4	  	  (73.8)	   0.84	  	  (0.17–4.05)	   0.26	  	  (0.04–1.53)	  3+	   4	  /	  5.7	  	  (70.7)	   0.60	  	  (0.23–1.57)	   0.84	  	  (0.35–2.01)	  Number	  of	  times	  had	  sex	  in	  the	  past	  3months	   P=0.14	   P=0.14	  0	   13	  /	  11.0	  (118.4)	   1	   1	  1	   0	  /	  6.2	  	  (0.0)	   –	   –	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2+	   13	  /	  11.5	  (112.7)	   0.21	  	  (0.02–1.69)	   0.21	  	  (0.02–1.69)	  Most	  recent	  male	  sexual	  partner	  was	  circumcised	   P=0.06	   P=0.18	  No	   15	  /	  13.7	  (109.7)	   1	   1	  Yes	   11	  /	  14.4	  (76.3)	   0.38	  	  (0.14–1.04)	   0.56	  	  (0.24–1.30)	  Don't	  know2	   0	  /	  0.5	  	  (0.0)	   –	   –	  Most	  recent	  sexual	  partner	  was	  in	  concurrent	  relationship	   	   	  No	   17	  /	  18.2	  (93.3)	   –	   –	  Yes	   0	  /	  1.6	  	  (0.0)	   –	   –	  Don't	  know2	   9	  /	  8.8	  	  (102.1)	   –	   –	  Used	  condom	  at	  last	  sex	   	   	   	  No	   26	  /	  26.9	  (96.8)	   –	   –	  Yes	   0	  /	  1.8	  	  (0.0)	   –	   –	  Partner	  put	  saliva	  on	  penis	   	   P=0.75	   P=0.75	  No	   18	  /	  22.0	  (81.8)	   1	   1	  Yes	   3	  /	  2.0	  	  (150.7)	   0.88	  	  (0.40–1.92)	   0.88	  	  (0.40–1.92)	  Don't	  know2	   –	   –	   –	  Partner	  use	  vaseline	  for	  sex	   	   	   	  No	   21	  /	  23.0	  (91.3)	   –	   –	  Yes	   0	  /	  1.0	  	  (0.0)	   –	   –	  Time	  had	  known	  most	  recent	  partner	  before	  sex	   P=0.13	   P=0.89	  <1m	   7	  /	  7.4	  	  (94.9)	   1	   1	  1-­‐6m	   17	  /	  17.2	  (98.6)	   2.05	  	  (0.64–6.53)	   0.98	  	  (0.30–3.15)	  6+m	   2	  /	  3.8	  	  (52.1)	   0.82	  	  (0.17–4.01)	   0.72	  	  (0.09–5.54)	  Cleansed	  vagina	  in	  past	  3	  months3	   	   P=0.02	   P=0.30	  No	   19	  /	  15.9	  (119.4)	   1	   1	  Yes	   7	  /	  12.8	  (54.5)	   0.26	  	  (0.08–0.83)	   0.49	  	  (0.13–1.87)	  1New	  infection	  defined	  as	  first	  positive	  test	  for	  the	  specific	  HPV	  type,	  among	  those	  not	  infected	  at	  enrolment	  or	  before	  reported	  sexual	  debut.	  	  Girls	  with	  gaps	  >180	  days	  in	  observation	  time	  are	  censored	  at	  last	  available	  HPV	  result	  before	  the	  gap.	  	  All	  P	  values	  are	  from	  likelihood	  ratio	  tests.	  	  	  	  2	  ‘Don’t	  know’	  responses	  considered	  missing	  data	  and	  not	  included	  in	  analysis	  3Vaginal	  cleansing	  is	  cleaning	  inside	  the	  vagina	  with	  water,	  soap	  or	  other	  products	  using	  fingers	  or	  a	  cloth.	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Figure	  5:2.	  HPV	  genotype	  point	  prevalence	  (95%	  confidence	  interval),	  and	  number	  of	  















	  	  	  
	  











































































Figure	  5:3.	  Time	  from	  sexual	  debut	  to	  first	  infection	  with	  any	  HPV,	  any	  HR	  HPV	  or	  any	  LR	  
HPV,	  among	  41	  girls	  who	  reported	  sexual	  debut	  during	  follow-­‐up	  and	  were	  HPV-­‐naïve	  at	  
time	  of	  reported	  sexual	  debut	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Abstract:	  Background	  Valid	  identification	  of	  sexually	  transmitted	  infection	  risk	  factors,	  and	  evaluation	  of	  interventions	  to	  modify	  these,	  depend	  on	  accurate	  sexual	  behaviour	  data.	  Audio	  computer-­‐assisted	  self-­‐interviews	  (ACASI)	  have	  demonstrated	  increased	  reporting	  of	  sensitive	  behaviours,	  although	  studies	  from	  low-­‐income	  countries	  are	  limited,	  and	  results	  somewhat	  inconsistent.	  We	  compared	  sexual	  behaviour	  reporting	  by	  ACASI	  and	  face-­‐to-­‐face	  (FtF)	  interviews	  in	  adolescent	  Tanzanian	  girls.	  	  Methods	  	   	  A	  cohort	  study	  examining	  the	  epidemiology	  of	  human	  papillomavirus	  (HPV)	  in	  Mwanza,	  Tanzania	  followed	  503	  girls	  3-­‐monthly	  for	  18	  months	  with	  FtF-­‐interviews.	  At	  the	  12-­‐month	  visit,	  we	  randomly	  selected	  girls	  to	  participate	  in	  a	  cross-­‐sectional	  comparison	  of	  ACASI	  (using	  a	  sub-­‐set	  of	  FtF-­‐interview	  sensitive	  behaviour	  questions)	  versus	  the	  standard	  FtF-­‐interview.	  Participants	  completed	  both	  interviews,	  the	  order	  of	  which	  was	  randomly	  allocated.	  Agreement	  between	  methods	  was	  measured	  using	  kappa	  statistics.	  Proportions	  reporting	  each	  behaviour	  by	  interview	  method	  were	  compared	  using	  the	  Mainland-­‐Gart	  test.	  Results	  Overall,	  203	  participants	  completed	  both	  interviews	  and	  correctly	  answered	  questions	  testing	  their	  understanding	  of	  the	  questions.	  Of	  these	  203,	  108	  (53.2%)	  were	  aged	  16	  and	  95	  (46.8%)	  aged	  17	  years.	  Fourteen	  (7.4%)	  reported	  recent	  kissing	  during	  ACASI	  compared	  to	  7	  (3.4%)	  on	  FtF-­‐interview	  (p=0.05,	  kappa=0.55).	  Conversely,	  ever	  having	  had	  vaginal	  sex	  was	  more	  frequently	  reported	  during	  FtF-­‐interviews	  than	  ACASI	  (15	  (7.4%)	  versus	  6	  (3.0%)	  respectively;	  p=0.02,	  kappa=0.45).	  There	  was	  no	  significant	  difference	  between	  methods	  for	  reporting	  of	  other	  behaviours,	  or	  order	  of	  interview.	  84.2%	  of	  participants	  preferred	  ACASI	  to	  FtF-­‐interviews,	  and	  97.6%	  found	  ACASI	  easy	  to	  use.	  	  Conclusion	  	  In	  this	  study	  of	  adolescent	  Tanzanian	  girls,	  ACASI	  was	  feasible	  and	  acceptable,	  but	  compared	  to	  FtF-­‐interviews	  did	  not	  result	  in	  higher	  reporting	  of	  vaginal	  sex	  or	  other	  sexual	  behaviours,	  with	  the	  exception	  of	  kissing.	  Reasons	  may	  include	  opportunities	  in	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FtF-­‐interviews	  to	  probe	  and	  explain	  sexual	  practices.	  Sexual	  behaviour	  interviews	  with	  ACASI	  should	  be	  evaluated	  in	  different	  settings	  before	  implementation.	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Introduction	  The	  HIV	  epidemic	  has	  disproportionately	  affected	  adolescent	  girls	  and	  young	  women[1].	  In	  sub-­‐Saharan	  Africa	  (SSA),	  72%	  of	  15-­‐24	  year	  olds	  with	  HIV	  are	  female[2].	  Identified	  risk	  factors	  include	  younger	  age	  at	  first	  sex	  and	  sex	  with	  an	  older	  male	  partner[3–5].	  Valid	  identification	  of	  sexual	  behaviour	  risk	  factors	  for	  HIV	  and	  other	  sexually	  transmitted	  infections	  (STI)	  in	  this	  population,	  and	  evaluation	  of	  interventions	  to	  modify	  these,	  are	  dependent	  on	  accurate	  collection	  of	  retrospective	  sexual	  behaviour	  data.	  	  	  The	  disclosure	  of	  sexual	  behaviour	  is	  highly	  prone	  to	  social	  desirability	  bias,	  with	  interviewees	  responding	  as	  they	  believe	  the	  interviewer	  or	  wider	  society	  think	  is	  appropriate	  or	  acceptable[6].	  This	  bias	  may	  be	  increased	  in	  studies	  of	  girls	  in	  SSA	  countries	  like	  Tanzania	  where	  sex	  outside	  marriage	  or	  whilst	  schooling	  may	  result	  in	  school	  expulsion,	  physical	  punishment	  or	  legal	  reprimand	  for	  the	  male	  partner[7,8].	  The	  use	  of	  bio-­‐markers	  of	  recent	  sex	  in	  this	  region	  have	  demonstrated	  that	  mis-­‐reporting	  of	  previous	  sex	  is	  common[9,10].	  	  Several	  methods	  to	  improve	  sexual	  behaviour	  data	  collection	  have	  been	  developed,	  including	  the	  use	  of	  audio	  computer-­‐assisted	  self-­‐interviews	  (ACASI).	  This	  method	  uses	  a	  desktop,	  laptop,	  tablet,	  or	  palm-­‐top	  computer	  with	  headphones	  to	  play	  pre-­‐recorded	  spoken	  questions,	  and	  the	  respondent	  selects	  answers	  using	  a	  mouse,	  keyboard	  or	  touch	  screen.	  It	  has	  been	  postulated	  that	  this	  method	  might	  reduce	  social	  desirability	  bias,	  intra-­‐observer	  variability	  and	  embarrassment	  since	  the	  respondent	  has	  no	  direct	  human	  interaction	  while	  completing	  the	  questionnaire[11].	  	  	  A	  systematic	  review	  of	  studies	  comparing	  ACASI	  with	  face-­‐to-­‐face	  (FtF)	  interviews	  in	  developing	  countries	  concluded	  that	  ACASI	  yielded	  higher	  overall	  reporting	  of	  sexual	  behaviours,	  and	  lower	  non-­‐response	  rates[12].	  A	  second	  review	  showed	  that	  increased	  reporting	  with	  ACASI	  is	  not	  consistently	  seen	  in	  studies	  in	  Africa[13].	  The	  number	  of	  studies	  in	  both	  reviews	  was	  limited,	  and	  significant	  heterogeneity	  was	  seen	  between	  studies.	  Low	  and	  middle-­‐income	  countries	  are	  diverse	  with	  respect	  to	  computer	  access,	  literacy,	  numeracy	  and	  social	  norms	  relating	  to	  adolescent	  sexual	  behaviour.	  It	  is	  therefore	  essential	  to	  explore	  the	  performance	  of	  ACASI	  in	  different	  settings	  in	  sub-­‐Saharan	  Africa[12].	  	  To	  evaluate	  the	  feasibility	  and	  acceptability	  of	  ACASI	  in	  adolescent	  girls	  in	  Tanzania	  and	  to	  compare	  rates	  of	  sexual	  behaviour	  disclosure	  between	  ACASI	  and	  FtF-­‐interviews,	  we	  nested	  a	  cross-­‐sectional	  comparison	  of	  ACASI	  and	  FtF-­‐interview	  within	  a	  cohort	  study	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examining	  acquisition	  of	  human	  papillomavirus	  (HPV)	  infection	  around	  the	  time	  of	  sexual	  debut.	  	  
Methods	  
HPV	  Epidemiology	  Study	  The	  ACASI	  sub-­‐study	  was	  carried	  out	  at	  the	  12-­‐month	  visit	  of	  the	  HPV	  Epidemiology	  Study,	  a	  cohort	  study	  investigating	  the	  epidemiology	  of	  HPV	  infection	  around	  the	  time	  of	  sexual	  debut	  in	  adolescent	  girls,	  which	  is	  described	  in	  detail	  elsewhere[14].	  Briefly,	  between	  January	  and	  August	  2012,	  481	  girls	  who	  reported	  no	  previous	  sex	  at	  enrolment,	  and	  22	  who	  reported	  sex	  (to	  reduce	  stigmatisation),	  who	  were	  aged	  15-­‐16	  years,	  and	  who	  were	  attending	  or	  had	  attended	  82	  randomly	  selected	  primary	  schools,	  were	  enrolled.	  The	  schools	  were	  randomly	  selected	  from	  all	  primary	  schools	  in	  3	  districts	  in	  Mwanza	  Region	  in	  north-­‐west	  Tanzania.	  Two	  of	  these	  districts	  were	  in	  Mwanza	  city	  and	  one	  was	  in	  a	  neighbouring	  rural	  district.	  Participants	  were	  seen	  every	  3	  months	  for	  a	  total	  of	  18	  months.	  At	  each	  visit,	  girls	  had	  a	  FtF-­‐interview	  with	  a	  female	  study	  nurse	  using	  a	  structured	  pre-­‐tested	  paper	  questionnaire,	  and	  provided	  one	  self-­‐administered	  nurse-­‐assisted	  vaginal	  swab.	  Questions	  were	  written	  in	  English,	  translated	  into	  Swahili	  and	  back-­‐translated	  for	  verification,	  and	  included	  colloquial	  terms	  for	  sexual	  behaviours	  that	  had	  been	  collected	  during	  focus	  group	  discussions	  with	  similar-­‐aged	  girls	  prior	  to	  commencement	  of	  the	  cohort	  study.	  The	  questionnaire	  covered	  demographic	  and	  socio-­‐economic	  details,	  non-­‐penetrative	  sexual	  behaviours	  including	  kissing,	  breast	  touching,	  oral	  sex,	  finger-­‐genital	  contact	  with	  a	  partner,	  penetrative	  vaginal	  sex,	  anal	  sex	  and	  the	  numbers	  and	  characteristics	  of	  sex	  partners.	  At	  each	  follow-­‐up	  visit,	  participants	  were	  asked	  about	  sexual	  behaviours	  since	  they	  were	  last	  seen	  by	  the	  study	  nurse.	  In	  order	  to	  check	  for	  pregnancy	  risk	  and	  potential	  passing	  of	  sexual	  debut	  between	  study	  visits,	  nurses	  had	  access	  to	  information	  on	  whether	  the	  participant	  had	  previously	  disclosed	  at	  an	  earlier	  visit	  ever	  having	  had	  sex,	  or	  breast	  touching	  or	  lip	  kissing	  (behaviours	  suggesting	  they	  were	  becoming	  increasingly	  sexually	  active).	  This	  information	  was	  coded	  on	  a	  form	  that	  was	  kept	  confidential.	  Nurses	  were	  trained	  to	  probe	  once	  if	  the	  participant	  offered	  an	  inconsistent	  response	  for	  a	  question	  that	  contradicted	  previously	  reported	  behaviours.	  Nurses	  did	  not	  disclose	  the	  answers	  from	  earlier	  visits	  and	  recorded	  the	  final	  answer	  given.	  	  
Sub-­‐study	  population	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Girls	  were	  randomly	  selected	  for	  this	  sub-­‐study.	  To	  be	  eligible,	  the	  ACASI	  sub-­‐study	  participants	  had	  to	  have	  attended	  the	  first	  follow-­‐up	  visit	  (month	  3),	  and	  to	  be	  resident	  in	  Mwanza	  city	  districts	  (Nyamangana	  and	  Ilemela)	  at	  that	  visit.	  The	  districts	  were	  selected	  for	  study	  logistics,	  and	  comprised	  both	  urban	  and	  rural	  administrative	  areas	  (known	  as	  wards).	  Further	  eligibility	  criteria	  were:	  attendance	  at	  the	  visit	  at	  which	  the	  sub-­‐study	  was	  performed	  (month	  12)	  and	  resident	  in	  Mwanza	  city	  districts	  at	  that	  visit,	  and	  being	  willing	  to	  participate	  in	  the	  sub-­‐study.	  
Sub-­‐study	  methods	  Eligible	  girls	  who	  agreed	  to	  participate	  underwent	  both	  ACASI	  and	  FtF-­‐interviews,	  the	  order	  of	  which	  (i.e.	  ACASI	  first	  or	  FtF-­‐interview	  first)	  had	  been	  randomly	  allocated	  at	  the	  time	  they	  were	  selected	  for	  inclusion,	  in	  a	  1:1	  ratio.	  Both	  interviews	  had	  to	  be	  completed	  within	  3	  consecutive	  days.	  All	  interviews	  took	  place	  in	  private	  at	  the	  participant’s	  home,	  school	  or	  a	  nearby	  health	  centre,	  depending	  on	  participant	  preference.	  The	  ACASI	  screen	  was	  only	  visible	  to	  the	  participant	  once	  she	  commenced	  the	  interview	  and	  FtF	  interviews	  were	  conducted	  where	  the	  interviewer	  and	  participant	  could	  not	  be	  overheard	  or	  seen.	  
Ethics	  The	  London	  School	  of	  Hygiene	  and	  Tropical	  Medicine	  (LSHTM)	  Ethics	  Committee	  and	  the	  Ethics	  Committee	  of	  the	  Medical	  Research	  Coordinating	  Committee	  (MRCC)	  in	  Tanzania	  approved	  the	  main	  study	  protocol	  (LSHTM	  approval	  6040,	  MRCC	  approval	  NIMR/HQ/R	  8a./Vol	  IX/1249).	  Since	  participants	  were	  under	  18	  years	  old	  at	  the	  time	  of	  enrolment	  into	  the	  main	  HPV	  Epidemiology	  Study,	  written	  informed	  parental	  consent	  was	  required	  before	  participants	  were	  approached	  for	  their	  assent	  for	  the	  main	  study.	  	  	  Both	  ethics	  committees	  approved	  the	  ACASI	  sub-­‐study	  as	  an	  amendment	  to	  the	  original	  study	  protocol,	  and	  did	  not	  require	  alteration	  of	  the	  informed	  consent	  from	  the	  main	  study	  (LSHTM	  amendment	  approval	  A354,	  MRCC	  amendment	  approval	  NIMR/HQ/R	  8a./Vol	  I/241).	  At	  the	  time	  of	  enrolment	  into	  the	  ACASI	  sub-­‐study,	  it	  was	  explained	  to	  the	  selected	  participants	  and	  they	  were	  invited	  to	  participate.	  Separate	  written	  consent/assent	  was	  not	  requested	  for	  the	  sub-­‐study.	  Participants	  were	  compensated	  for	  their	  time	  at	  each	  follow-­‐up	  visit	  of	  the	  main	  study	  with	  a	  health-­‐related	  item	  such	  as	  soap	  or	  a	  toothbrush.	  No	  additional	  compensation	  was	  offered	  for	  participating	  in	  the	  ACASI	  sub-­‐study.	  
ACASI	  development	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Development	  of	  the	  ACASI	  questionnaire	  and	  data	  management	  used	  QDSTM	  Version	  2.6.1	  software	  (NOVA	  Research	  Company,	  Bethesda,	  USA).	  The	  ACASI	  interviews	  were	  administered	  using	  a	  touch-­‐screen	  tablet	  computer	  (ViewSonic®	  ViewPad	  10Pro	  with	  Windows	  7	  Operating	  System).	  Structured	  questions,	  and	  a	  choice	  of	  answers	  or	  a	  number	  keypad,	  appeared	  on	  the	  screen	  at	  the	  same	  time	  as	  the	  audio-­‐recorded	  female	  voice	  (in	  Swahili)	  was	  heard	  through	  headphones.	  The	  touch	  screen	  only	  became	  responsive	  once	  the	  audio	  track,	  including	  instructions	  on	  how	  to	  answer	  and	  the	  available	  answers,	  had	  finished.	  No	  pictures	  were	  shown	  on	  the	  screen.	  There	  were	  8	  initial	  questions	  designed	  to	  help	  the	  participant	  practice	  using	  the	  tablet	  and	  which	  were	  used	  as	  a	  final	  competence-­‐check	  at	  analysis.	  These	  questions	  covered	  non-­‐sensitive	  topics,	  including	  ever	  having	  made	  a	  trip	  to	  the	  market,	  the	  number	  of	  people	  living	  in	  the	  house	  and	  the	  person	  the	  respondent	  last	  spoke	  to	  before	  ACASI,	  and	  were	  completed	  by	  the	  participant	  with	  the	  assistance	  of	  a	  non-­‐clinical	  research	  assistant.	  These	  8	  initial	  questions	  were	  then	  re-­‐started	  and	  the	  participant	  was	  requested	  to	  complete	  the	  questions	  alone.	  The	  participant	  could	  then	  choose	  to	  repeat	  the	  8	  questions	  any	  number	  of	  times	  before	  commencing	  the	  interview.	  Participants	  who	  incorrectly	  answered	  2	  key	  competence-­‐check	  questions	  of	  the	  8	  practice	  questions	  at	  the	  final	  attempt	  (‘Are	  you	  in	  Tanzania	  now?’	  and	  ‘Are	  you	  a	  boy	  or	  a	  girl?’)	  were	  permitted	  to	  complete	  the	  full	  interview,	  but	  their	  data	  were	  excluded	  from	  the	  analysis.	  The	  questions	  in	  ACASI	  were	  a	  sub-­‐set	  of	  questions	  from	  the	  FtF-­‐interview	  and	  the	  same	  wording	  was	  used	  in	  both,	  including	  colloquial	  terminology	  to	  describe	  sexual	  behaviours	  such	  as	  oral	  sex.	  Participants	  were	  asked	  whether	  they	  had	  ever	  had	  vaginal	  sex	  and,	  for	  other	  sexual	  behaviours,	  whether	  they	  had	  experienced	  these	  since	  they	  were	  last	  seen	  in	  the	  study.	  	  In	  the	  FtF	  questionnaire,	  nurses	  were	  not	  able	  to	  enter	  ‘don’t	  know’	  for	  the	  question	  on	  whether	  the	  participant	  had	  ever	  had	  sex.	  The	  limited	  response	  option	  for	  that	  question	  was	  intentionally	  included	  in	  the	  FtF-­‐questionnaire	  from	  the	  start	  of	  the	  main	  HPV	  Epidemiology	  Study	  so	  that	  participants	  were	  probed	  to	  answer	  the	  question.	  It	  was	  felt	  that	  in	  ACASI	  the	  ‘don’t	  know’	  response	  should	  be	  included	  for	  this	  question	  because	  the	  format	  would	  then	  be	  consistent	  throughout	  the	  interview,	  and	  would	  prevent	  those	  who	  were	  confused	  from	  guessing	  a	  yes/no	  answer.	  The	  ‘don’t	  know’	  responses	  in	  ACASI	  are	  presented,	  but	  the	  analysis	  of	  the	  reporting	  of	  ever	  having	  had	  sex	  was	  restricted	  to	  participants	  who	  did	  not	  select	  ‘don’t	  know’	  responses	  in	  ACASI.	  Once	  participants	  had	  completed	  both	  interviews,	  the	  research	  assistant	  conducted	  a	  brief	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face-­‐to-­‐face	  interview	  in	  Swahili	  to	  ascertain	  the	  participant’s	  experience	  with,	  and	  opinions	  of,	  ACASI.	  	  
Data	  management	  and	  statistical	  analysis	  FtF-­‐interview	  questionnaires	  were	  double-­‐entered	  into	  OpenClinica	  LLC	  (Akaza	  Research,	  Waltham,	  MA,	  USA).	  ACASI	  data	  were	  downloaded	  at	  the	  end	  of	  every	  day	  from	  the	  tablet	  computer.	  Data	  were	  merged	  and	  analysed	  using	  STATA	  V12.0	  (StataCorp	  LP,	  College	  Station,	  Texas,	  USA)	  and	  are	  available	  on	  request	  from	  the	  Data	  Access	  Committee	  at	  the	  Mwanza	  Interventional	  Trials	  Unit,	  via	  the	  website	  http://www.mitu.or.tz.	  Participant	  characteristics	  were	  summarised	  using	  information	  collected	  during	  the	  FtF-­‐interviews.	  Cross-­‐tabulations	  of	  reported	  behaviours	  were	  performed,	  and	  agreement	  measured	  using	  kappa	  statistics.	  The	  Mainland-­‐Gart	  test[15]	  for	  paired	  data	  was	  used	  to	  compare	  the	  proportion	  reporting	  each	  behaviour	  by	  (a)	  the	  order	  of	  interviews,	  and	  (b)	  whether	  the	  interviews	  were	  performed	  on	  the	  same	  or	  different	  days.	  Odds	  ratios	  (OR)	  and	  95%	  confidence	  intervals	  (CIs)	  for	  the	  association	  of	  interview	  method	  with	  disclosure	  of	  each	  behaviour	  were	  calculated	  using	  exact	  conditional	  logistic	  regression.	  Interaction	  terms	  were	  not	  incorporated	  into	  the	  model	  since	  numbers	  reporting	  behaviours	  were	  small.	  	  In	  secondary	  analyses,	  we	  compared	  reporting	  in	  FtF-­‐interviews	  in	  those	  who	  had	  versus	  had	  not	  completed	  a	  prior	  ACASI,	  using	  Fisher’s	  exact	  tests,	  in	  order	  to	  investigate	  the	  effect	  of	  previous	  ACASI	  on	  FtF-­‐interview	  reporting.	  We	  further	  compared	  reporting	  in	  ACASI	  in	  those	  who	  had	  not	  completed	  a	  previous	  FtF-­‐interview	  versus	  reporting	  in	  FtF-­‐interview	  in	  those	  who	  had	  not	  completed	  a	  prior	  ACASI,	  to	  examine	  whether	  reporting	  differences	  between	  ACASI	  and	  FtF-­‐interview	  in	  this	  sub-­‐group	  were	  similar	  to	  the	  primary	  analyses.	  	  	  
Sample	  size	  calculations	  Statistical	  power	  for	  the	  comparison	  of	  disclosure	  of	  sexual	  behaviours	  was	  estimated	  using	  methods	  for	  matched	  case-­‐control	  studies,	  where	  the	  OR	  is	  calculated	  from	  the	  number	  of	  discordant	  pairs	  (those	  who	  answer	  differently	  between	  each	  method)[16].	  A	  sample	  size	  of	  200	  participants	  was	  selected.	  For	  a	  behaviour	  with	  a	  disclosure	  prevalence	  of	  10%	  in	  FtF-­‐interview	  and	  15%	  in	  ACASI	  (reported	  sex	  was	  expected	  to	  be	  this	  or	  higher	  in	  the	  study	  population[17,18]),	  this	  sample	  size	  gave	  85%	  power	  to	  detect	  an	  OR	  of	  6.0	  or	  greater.	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Results	  Of	  503	  participants	  enrolled	  in	  the	  cohort	  study,	  334	  attended	  the	  3	  month	  visit	  and	  were	  resident	  in	  one	  of	  the	  two	  selected	  districts	  (Figure	  6.1).	  Of	  those,	  230	  (69%)	  participants	  were	  randomly	  selected	  to	  participate	  in	  the	  ACASI	  sub-­‐study.	  At	  the	  12	  month	  visit,	  12	  girls	  had	  moved	  outside	  the	  study	  districts,	  7	  had	  withdrawn	  from	  the	  cohort	  study,	  4	  were	  not	  found	  and	  2	  were	  deaf	  and	  not	  able	  to	  hear	  questions	  through	  the	  headphones.	  All	  205	  remaining	  participants	  were	  invited	  to	  complete	  an	  additional	  ACASI	  questionnaire	  and	  agreed	  to	  do	  so.	  Two	  were	  excluded	  from	  the	  analysis	  because	  they	  incorrectly	  answered	  the	  competence-­‐check	  question	  “Are	  you	  in	  Tanzania	  now?”.	  	  Of	  the	  203	  included	  participants,	  53%	  and	  47%	  were	  aged	  16	  and	  17	  years,	  respectively	  (Table	  6.1),	  the	  majority	  (72%,	  N=147)	  were	  attending	  secondary	  school,	  and	  one	  participant	  was	  married.	  Overall,	  104	  (51%)	  participants	  underwent	  ACASI	  first.	  Most	  participants	  (89%,	  N=181)	  underwent	  both	  interviews	  on	  the	  same	  day,	  17	  (8%)	  had	  the	  second	  interview	  on	  the	  following	  day	  and	  the	  remainder	  (2%,	  N=5)	  were	  interviewed	  two	  days	  later.	  The	  order	  of	  the	  interviews	  (ACASI	  first	  or	  FtF-­‐interview	  first)	  was	  evenly	  distributed	  amongst	  those	  interviewed	  by	  both	  methods	  on	  the	  same	  day	  or	  different	  days	  (Fisher’s	  exact	  test	  p>0.99).	  Half	  of	  the	  interviews	  (50%,	  N=101)	  took	  place	  in	  the	  participant’s	  home,	  71	  (35%)	  at	  school,	  25	  (12%)	  at	  a	  clinic	  and	  6	  (3.0%)	  in	  other	  locations.	  	  Twice	  as	  many	  participants	  reported	  that	  they	  had	  kissed	  a	  boy	  on	  the	  lips	  since	  they	  were	  last	  seen	  during	  ACASI	  compared	  to	  the	  FtF-­‐interview	  (14	  (7.4%)	  versus	  7	  (3.4%)	  respectively,	  p=0.05,	  kappa=0.55,	  Table	  6.2).	  The	  OR	  of	  disclosure	  of	  having	  kissed	  on	  the	  lips	  with	  ACASI	  compared	  to	  FtF-­‐interview	  was	  8.0	  (95%	  CI	  1.1-­‐355.0)	  (Table	  6.2).	  Conversely,	  there	  were	  more	  than	  twice	  as	  many	  reports	  of	  ever	  having	  had	  vaginal	  sex	  during	  FtF-­‐interview	  than	  by	  ACASI	  (15	  (7.4%)	  versus	  6	  (3.0%)	  respectively,	  p=0.02,	  kappa=0.45).	  The	  OR	  of	  disclosure	  of	  ever	  having	  had	  sex	  with	  ACASI	  compared	  to	  FtF-­‐interview	  was	  0.10	  (95%	  CI	  <0.01-­‐0.70).	  	  The	  reporting	  of	  other	  non-­‐penetrative	  sexual	  behaviours	  was	  infrequent	  in	  both	  interviews,	  with	  no	  strong	  evidence	  of	  increased	  reporting	  by	  either	  interview	  method.	  Five	  girls	  reported	  recent	  kissing	  with	  tongues	  during	  FtF-­‐interview,	  while	  6	  reported	  this	  in	  ACASI,	  and	  6	  reported	  breast	  touching	  in	  both	  interviews.	  Both	  the	  reporting	  of	  kissing	  with	  tongues	  and	  breast	  touching	  showed	  good	  agreement	  (kappa=0.91	  and	  0.66	  respectively).	  In	  each	  of	  the	  ACASI	  and	  FtF-­‐interviews,	  3	  participants	  reported	  that	  they	  had	  recently	  touched	  a	  boy’s	  penis	  with	  their	  hand;	  2	  of	  the	  3	  reported	  this	  in	  both	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interviews.	  In	  FtF-­‐interview,	  2	  participants	  reported	  that	  a	  boy	  had	  touched	  their	  vagina	  with	  his	  hand,	  compared	  to	  3	  reporting	  this	  in	  ACASI	  (kappa=0.39).	  Only	  one	  participant	  reported	  this	  in	  both	  interviews.	  Oral-­‐penile	  and	  oral-­‐vaginal	  contact	  were	  both	  reported	  once	  in	  a	  FtF-­‐interview	  and	  once	  in	  ACASI,	  by	  the	  same	  participant	  (kappa	  for	  both=1.00).	  Anal	  sex	  was	  reported	  by	  one	  participant	  during	  ACASI,	  and	  not	  reported	  during	  FtF-­‐interview.	  	  There	  was	  no	  evidence	  of	  an	  effect	  of	  interview	  order	  (ACASI	  first	  or	  FtF-­‐interview	  first)	  (Table	  6.2)	  or	  of	  whether	  the	  interview	  was	  carried	  out	  on	  the	  same	  day	  or	  different	  days	  (p=1.0	  for	  all	  behaviours	  except	  hand-­‐vaginal	  contact	  where	  p=0.69)	  on	  the	  reporting	  of	  sexual	  behaviours,	  although	  the	  power	  for	  these	  comparisons	  is	  low	  due	  to	  the	  low	  numbers	  reporting	  these	  behaviours.	  	  In	  the	  secondary	  analyses,	  comparing	  reporting	  in	  only	  FtF-­‐interviews,	  there	  was	  no	  evidence	  of	  an	  effect	  on	  reporting	  of	  having	  previously	  completed	  an	  ACASI	  (Supplementary	  Table	  6.4).	  Comparing	  reporting	  in	  ACASI	  with	  reporting	  in	  FtF-­‐interview	  from	  the	  first	  interviews	  only	  (i.e.	  ACASI	  without	  a	  prior	  FtF-­‐interview,	  and	  FtF-­‐interview	  with	  a	  prior	  ACASI),	  we	  observed	  similar	  trends	  as	  for	  the	  primary	  analyses	  (Supplementary	  Table	  6.5),	  but	  the	  power	  for	  the	  comparisons	  in	  these	  secondary	  analyses	  was	  low	  due	  to	  the	  low	  frequencies	  of	  reporting	  of	  behaviours.	  	  Combining	  any	  sexual	  behaviour	  into	  a	  single	  variable	  did	  not	  demonstrate	  any	  significant	  difference	  between	  interview	  methods.	  	  The	  majority	  of	  participants	  felt	  that	  ACASI	  was	  more	  secret	  than	  FtF-­‐interview	  (83%,	  N=168),	  and	  preferred	  ACASI	  to	  FtF-­‐interview	  for	  questions	  about	  sex	  (84%,	  N=171)	  (Table	  6.3).	  Two-­‐thirds	  of	  participants	  (70%,	  N=141)	  found	  ACASI	  “easy”	  and	  28%	  (N=57)	  found	  it	  “very	  easy”.	  One	  participant	  (0.5%)	  found	  it	  “difficult”.	  	  
	  
Discussion	  This	  study	  contributes	  important	  evidence	  to	  the	  debate	  around	  the	  feasibility,	  acceptability	  and	  validity	  of	  performing	  sensitive	  interviews	  using	  electronic	  self-­‐completed	  questionnaires	  in	  adolescents	  in	  a	  sub-­‐Saharan	  African	  setting.	  In	  Tanzanian	  girls	  aged	  16-­‐17	  years,	  we	  have	  demonstrated	  significantly	  higher	  reporting	  of	  kissing	  with	  ACASI	  compared	  to	  FtF-­‐interviews,	  but	  significantly	  lower	  reporting	  of	  ever	  having	  had	  penetrative	  vaginal	  sex.	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To	  our	  knowledge,	  our	  findings	  are	  the	  first	  published	  evaluation	  of	  ACASI	  in	  Tanzania,	  and	  the	  results	  conflict	  with	  some	  previous	  studies	  from	  the	  region.	  Most	  studies	  of	  ACASI	  in	  sub-­‐Saharan	  Africa,	  but	  not	  all,	  have	  shown	  higher	  reporting	  of	  sensitive	  behaviours	  compared	  to	  standard	  interview	  methods[12,13].	  A	  large	  randomised	  trial,	  in	  1495	  individuals	  aged	  15-­‐23	  years	  in	  Zimbabwe	  who	  had	  completed	  a	  baseline	  interview,	  allocated	  participants	  to	  one	  of	  four	  interview	  methods	  and	  found	  that	  the	  adjusted	  odds	  of	  reporting	  sex	  were	  doubled	  with	  ACASI	  compared	  to	  self-­‐completed	  questionnaires	  (SCQ)	  or	  interviewer-­‐administered	  questionnaires	  where	  the	  participant	  placed	  sensitive	  answers	  in	  a	  confidential	  voting	  box	  (12%	  reported	  sex	  with	  SCQ	  or	  using	  the	  confidential	  voting	  box	  compared	  to	  16%	  with	  ACASI)[19].	  Within	  a	  sub-­‐set	  of	  395	  participants	  who	  completed	  both	  ACASI	  and	  SCQ,	  this	  trend	  held	  although	  was	  weaker.	  Other	  studies	  have	  nested	  a	  test-­‐retest	  comparison	  (within	  the	  same	  participants)	  of	  methods	  within	  a	  longitudinal	  study,	  in	  a	  similar	  methodology	  to	  our	  study.	  A	  comparison	  of	  ACASI	  versus	  FtF-­‐interview	  in	  male	  and	  female	  sex	  workers	  in	  Kenya	  aged	  23-­‐32	  years	  was	  nested	  in	  the	  enrolment	  visit	  of	  a	  cohort	  study	  and	  demonstrated	  significantly	  higher	  reporting	  of	  sex	  partners	  in	  the	  past	  week	  and	  intra-­‐venous	  drug	  use	  with	  ACASI,	  but	  no	  significant	  difference	  in	  the	  reporting	  of	  condom	  use,	  anal	  sex	  or	  forced	  sex[20].	  A	  microbicides	  trial	  in	  Malawi	  compared	  ACASI	  used	  at	  a	  single	  visit	  to	  their	  standard	  FtF-­‐interview	  which	  was	  used	  during	  quarterly	  follow-­‐up	  (participants	  had	  completed	  a	  varying	  number	  of	  previous	  visits)[21].	  In	  585	  women	  aged	  18-­‐53	  years,	  reporting	  of	  anal	  intercourse	  and	  number	  of	  sex	  partners	  was	  higher	  using	  ACASI,	  and	  reported	  condom	  use	  was	  lower.	  Finally,	  a	  cohort	  study	  of	  adolescent	  sexual	  behaviour	  and	  schooling	  in	  Malawi,	  with	  participants	  aged	  16-­‐18	  years,	  used	  ACASI	  administered	  at	  every	  annual	  round.	  This	  was	  compared	  with	  FtF-­‐interview	  at	  the	  third	  round,	  and	  no	  significant	  difference	  was	  found	  in	  the	  reporting	  of	  sex[22].	  These	  studies,	  all	  of	  which	  examined	  responses	  given	  by	  the	  same	  individual	  exposed	  to	  both	  ACASI	  and	  FtF-­‐interviews	  during	  a	  longitudinal	  study,	  showed	  either	  higher	  reporting	  of	  sensitive	  sexual	  behaviours	  with	  ACASI,	  or	  no	  significant	  difference	  between	  the	  methods,	  in	  contrast	  to	  our	  finding	  of	  lower	  reporting	  of	  vaginal	  sex	  with	  ACASI.	  	  An	  explanation	  for	  the	  significantly	  lower	  reporting	  of	  vaginal	  sex	  with	  ACASI	  observed	  in	  our	  study	  may	  be	  related	  to	  the	  longitudinal	  design	  and	  intensity	  of	  follow-­‐up.	  Of	  the	  previous	  studies,	  one	  tested	  ACASI	  at	  the	  first	  interaction	  with	  a	  participant[20]	  and	  one	  nested	  a	  one-­‐off	  FtF-­‐interview	  when	  ACASI	  was	  used	  at	  every	  visit[22].	  In	  our	  study,	  similar	  to	  the	  microbicides	  trial	  cohort	  	  in	  Malawi[21],	  participants	  had	  already	  seen	  a	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study	  nurse	  at	  enrolment	  and	  at	  up	  to	  3	  follow-­‐up	  visits,	  during	  which	  they	  had	  been	  asked	  sensitive	  questions	  on	  sexual	  behaviour	  and	  intravaginal	  practices.	  	  We	  propose	  3	  possible	  explanations	  for	  our	  results.	  Firstly	  the	  participants	  may	  have	  developed	  a	  more	  trusting	  and	  comfortable	  relationship	  with	  the	  nurses	  in	  our	  study,	  since	  our	  study	  team	  consisted	  of	  only	  3	  nurses	  who	  were	  very	  experienced	  in	  counselling	  and	  adolescent	  sexual	  behaviour	  research,	  and	  each	  nurse	  tried	  to	  see	  the	  same	  participant	  at	  each	  interview.	  Secondly	  our	  nurse-­‐interviewers	  were	  encouraged	  to	  probe	  once,	  specifically	  if	  there	  were	  non-­‐verbal	  cues	  in	  the	  adolescent	  suggesting	  commencement	  of	  sexual	  activity	  (e.g.	  changes	  in	  physical	  appearance,	  changes	  in	  body	  language	  during	  discussion	  of	  sexual	  practices),	  and	  thirdly	  our	  nurse-­‐interviewers	  had	  access	  to	  previous	  data	  which	  would	  allow	  them	  to	  probe	  if	  there	  were	  inconsistencies	  in	  the	  participant’s	  reporting	  of	  sexual	  behaviour	  over	  time.	  This	  last	  point	  is	  especially	  relevant	  since	  it	  has	  been	  clearly	  shown	  that,	  irrespective	  of	  interview	  method,	  individuals	  change	  their	  disclosure	  of	  sexual	  behaviours	  during	  longitudinal	  follow-­‐up	  (e.g.	  reporting	  a	  lower	  number	  of	  sex	  partners	  over	  time)[23,24].	  In	  the	  previous	  cohort	  studies	  comparing	  FtF-­‐interviews	  with	  ACASI,	  it	  is	  not	  clear	  whether	  interviewers	  had	  access	  to	  previously-­‐reported	  sexual	  behaviour	  data	  [21,22].	  	  Explaining	  the	  meaning	  of	  medicalised	  terms	  for	  sexual	  practices	  is	  essential	  for	  accurate	  data	  collection,	  especially	  since	  what	  constitutes	  “sex”	  is	  not	  consistent	  within	  and	  between	  populations[25,26],	  and	  an	  interactive	  discussion	  of	  this	  may	  be	  helpful.	  In	  our	  study,	  sexual	  behaviours	  were	  described	  graphically	  (e.g	  vaginal	  sex	  was	  explained	  as	  “a	  penis	  going	  inside	  a	  vagina”)	  and	  colloquial	  terms	  for	  non-­‐penetrative	  sex	  behaviours	  such	  as	  oral-­‐genital	  contact	  were	  also	  used	  (e.g.	  the	  Swahili	  term	  “kula	  muhogo”,	  which	  directly	  translates	  as	  “eating	  cassava”,	  is	  a	  colloquial	  term	  for	  fellatio	  used	  by	  some	  adolescents	  and	  adults	  in	  our	  study	  area).	  In	  a	  FtF-­‐interview,	  the	  nurse	  could	  check	  the	  participant's	  understanding	  of	  each	  of	  these	  terms	  if	  the	  participant	  appeared	  confused,	  and	  the	  participant	  could	  ask	  questions.	  However,	  in	  ACASI,	  although	  the	  participants	  had	  heard	  these	  terms	  during	  previous	  FtF-­‐interviews,	  the	  recorded	  question	  was	  followed	  by	  the	  audio	  list	  of	  colloquial	  terms.	  This	  may	  have	  been	  confusing,	  and	  could	  be	  one	  explanation	  for	  the	  lower	  rates	  of	  sex	  reported	  in	  ACASI.	  Previous	  studies	  have	  argued	  that	  use	  of	  images	  in	  sensitive	  interviews,	  for	  example	  in	  coital	  diaries,	  can	  improve	  the	  reporting	  of	  sensitive	  behaviours[27,28].	  Such	  images	  were	  used	  in	  ACASI	  (but	  not	  the	  FtF-­‐interview)	  in	  the	  Zimbabwe	  study	  which	  found	  higher	  reporting	  of	  sexual	  acts	  with	  ACASI[21].	  However,	  we	  were	  advised	  that,	  because	  our	  study	  participants	  were	  considered	  legal	  minors,	  incorporation	  of	  explicit	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images	  of	  sexual	  behaviours	  into	  ACASI	  was	  not	  appropriate.	  	  	  Although	  we	  found	  lower	  reporting	  of	  sex	  with	  ACASI	  versus	  FtF-­‐interview,	  there	  was	  significantly	  higher	  reporting	  of	  kissing	  on	  the	  lips	  but	  not	  kissing	  with	  tongues.	  This	  could	  also	  be	  due	  to	  a	  misunderstanding	  of	  what	  constitutes	  a	  sexual	  kiss	  on	  the	  lips	  and,	  with	  no	  nurse	  to	  clarify	  this,	  over-­‐reporting	  could	  have	  been	  seen	  in	  ACASI.	  	  	  Overall	  reporting	  of	  anal	  sex	  and	  non-­‐penetrative	  sex	  behaviours	  was	  low,	  either	  because	  of	  under-­‐reporting	  or	  because	  these	  behaviours	  are	  uncommon	  in	  girls	  of	  this	  age-­‐group	  in	  the	  region[7].	  Kissing	  and	  breast-­‐touching	  were	  reported	  by	  girls	  who	  had,	  and	  those	  who	  had	  not,	  previously	  reported	  sex.	  However,	  oral	  sex	  and	  hand-­‐genital	  contact	  were	  only	  reported	  by	  girls	  who	  also	  reported	  previous	  sex.	  The	  low	  frequency	  of	  reporting	  limited	  the	  power	  to	  detect	  a	  difference	  between	  reporting	  methods.	  This	  also	  limited	  the	  power	  to	  detect	  the	  effect	  of	  the	  order	  of	  the	  interviews	  or	  time	  between	  interviews,	  on	  reporting.	  	  	  	  We	  were	  not	  able	  to	  validate	  reporting	  of	  sex	  with	  biological	  markers	  in	  this	  study.	  Although	  vaginal	  swabs	  were	  collected,	  and	  will	  be	  tested	  for	  HPV	  which	  is	  a	  common	  sexually	  transmitted	  virus,	  a	  longitudinal	  study	  conducted	  in	  the	  USA	  has	  shown	  that	  only	  39%	  of	  girls	  acquired	  HPV	  during	  the	  24	  months	  after	  first	  sex,	  and	  therefore	  this	  infection	  has	  a	  limited	  role	  as	  a	  marker	  for	  sexual	  debut	  in	  our	  study[29].	  In	  our	  region,	  antibodies	  to	  HSV2	  have	  been	  shown	  to	  be	  a	  marker	  of	  sexual	  activity	  in	  females	  aged	  15-­‐29	  years[30].	  However,	  given	  the	  age	  of	  our	  study	  participants,	  as	  well	  as	  the	  selection	  criteria	  (which,	  for	  the	  majority,	  included	  reporting	  no	  previous	  sex),	  the	  number	  of	  times	  of	  previous	  sex	  in	  those	  reporting	  and	  not	  reporting	  previous	  sex	  may	  have	  been	  low.	  Since	  the	  transmission	  probability	  of	  HSV2	  at	  first	  sex	  is	  not	  100%,	  and	  it	  is	  not	  recommended	  as	  a	  marker	  of	  sexual	  debut,	  its	  use	  as	  a	  biomarker	  in	  our	  study	  may	  have	  been	  limited[31].	  Alternative	  vaginal	  biomarkers	  of	  previous	  sex	  such	  as	  Y-­‐chromosome	  DNA,	  semenogelin	  or	  prostate-­‐specific	  antigen	  can	  only	  be	  utilised	  to	  validate	  self-­‐reported	  sex	  if	  samples	  are	  taken	  within	  days	  of	  reported	  sex[32].	  The	  use	  of	  in-­‐depth	  interviews	  may	  have	  offered	  another	  source	  of	  data	  for	  validation	  of	  the	  interview	  methods,	  and	  may	  have	  provided	  insight	  into	  participants'	  understanding	  of	  questions	  during	  ACASI[10].	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Further	  research	  should	  explore	  how	  well	  questions	  are	  understood	  with	  ACASI	  compared	  to	  other	  interview	  methods,	  and	  further	  attempts	  should	  be	  made	  to	  validate	  ACASI	  using	  in-­‐depth	  interviews	  or	  biomarkers	  such	  as	  HSV2	  if	  appropriate	  to	  the	  study	  population.	  Finally,	  our	  data	  demonstrate	  that	  the	  disclosure	  of	  sensitive	  behaviours	  with	  ACASI	  is	  population-­‐specific	  and	  this	  method	  should	  be	  tested	  locally	  before	  implementation	  in	  studies	  collecting	  such	  data.	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Table	  6:1.	  Socio-­‐demographic	  characteristics	  of	  203	  girls	  in	  Tanzania	  in	  the	  ACASI	  
versus	  FtF-­‐interview	  sub-­‐study	  	  	   Number	  (%)	  Age	  (years)	   16	   108	  (53.2)	  	  	   17	   95	  (46.8)	  
Currently	  married	  /	  living	  as	  married	  	   No	  	   202	  (99.5)	  Yes	   1	  (0.5)	  Area	  of	  residence	   Urban	   114	  (56.2)	  
	   Rural	   89	  (43.8)	  Lives	  with	   One	  or	  both	  parents1	   142	  (70.0)	  	  	   Other	  relative	  or	  friend	   57	  (28.1)	  	  	   Husband	   1	  (0.5)	  	  	   Employer	   3	  (1.5)	  Occupation	  	   Primary	  School	   13	  (6.4)	  	  	   Secondary	  School	  	   147	  (72.4)	  	  	   Working	  /	  vocational	  training	   13	  (6.4)	  	  	   At	  home	  &	  not	  working	  or	  schooling	   30	  (14.8)	  Religion	   Christian	   179	  (88.2)	  	  	   Muslim	   21	  (10.3)	  	  	   Other	  religion	   2	  (1.0)	  	  	   None	   1	  (0.5)	  Passed	  menarche	   No	   12	  (5.9)	  	  	   Yes	   191	  (94.1)	  1.	  Living	  with	  one	  or	  both	  parents	  does	  not	  exclude	  other	  family	  members	  residing	  in	  the	  household	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Table	  6:2.	  Reporting	  of	  sexual	  behaviours	  in	  FtF-­‐interview	  and	  ACASI	  in	  203	  girls	  in	  Tanzania	  aged	  16	  and	  17	  years	  	  
Sexual	  






yes	  in	  both	  
N	  (%)2	  
Kappa	  
p	  for	  diff	  
by	  
order3,4,5	  





Kissed	  (on	  lips)	  since	  last	  seen	   Yes	   7	  (3.4)	   14	  (7.4)	   6	  (4.0)	   0.55	   0.44	   8.0	  (1.1-­‐355.0)	   0.04	  No	   196	  (96.6)	   176	  (92.6)	   	   	   	   	   	  Don't	  know	   0	   13	   	   	   	   	   	  
Kissed	  (using	  tongues)	  since	  last	  seen	  
Yes	   5	  (2.5)	   6	  (3.0)	   5	  (3.5)	   0.91	   1.0	   -­‐	  8	   -­‐	  No	   198	  (97.5)	   191	  (97.0)	   	   	   	   	   	  Don't	  know	   0	   6	   	   	   	   	   	  
Breast	  touching	  since	  last	  seen	   Yes	   6	  (3.0)	   6	  (3.1)	   4	  (3.0)	   0.66	   1.0	   1.0	  (0.1-­‐13.8)	   1.00	  No	   197	  (97.0)	   189(96.9)	   	   	   	   	   	  Don't	  know	   0	   8	   	   	   	   	   	  
Hand	  (F)-­‐	  penis	  contact	  since	  last	  seen	  
Yes	   3	  (1.5)	   3	  (1.5)	   2	  (1.5)	   0.66	   1.0	   1.0	  (0.0-­‐78.5)	   1.00	  No	   200	  (98.5)	   194	  (98.5)	   	   	   	   	   	  Don't	  know	   0	   6	   	   	   	   	   	  
Hand	  (M)-­‐vagina	  contact	  since	  last	   Yes	   2	  (1.0)	   3	  (1.5)	   1	  (1.0)	   0.39	   1.0	   2.0	  (0.1-­‐118.0)	   1.00	  No	   201	  (99.0)	   196	  (98.5)	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seen	   Don't	  know	   0	   4	   	   	   	   	   	  
Oral	  (F)-­‐penis	  contact	  since	  last	  seen	  
Yes	   1	  (0.5)	   1	  (0.5)	   1	  (1.0)	   1.0	   1.0	   -­‐	  8	   -­‐	  No	   202	  (99.5)	   197	  (99.5)	   	   	   	   	   	  Don't	  know	   0	   5	   	   	   	   	   	  
Oral	  (M)-­‐vagina	  contact	  since	  last	  seen	  
Yes	   1	  (0.5)	   1	  (0.5)	   1	  (1.0)	   1.0	   1.0	   -­‐	  8	   -­‐	  No	   202	  (99.5)	   196	  (99.5)	   	   	   	   	   	  Don't	  know	   0	   6	   	   	   	   	   	  
Anal	  sex	  since	  last	  seen	   Yes	   0	   1	  (0.5)	   0	   1.0	   1.0	   -­‐	  
8	   -­‐	  No	   203	  (100)	   197	  (99.5)	   	   	   	   	   	  Don't	  know	   0	   5	   	   	   	   	   	  
Vaginal	  sex,	  ever	   Yes	   15	  (7.4)	   6	  (3.0)	   5	  (2.5)	   0.45	   1.0	   0.10	  (<0.01-­‐0.70)	   0.01	  No	   188	  (92.6)	   192	  (97.0)	   	   	   	   	   	  Don't	  know	   -­‐1	   5	   	   	   	   	   	  M	  is	  male,	  F	  is	  female.	  1.	  For	  FtF-­‐interviews,	  the	  “don't	  know”	  response	  was	  not	  available	  for	  questions	  on	  ever	  having	  had	  vaginal	  sex.	  2.	  The	  denominator	  is	  those	  responding	  either	  yes	  or	  no,	  and	  does	  not	  include	  those	  who	  responded	  “don't	  know”	  in	  either	  interview.	  3.	  From	  Mainland-­‐Gart	  test;	  “don’t	  know”	  responses	  were	  dropped	  from	  the	  analysis.	  The	  Mainland-­‐Gart	  test	  compares	  the	  discordant	  responses	  by	  sequence	  (ACASI	  first	  or	  FtF	  first)	  so	  the	  p	  values	  are	  not	  based	  on	  the	  cell	  frequencies	  as	  displayed	  in	  this	  table.	  4.	  Test	  for	  difference	  in	  response	  depending	  on	  which	  interview	  was	  given	  first	  (FtF-­‐first	  or	  ACASI	  first).	  	  5.	  p=1.0	  indicates	  that	  the	  distribution	  is	  degenerate,	  due	  to	  one	  of	  the	  marginal	  totals	  	  for	  the	  Mainland-­‐Gart	  test	  being	  zero.	  6.	  Odds	  of	  reporting	  the	  behaviour	  in	  ACASI	  versus	  reporting	  the	  behaviour	  in	  FtF-­‐interview	  from	  exact	  conditional	  logistic	  regression;	  “don’t	  know”	  responses	  were	  dropped	  from	  the	  analysis.	  	  7.	  Exact	  p-­‐values	  based	  on	  the	  binomial	  distribution.	  	  8.	  Odds	  ratios	  could	  not	  be	  estimated	  because	  there	  was	  only	  one	  or	  no	  discordant	  pairs.
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Table	  6:3	  Perceptions	  of	  ACASI	  and	  FtF-­‐interview	  in	  203	  Tanzanian	  girls	  aged	  16	  
and	  17	  years	   	   	  	   Number	  (%)	  
Secrecy	  of	  ACASI	  compared	  to	  FtF-­‐interview	   ACASI	  more	  secret	   168	  (82.8)	  ACASI	  less	  secret	   4	  (2.0)	  	  	   Equal	  secrecy	   26	  (12.8)	  	  	   Don't	  know	   5	  (2.5)	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Figure	  6:1.	  Flow	  diagram	  of	  inclusion	  in	  the	  ACASI	  versus	  FtF-­‐interview	  sub-­‐study.	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Supplementary	  tables	  
Table	  S6:4	  Reporting	  during	  FtF-­‐interview	  in	  those	  who	  completed	  the	  FtF-­‐
interview	  first	  (without	  prior	  ACASI)	  and	  reporting	  during	  FtF-­‐interview	  in	  those	  
who	  completed	  the	  FtF-­‐interview	  after	  a	  prior	  ACASI	  	  
	  M	  is	  male,	  F	  is	  female.	  1.	  Calculated	  using	  Fisher’s	  exact	  test	  	  	  	  
Sexual	  behaviour	  	  	   Reported	   FtF-­‐interview	  in	  those	  who	  had	  not	  completed	  a	  prior	  ACASI	  	  N	  (%)	  
FtF-­‐interview	  in	  those	  who	  completed	  FtF-­‐interview	  after	  ACASI	  	  N	  (%)	  
p1	  
Kissed	  (on	  lips)	  since	  last	  seen	   Yes	   2	  (2.0)	   5	  (4.8)	   0.44	  No	   97	  (98.0)	   99	  (95.2)	   	  Don’t	  know	   0	   0	   	  Kissed	  (using	  tongues)	  since	  last	  seen	   Yes	   1	  (1.0)	   4	  (3.9)	   0.37	  No	   98	  (99.0)	   100	  (96.2)	   	  Don’t	  know	   0	   0	   	  Breast	  touching	  since	  last	  seen	   Yes	   1	  (1.0)	   5	  (4.8)	   0.21	  No	   98	  (99.0)	   99	  (95.2)	   	  Don’t	  know	   0	   0	   	  Hand	  (F)-­‐	  penis	  contact	  since	  last	  seen	   Yes	   0	  (0.0)	   3	  (2.9)	   0.25	  No	   99	  (100.0)	   101	  (97.1)	   	  Don’t	  know	   0	   0	   	  Hand	  (M)-­‐vagina	  contact	  since	  last	  seen	   Yes	   0	  (0.0)	   2	  (1.9)	   0.50	  No	   99	  (100.0)	   102	  (98.1)	   	  Don’t	  know	   0	   0	   	  Oral	  (F)-­‐penis	  contact	  since	  last	  seen	   Yes	   0	  (0.0)	   1	  (1.0)	   1.0	  No	   99	  (100.0)	   103	  (99.0)	   	  Don’t	  know	   0	   0	   	  Oral	  (M)-­‐vagina	  contact	  since	  last	  seen	   Yes	   0	  (0.0)	   1	  (1.0)	   1.0	  No	   99	  (100.0)	   103	  (99.0)	   	  Don’t	  know	   0	   0	   	  Anal	  sex	  since	  last	  seen	   Yes	   0	  (0.0)	   0	  (0.0)	   1.0	  No	   99	  (100.0)	   104	  (100.0)	   	  Don’t	  know	   0	   0	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Table	  S6:5.	  Reporting	  during	  ACASI	  in	  those	  who	  had	  not	  completed	  a	  prior	  F2F-­‐
interview	  and	  reporting	  in	  F2F-­‐interview	  in	  those	  who	  had	  not	  completed	  a	  prior	  
ACASI	  
	  	  M	  is	  male,	  F	  is	  female.	  1.	  The	  denominator	  is	  those	  responding	  either	  yes	  or	  no,	  and	  does	  not	  include	  those	  who	  responded	  “don't	  know”	  in	  either	  interview.	  2.	  This	  combined	  variable	  excludes	  vaginal	  sex.	  Vaginal	  sex	  is	  not	  included	  since	  the	  “don’t	  know”	  option	  was	  not	  available	  in	  FtF-­‐interviews.	  3.	  Calculated	  using	  Fisher’s	  exact	  test.	  4.	  Includes	  only	  those	  who	  answered	  “don’t	  know”	  to	  all	  sexual	  behaviours.	  
Sexual	  behaviour	  	  	   Reported	   FtF-­‐interview	  in	  those	  who	  had	  not	  completed	  a	  prior	  ACASI	  N	  (%)1	  
ACASI	  in	  those	  who	  had	  not	  completed	  a	  prior	  FtF-­‐interview	  	  	  N	  (%)1	  
p3	  
Kissed	  (on	  lips)	  since	  last	  seen	   Yes	   2	  (2.0)	   7	  (7.1)	   0.17	  No	   97	  (98.0)	   92	  (92.9)	   	  Don’t	  know	   0	   5	   	  Kissed	  (using	  tongues)	  since	  last	  seen	   Yes	   1	  (1.0)	   4	  (3.9)	   0.37	  No	   98	  (99.0)	   98	  (96.1)	   	  Don’t	  know	   0	   2	   	  Breast	  touching	  since	  last	  seen	   Yes	   1	  (1.0)	   5	  (5.0)	   0.21	  No	   98	  (99.0)	   96	  (95.0)	   	  Don’t	  know	   0	   3	   	  Hand	  (F)-­‐	  penis	  contact	  since	  last	  seen	   Yes	   0	  (0.0)	   2	  (2.0)	   0.50	  No	   99	  (100.0)	   99	  (98.0)	   	  Don’t	  know	   0	   3	   	  Hand	  (M)-­‐vagina	  contact	  since	  last	  seen	   Yes	   0	  (0.0)	   2	  (1.9)	   0.50	  No	   99	  (100.0)	   101	  (98.1)	   	  Don’t	  know	   0	   1	   	  Oral	  (F)-­‐penis	  contact	  since	  last	  seen	   Yes	   0	  (0.0)	   1	  (1.0)	   1.0	  No	   99	  (100.0)	   101	  (99.0)	   	  Don’t	  know	   0	   2	   	  Oral	  (M)-­‐vagina	  contact	  since	  last	  seen	   Yes	   0	  (0.0)	   1	  (1.0)	   1.0	  No	   99	  (100.0)	   101	  (99.0)	   	  Don’t	  know	   0	   2	   	  Anal	  sex	  since	  last	  seen	   Yes	   0	  (0.0)	   0	  (0.0)	   1.0	  No	   99	  (100.0)	   101	  (100.0)	   	  Don’t	  know	   0	   3	   	  Reported	  any	  sexual	  behaviour2,	  ever	   Yes	   8	  (8.0)	   10	  (4.9)	   0.81	  No	   91	  (92)	   93	  (90.3)	   	  Don’t	  know4	   0	   1	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7 Discussion	  
7.1 Summary	  of	  results	  	  This	  chapter	  summarises	  the	  key	  results	  from	  each	  publication	  and	  how	  these	  link	  together.	  Since	  manuscripts	  1	  and	  2	  describe	  HPV	  prevalence	  and	  natural	  history	  in	  girls	  who	  did	  not	  report	  sex,	  they	  are	  summarised	  together.	  
7.1.1 Manuscript	  1	  and	  2:	  Prevalence,	  incidence	  and	  clearance	  of	  HPV	  in	  adolescent	  
girls	  before	  reported	  sexual	  debut	  The	  first	  and	  second	  manuscripts	  in	  this	  thesis	  aimed	  to	  determine	  the	  prevalence	  and	  incidence	  of	  HPV	  in	  girls	  who	  reported	  no	  previous	  sex,	  and	  associated	  risk	  factors.	  The	  HPV	  vaccine	  is	  recommended	  for	  girls	  before	  first	  sex,	  since	  it	  has	  the	  highest	  efficacy	  in	  girls	  and	  women	  who	  have	  not	  been	  exposed	  to	  HPV	  genotypes	  in	  currently	  available	  vaccines.	  HPV	  prevalence	  and	  incidence	  have	  been	  described	  in	  girls	  before	  first	  sex	  in	  high-­‐income	  countries,	  but	  not	  in	  SSA	  where	  the	  highest	  incidence	  of	  cervical	  cancer	  is	  seen	  and,	  therefore,	  where	  HPV	  vaccines	  may	  have	  the	  largest	  impact	  on	  cervical	  cancer	  incidence	  and	  mortality.	  	  The	  prevalence	  of	  HPV	  DNA	  of	  any	  genotype	  in	  474	  girls	  who	  were	  enrolled	  into	  the	  cohort	  and	  who	  reported	  no	  previous	  sex	  was	  8.4%,	  and	  of	  HR	  HPV	  DNA	  was	  5.3%.	  HPV	  prevalence	  in	  these	  girls	  was	  associated	  with	  a	  more	  than	  doubled	  odds	  of	  ever	  having	  practiced	  intravaginal	  cleansing,	  with	  evidence	  of	  a	  dose	  response.	  It	  is	  possible	  that	  reported	  intravaginal	  cleansing	  at	  enrolment	  was	  a	  marker	  for	  unreported	  sex[1].	  In	  a	  randomly	  selected	  subset	  of	  this	  group	  who	  did	  not	  report	  sex	  during	  18	  months	  of	  follow-­‐up,	  and	  excluding	  one	  who	  spontaneously	  reported	  being	  HIV	  positive	  (119	  girls),	  51	  new	  HPV	  infections	  were	  detected	  in	  438	  (11.6%)	  visits	  attended.	  The	  overall	  incidence	  rate	  of	  new	  HPV	  infections	  in	  these	  girls	  was	  29.4	  per	  100	  person-­‐years	  (95%CI:15.9-­‐54.2).	  Reporting	  having	  recently,	  or	  ever,	  cleansed	  inside	  the	  vagina	  during	  follow-­‐up	  was	  not	  associated	  with	  a	  new	  incident	  HPV	  infection.	  The	  detection	  of	  a	  new	  HPV	  infection	  was	  associated	  with	  having	  recently	  (in	  the	  past	  6	  months)	  spent	  a	  night	  away	  from	  home	  and,	  therefore,	  may	  be	  due	  to	  unreported	  sex.	  This	  finding	  supports	  the	  delivery	  of	  the	  HPV	  vaccine	  to	  girls	  several	  years	  before	  the	  expected	  age	  of	  sexual	  debut	  in	  a	  population.	  Although	  HPV	  was	  detected	  in	  8.4%	  of	  15	  or	  16	  year	  old	  girls	  at	  enrolment	  who	  reported	  no	  previous	  sex,	  only	  0.8%	  of	  these	  girls	  had	  infection	  with	  HPV16	  or	  -­‐18.	  During	  follow-­‐up	  of	  these	  girls	  who	  reported	  no	  previous	  sex,	  HPV16	  had	  the	  highest	  incidence,	  but	  was	  only	  detected	  in	  2.1%	  of	  follow-­‐up	  samples.	  HPV16	  and	  -­‐18	  are	  associated	  with	  over	  70%	  of	  cervical	  cancer	  cases,	  and	  are	  covered	  by	  both	  the	  bivalent	  and	  quadrivalent	  HPV	  vaccines	  which	  have	  a	  high	  efficacy	  at	  preventing	  infection	  and	  precancerous	  lesions	  with	  these	  genotypes[2,3].	  Since	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HPV16	  and	  -­‐18	  were	  infrequently	  seen,	  the	  HPV	  vaccines	  are	  likely	  to	  have	  high	  efficacy	  against	  both	  infection	  with	  HPV16	  and	  -­‐18	  and	  pre-­‐cancerous	  lesions	  caused	  by	  these	  genotypes,	  even	  if	  given	  to	  girls	  who	  are	  4-­‐5	  years	  older	  than	  the	  target	  age	  of	  9-­‐13	  years.	  
7.1.2 Manuscript	  3:	  HPV	  Incidence	  around	  the	  time	  of	  sexual	  debut	  in	  adolescent	  girls	  
in	  Tanzania.	  The	  third	  manuscript	  in	  this	  thesis	  describes	  the	  acquisition,	  duration	  and	  clearance	  of	  HPV	  in	  girls	  after	  reported	  sexual	  debut.	  Previous	  studies	  in	  middle	  and	  high-­‐income	  countries	  have	  shown	  a	  very	  high	  cumulative	  incidence	  of	  HPV	  around	  the	  time	  of	  sexual	  debut	  (38.9%	  at	  24	  months)[4],	  and	  factors	  associated	  with	  HPV	  incidence,	  as	  well	  clearance	  have	  been	  identified	  in	  these	  girls[5–7].	  There	  are	  few	  studies	  that	  describe	  HPV	  incidence	  and	  clearance	  in	  SSA[8–10],	  and	  none	  describing	  this	  around	  the	  time	  of	  sexual	  debut	  when	  incidence	  is	  likely	  to	  be	  highest.	  Girls	  included	  in	  this	  analysis	  were	  those	  who	  reported	  that	  they	  had	  passed	  sexual	  debut	  in	  the	  year	  prior	  to	  the	  start	  of	  the	  study	  (n=29),	  and	  those	  who	  reported	  passing	  sexual	  debut	  during	  the	  study	  (n=77).	  In	  those	  who	  reported	  sexual	  debut	  during	  the	  study,	  and	  who	  were	  HIV	  negative	  if	  tested,	  the	  median	  time	  from	  the	  reported	  date	  of	  first	  sex	  to	  HPV	  detection	  was	  4.9	  months.	  Within	  6	  months	  from	  the	  reported	  date	  of	  first	  sex,	  52.8%	  of	  girls	  had	  acquired	  HPV,	  and	  35.8%	  had	  acquired	  a	  HR	  type.	  The	  incidence	  of	  a	  new	  HPV	  infection	  in	  all	  girls	  who	  reported	  sex	  before	  or	  during	  the	  study	  was	  225	  per	  100	  person-­‐years	  (95%CI:166-­‐305).	  The	  incidence	  of	  HPV	  girls	  in	  this	  study	  was	  one	  of	  the	  highest	  reported	  in	  the	  current	  literature	  in	  studies	  where	  incidence	  in	  person-­‐years	  has	  been	  presented[10–15].	  	  There	  was	  a	  more	  than	  a	  two-­‐fold	  risk	  (aRR	  2.48)	  of	  acquisition	  of	  an	  incident	  HPV	  infection	  in	  girls	  who	  reported	  having	  had	  sex	  once	  (compared	  to	  reporting	  no	  sex)	  in	  the	  past	  3	  months.	  This	  was	  in	  keeping	  with	  other	  studies	  of	  HPV	  incidence	  in	  predominantly	  middle-­‐age	  women	  in	  North	  and	  South	  America,	  that	  report	  that	  recent	  sex	  is	  associated	  with	  HPV	  acquisition[16,17].	  Knowing	  the	  most	  recent	  sex	  partner	  for	  at	  least	  6	  months,	  compared	  to	  knowing	  them	  for	  less	  than	  1	  month,	  was	  associated	  with	  a	  more	  than	  triple	  risk	  of	  new	  HPV	  infection	  (aRR	  3.15).	  The	  reason	  for	  this	  is	  not	  clear,	  but	  the	  number	  of	  infections	  in	  those	  who	  had	  known	  their	  partner	  for	  under	  6	  months	  was	  small	  (26).	  Unlike	  other	  studies,	  we	  did	  not	  observe	  strong	  associations	  between	  factors	  associated	  with	  lower	  risk	  of	  HPV	  infection,	  such	  as	  most	  recent	  sex	  partner	  being	  circumcised[18]	  and	  condom	  use[7,19].	  This	  may	  be	  because	  condom	  use	  was	  rare,	  and	  because	  girls	  were	  not	  able	  to	  identify	  whether	  their	  male	  partners	  were	  circumcised	  or	  not.	  This	  has	  been	  demonstrated	  in	  a	  study	  of	  female	  partners	  (age18-­‐50	  years)	  of	  men	  in	  Zambia	  and	  Swaziland:	  11-­‐15%	  of	  women	  mis-­‐reported	  their	  male	  partner’s	  circumcision	  (in	  both	  directions)[20].	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The	  median	  duration	  of	  infection	  seen	  in	  our	  study	  was	  6.1	  months	  and	  was	  similar	  for	  HR	  and	  LR	  genotypes	  (6.0	  and	  6.1	  months	  respectively).	  Studies	  in	  younger	  women	  in	  the	  USA	  have	  shown	  similar	  duration	  of	  infection:	  in	  women	  with	  a	  median	  age	  15	  years,	  the	  median	  duration	  of	  HR/LR	  HPV	  types	  were	  7.5/5.6	  months[21],	  and	  in	  women	  with	  a	  mean	  age	  of	  24.2	  years,	  were	  9.8/4.3	  months[16].	  However,	  this	  is	  shorter	  than	  in	  many	  other	  reported	  studies.	  The	  median	  duration	  of	  HPV	  infection	  in	  women	  with	  a	  median	  age	  of	  32.3	  years	  in	  Columbia	  was	  14.8	  /11.1	  months	  for	  HR/LR	  infections	  respectively[17].	  Two	  studies	  in	  younger	  women	  in	  the	  US	  and	  USA	  showed	  a	  longer	  duration	  of	  infection	  that	  in	  our	  study.	  In	  the	  UK,	  women	  who	  had	  a	  median	  age	  of	  18	  years	  had	  a	  median	  duration	  of	  infection	  of	  13.7	  months[22],	  and	  the	  time	  to	  negative	  test	  in	  women	  with	  a	  mean	  age	  of	  19	  years	  in	  the	  USA	  was	  9.4	  months[23].	  All	  of	  these	  studies	  included	  women	  who	  were	  already	  sexually	  active.	  It	  is	  likely	  that	  the	  short	  duration	  of	  infection	  seen	  in	  women	  in	  our	  study	  was	  due	  to	  both	  younger	  age	  and	  first	  exposure	  to	  HPV	  at	  first	  sex.	  Additionally,	  differences	  in	  host	  genetics,	  which	  influence	  immune	  response	  and	  therefore	  HPV	  clearance,	  and	  variance	  within	  HPV	  genotypes,	  particularly	  in	  HPV16,	  may	  explain	  some	  of	  the	  variation	  in	  the	  duration	  of	  infection[24–26].	  	  	  
7.1.3 	  	  	  Manuscript	  4:	  Comparison	  of	  Audio	  Computer-­‐Assisted	  Self-­‐Interview	  with	  face-­‐
to-­‐face	  interview	  for	  disclosure	  of	  sexual	  behaviour	  in	  adolescent	  girls	  in	  
Tanzania	  The	  fourth	  manuscript	  in	  this	  thesis	  describes	  the	  examination	  of	  alternative	  methods	  for	  the	  collection	  of	  sensitive	  sexual	  behaviour	  data	  in	  the	  study	  population.	  This	  study	  was	  conducted	  	  after	  we	  observed	  a	  higher	  than	  expected	  prevalence	  of	  HPV	  in	  girls	  who	  denied	  previous	  sexual	  activity	  at	  the	  enrolment	  visit	  of	  the	  cohort	  study,	  where	  there	  might	  have	  been	  potential	  under-­‐reporting	  of	  penetrative	  sex	  or	  non-­‐penetrative	  sexual	  behaviours.	  Higher	  rates	  of	  reporting	  of	  sensitive	  behaviours	  had	  been	  previously	  demonstrated	  with	  the	  use	  of	  ACASI	  compared	  to	  other	  interview	  methods	  in	  Kenya	  and	  Zimbabwe[27,28].	  We	  elected	  to	  conduct	  a	  comparison	  of	  ACASI	  with	  FtF-­‐interview	  at	  the	  12	  month	  visit	  of	  the	  study	  to	  examine	  reporting	  of	  sexual	  behaviours.	  This	  comparison	  could	  not	  be	  performed	  earlier	  in	  the	  cohort	  study,	  as	  a	  protocol	  amendment	  and	  resubmission	  for	  ethics	  committee	  approval	  were	  required.	  Overall,	  203	  of	  the	  230	  randomly	  selected	  girls	  met	  eligibility	  criteria	  and	  successfully	  completed	  an	  ACASI	  in	  addition	  to	  their	  standard	  FtF-­‐interview,	  the	  order	  of	  which	  (ACASI	  first	  or	  FtF-­‐interview	  first)	  was	  randomly	  allocated.	  	  During	  ACASI,	  twice	  as	  many	  participants	  reported	  that	  they	  had	  kissed	  a	  boy	  on	  the	  lips	  since	  they	  were	  last	  seen	  compared	  to	  the	  reporting	  of	  this	  in	  the	  FtF-­‐interview	  17.4%	  vs.	  3.4%	  respectively;	  p=0.05,	  kappa=0.55).	  	  In	  contrast,	  more	  than	  twice	  as	  many	  girls	  reported	  that	  they	  had	  had	  vaginal	  sex	  during	  FtF-­‐interview	  than	  in	  ACASI	  (7.4	  vs.	  3.0%;	  p=0.02,	  kappa=0.45).	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Other	  behaviours	  (kissing,	  breast	  touching,	  hand-­‐genital	  contact,	  oral-­‐genital	  contact	  and	  anal	  sex)	  were	  infrequently	  reported	  and	  were	  not	  reported	  at	  significantly	  different	  rates	  between	  interview	  methods.	  	  	  These	  results	  reflect	  the	  challenge	  of	  obtaining	  consistent	  reports	  of	  sexual	  behaviours.	  Identifying	  which	  method	  is	  more	  valid	  is	  not	  possible,	  since	  there	  is	  no	  ‘gold	  standard’;	  reviews	  of	  ACASI	  compared	  to	  other	  methods	  of	  interview	  demonstrate	  conflicting	  results[29–31].	  The	  use	  of	  ACASI	  during	  the	  study	  was	  feasible,	  and	  97.6%	  of	  participants	  found	  ACASI	  easy	  to	  use,	  and	  84.2%	  preferred	  this	  interview	  method	  to	  FtF-­‐interview.	  It	  is	  likely	  that	  the	  characteristics	  of	  the	  populations	  studied	  (e.g.	  age,	  sex,	  ethnicity,	  educational	  level),	  the	  setting	  (e.g.	  clinics,	  home),	  the	  study	  design	  (e.g.	  longitudinal,	  cross-­‐sectional)	  and	  the	  technology	  employed	  (e.g.	  desk	  top	  computer,	  tablet,	  mobile	  phone)	  can	  influence	  the	  reporting	  of	  sexual	  behaviours	  in	  various	  studies[27,29,30,32].	  In	  this	  study,	  it	  is	  likely	  that	  the	  nurse’s	  ability	  to	  probe,	  especially	  given	  access	  to	  previous	  data,	  and	  the	  likelihood	  that	  nurses	  developed	  a	  trusting	  relationship	  with	  participants	  during	  previous	  FtF-­‐interviews	  may	  have	  led	  to	  higher	  reporting	  of	  sex	  in	  FtF-­‐interview.	  ACASI	  should	  be	  evaluated	  and	  compared	  to	  other	  interview	  methods	  in	  study	  settings	  that	  have	  not	  used	  this	  data	  collection	  modality	  before,	  prior	  to	  its	  use	  in	  studies	  that	  aim	  to	  collect	  accurate	  sexual	  behaviour	  data.	  	  	  	  	  	  
7.2 	  Methodological	  challenges	  
7.2.1 Strengths	  	  Major	  strengths	  of	  this	  study	  include	  the	  representativeness	  of	  the	  sample	  and	  high	  retention	  rate;	  416	  of	  the	  503	  (82.7%)	  enrolled	  participants	  attended	  the	  final	  visit.	  Participants	  were	  enrolled	  from	  primary	  school	  registers	  and	  registration	  at	  a	  primary	  school	  is	  a	  legal	  requirement	  in	  Tanzania.	  Included	  schools	  were	  a	  random	  selection	  of	  all	  government	  primary	  schools	  in	  the	  district	  and	  enrolled	  participants	  included	  those	  living	  in	  both	  rural	  and	  urban	  areas.	  	  The	  questionnaire	  included	  colloquial	  terms	  for	  sexual	  behaviours	  collected	  from	  girls	  of	  the	  same	  age	  and	  the	  interviewers	  employed	  were	  highly	  experienced	  in	  sexual	  behaviour	  research.	  Nurses	  in	  the	  study	  directly	  observed	  sample	  collection	  and	  requested	  repeat	  samples	  if	  necessary,	  leading	  to	  a	  low	  proportion	  of	  self-­‐administered	  swabs	  being	  considered	  inadequate.	  Another	  major	  strength	  of	  this	  study	  was	  the	  frequency	  of	  follow-­‐up.	  HPV	  incidence	  and	  clearance	  as	  well	  as	  updated	  data	  on	  sexual	  and	  other	  behaviours	  were	  measured	  at	  3	  monthly	  visits,	  allowing	  more	  accurate	  description	  of	  the	  natural	  history	  of	  infection	  than	  is	  available	  from	  studies	  that	  record	  these	  every	  4-­‐6	  months[4,11,12,14].	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7.2.2 Limitations	  The	  major	  limitations	  of	  this	  study	  include	  the	  potential	  for	  misclassification	  of	  sexual	  behaviour	  data.	  It	  is	  likely	  that	  sexual	  behaviours,	  including	  previous	  penetrative	  and	  non-­‐penetrative	  sex	  (i.e.	  kissing,	  breast	  touching,	  hand-­‐genital	  contact	  and	  oral	  sex)	  in	  our	  population	  of	  adolescent	  girls	  were	  under	  rather	  than	  over-­‐reported.	  This	  reporting	  bias	  is	  likely	  to	  have	  reduced	  the	  strength	  of	  associations	  seen.	  Further	  important	  exposure	  data	  include	  the	  reporting	  of	  intravaginal	  cleansing.	  It	  is	  not	  clear	  whether	  participants	  were	  more	  or	  less	  likely	  to	  report	  this.	  Ever	  having	  performed	  intravaginal	  cleansing	  was	  reported	  by	  34	  of	  106	  (32.1%)	  who	  reported	  sex	  at	  enrolment	  or	  follow-­‐up,	  and	  by	  141	  of	  397	  (35.5%)	  who	  did	  not	  report	  sex	  during	  follow-­‐up	  (p	  difference=0.51).	  	  In	  the	  baseline	  data	  (Chapter	  3)	  prevalent	  HPV	  was	  associated	  with	  the	  reporting	  of	  intravaginal	  cleansing	  with	  a	  clear	  dose	  response:	  increased	  frequency	  of	  cleansing	  was	  associated	  with	  higher	  odds	  of	  prevalent	  HPV.	  If	  performing	  intravaginal	  cleansing	  is	  a	  true	  risk	  factor	  for	  HPV	  acquisition,	  it	  is	  likely	  that	  a	  temporal	  association	  would	  be	  seen	  during	  follow-­‐up	  (i.e.	  recent	  intravaginal	  cleansing	  would	  be	  associated	  with	  incident	  HPV),	  and	  no	  association	  was	  seen	  during	  follow-­‐up	  in	  girls	  who	  did,	  and	  who	  did	  not	  report	  sex.	  However,	  this	  may	  be	  due	  to	  under-­‐reporting	  of	  intravaginal	  cleansing	  during	  follow-­‐up.	  We	  cannot	  rule	  out	  reporting	  bias	  if	  study	  nurses	  discouraged	  girls	  from	  practicing	  intravaginal	  cleansing	  because	  they	  were	  aware	  of	  potential	  adverse	  health	  consequences	  of	  this	  practice.	  	  Reporting	  bias	  (inaccurate	  information	  disclosed	  by	  the	  interviewee)	  and	  interview	  bias	  (inaccurate	  information	  recorded	  by	  the	  interviewer)	  remain	  significant	  problems	  in	  studies	  collecting	  data	  on	  sensitive	  behaviours.	  Staff	  training	  and	  the	  exploration	  of	  alternative	  interview	  methods	  are	  essential	  techniques	  to	  address	  this.	  In	  addition	  to	  staff	  training	  during	  this	  study,	  ACASI	  was	  trialled	  during	  follow-­‐up	  as	  an	  alternative	  interview	  method.	  This	  did	  not	  lead	  to	  higher	  reporting	  of	  penetrative	  vaginal	  sex,	  and	  was	  not	  continued	  during	  the	  study.	  	  	  	  	  
7.2.3 Sample	  size,	  study	  duration	  and	  missed	  visits	  Another	  limitation	  of	  this	  study	  in	  terms	  of	  describing	  the	  incidence,	  clearance	  and	  duration	  of	  HPV	  in	  girls	  who	  reported	  sex	  and	  associated	  risk	  factors,	  was	  the	  sample	  size	  and	  the	  duration	  of	  follow-­‐up.	  	  We	  had	  aimed	  to	  enrol	  500	  girls	  who	  reported	  that	  they	  had	  not	  passed	  sexual	  debut,	  of	  whom	  200	  (40%)	  were	  expected	  to	  report	  sex	  during	  18	  months	  of	  follow-­‐up	  based	  on	  a	  previous	  study	  in	  the	  region[33].	  We	  further	  intended	  to	  include	  26	  girls	  who	  reported	  sexual	  debut	  before	  enrolment.	  At	  the	  end	  of	  the	  recruitment	  period,	  we	  had	  enrolled	  481	  girls	  who,	  at	  the	  time	  they	  were	  recruited,	  reported	  no	  previous	  sex	  (96.2%	  of	  the	  500	  expected),	  and	  22	  who	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reported	  having	  passed	  sexual	  debut	  not	  more	  than	  one	  year	  prior	  to	  enrolment	  (84.6%	  of	  26	  expected).	  Of	  greatest	  concern	  was	  that,	  of	  the	  481	  who	  reported	  no	  previous	  sex	  at	  enrolment,	  22.0%	  (N=106	  ),	  rather	  than	  the	  40%	  expected,	  reported	  first	  sex	  by	  the	  end	  of	  the	  study.	  This	  smaller	  sample	  size	  of	  girls	  who	  reported	  that	  they	  had	  ever	  had	  sex	  at	  the	  end	  of	  the	  study	  led	  to	  lower	  power	  to	  detect	  the	  same	  effect	  size.	  We	  were	  unable	  to	  increase	  the	  sample	  size	  because	  of	  logistic	  and	  budget	  constraints.	  The	  proportion	  of	  girls	  expected	  to	  acquire	  HPV	  over	  12	  months	  after	  sexual	  debut	  was	  28.5%,	  based	  on	  a	  study	  in	  the	  USA	  in	  girls	  reporting	  first	  sex	  during	  follow-­‐up[34].	  In	  our	  study	  the	  median	  (IQR)	  follow-­‐up	  time	  after	  first	  sex	  was	  only	  5.8	  months	  (1.5-­‐10.4).	  Therefore,	  both	  the	  number	  of	  girls	  included	  in	  the	  study	  of	  incident	  HPV	  after	  first	  sex,	  and	  the	  number	  of	  follow-­‐up	  visits	  attended	  (due	  to	  the	  length	  of	  the	  study)	  were	  limited,	  reducing	  the	  period	  of	  exposure	  for	  analysis.	  However,	  due	  to	  the	  high	  incidence	  of	  HPV	  in	  the	  study	  population,	  after	  6	  months	  52.8%	  of	  girls	  who	  had	  no	  HPV	  prior	  to	  first	  sex,	  and	  who	  passed	  sexual	  debut	  during	  follow-­‐up,	  had	  acquired	  HPV,	  which	  mitigated	  the	  low	  power	  of	  the	  small	  study	  size.	  Exposures	  of	  interest	  (condom	  use,	  male	  circumcision,	  partner	  in	  a	  concurrent	  relationship,	  etc.)	  were	  reported	  by	  only	  a	  few	  girls,	  resulting	  in	  low	  power	  to	  detect	  associations	  between	  these	  and	  HPV	  prevalence,	  incidence	  and	  clearance.	  Further,	  because	  of	  the	  limited	  data,	  it	  was	  difficult	  to	  calculate	  an	  effect	  estimate	  adjusted	  for	  all	  potential	  confounders,	  and	  effect	  estimates	  may	  therefore	  be	  biased	  away	  from	  the	  null.	  	  For	  budget	  reasons,	  in	  the	  analysis	  of	  girls	  who	  reported	  no	  sex	  prior	  to	  or	  during	  the	  study,	  only	  samples	  collected	  at	  enrolment	  and	  at	  months	  6,	  12	  and	  18	  were	  tested	  for	  HPV.	  Samples	  collected	  at	  month	  3,	  9	  and	  15	  were	  not	  tested.	  Sexual	  behaviour,	  intravaginal	  practice	  and	  socio-­‐demographic	  data	  that	  had	  been	  collected	  during	  those	  visits	  (months	  3,	  9	  and	  15)	  were	  incorporated	  by	  generating	  variables	  which	  combined	  reported	  behaviour	  in	  the	  current	  visit	  and	  the	  visit	  3	  months	  earlier,	  if	  attended.	  Sensitivity	  analyses	  were	  performed	  to	  examine	  behaviours	  reported	  in	  the	  previous	  3	  months	  compared	  to	  behaviours	  reported	  over	  the	  previous	  6	  months,	  and	  no	  differences	  were	  seen	  in	  the	  associations	  between	  behaviour	  and	  HPV	  incidence.	  Since	  HPV	  infections	  can	  be	  transient	  (the	  median	  duration	  in	  our	  study	  of	  girls	  reporting	  sex	  was	  6.1	  months)	  it	  is	  likely	  that	  some	  infections,	  which	  were	  acquired	  and	  cleared	  between	  visits	  6	  months	  apart,	  were	  missed.	  Not	  capturing	  these	  transient	  infections	  may	  have	  diluted	  any	  associations	  between	  the	  infrequently	  reported	  non-­‐penetrative	  sexual	  behaviours	  and	  HPV	  acquisition	  (i.e.	  resulted	  in	  a	  bias	  towards	  the	  null).	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7.2.4 Study	  retention	  The	  final	  study	  visit	  was	  attended	  by	  416	  of	  the	  503	  (82.7%)	  enrolled	  participants.	  Table	  7.1	  summarises	  sociodemographic	  factors	  and	  sexual	  behaviours	  reported	  at	  enrolment	  by	  participants	  who	  did	  and	  did	  not	  attend	  the	  final	  visit.	  There	  were	  no	  significant	  differences	  in	  reported	  sexual	  behaviours.	  However,	  those	  who	  did	  not	  attend	  the	  final	  visit	  were	  more	  likely	  to	  be	  of	  non-­‐Christian	  religion,	  and	  were	  not	  attending	  school	  at	  enrolment.	  Importantly,	  those	  who	  did	  not	  attend	  the	  final	  visit	  were	  more	  likely	  to	  have	  HPV	  at	  enrolment	  (15	  of	  87	  (17.4%)	  versus	  32	  of	  415	  (7.8%),	  p<0.001).	  Since	  girls	  did	  not	  know	  their	  HPV	  result	  from	  the	  enrolment	  visit,	  their	  attendance	  was	  not	  influenced	  by	  the	  outcome,	  and	  this	  may	  have	  only	  had	  the	  effect	  of	  reducing	  the	  sample	  size	  and	  reducing	  the	  power	  to	  detect	  associations	  between	  behaviours	  during	  follow-­‐up	  and	  incident	  HPV.	  However,	  it	  is	  also	  possible	  that	  girls	  who	  were	  lost	  to	  follow-­‐up	  were	  more	  likely	  to	  acquire	  HPV	  over	  follow-­‐up	  (even	  if	  they	  did	  not	  differ	  in	  other	  baseline	  covariates)	  compared	  to	  those	  who	  remained	  in	  the	  study.	  	  	  
Table	  7:1.	  Distribution	  of	  selected	  variables	  at	  baseline	  in	  girls	  among	  those	  who	  
attended	  and	  those	  who	  did	  not	  attend	  the	  final	  study	  visit	  at	  18	  months	  
Baseline	  characteristics	   Attended	  final	  visit	  n=416,	  n	  (%)	  
Did	  not	  attended	  final	  
visit	  	  n=87,	  n	  (%)	   p-­‐value
1	  Age	  (years)	   	   	   	  	  	  	  	  	  15	  	   201	  (48.3)	   37	  (42.5)	   	  	  	  	  	  	  16	  	   215	  (51.7)	   50	  (57.5)	   0.33	  Residence	   	   	   	  	  	  	  	  	  	  Urban	   198	  (47.6)	   47	  (54.0)	   	  	  	  	  	  	  	  Rural	   218	  (52.4)	   40	  (46.0)	   0.23	  Composite	  household	  wealth	   	   	   	  	  	  	  	  	  Low	   138	  (33.2)	   30	  (34.5)	   	  	  	  	  	  	  Medium	   139	  (33.4)	   29	  (33.3)	   	  	  	  	  	  	  High	   139	  (33.4)	   28	  (32.2)	   0.97	  Occupation	   	   	   	  	  	  	  	  	  Schooling	   292	  (70.2)	   50	  (57.5)	   	  	  	  	  	  	  Working	  or	  vocational	  training	   4	  (1.0)	   2	  (2.3)	   	  	  	  	  	  	  Not	  working	  or	  schooling	   120	  (28.9)	   35	  (40.2)	   0.05	  Religion	   	   	   	  	  	  	  	  	  Christian	   370	  (89.0)	   71	  (81.6)	   	  	  	  	  	  	  Muslim	   36	  (8.7)	   10	  (11.5)	   	  	  	  	  	  	  Non-­‐Muslim	  non-­‐Christian	   10	  (2.4)	   6	  (6.9)	   0.06	  Kissed,	  ever	   	   	   	  	  	  	  	  	  Yes	   18	  (4.3)	   3	  (3.5)	   	  	  	  	  	  	  No	   398	  (95.7)	   84	  (96.6)	   0.71	  Hand-­‐genital	  contact,	  ever	   	   	  	  	  	  	  	  Yes	   4	  (1.0)	   1	  (1.2)	   	  	  	  	  	  	  No	   412	  (99.0)	   86	  (98.9)	   0.87	  Breast	  touching,	  ever	  	  	  	  	  	  Yes	   37	  (8.9)	   6	  (6.9)	   	  	  	  	  	  	  No	   379	  (91.1)	   81	  (93.1)	   0.54	  Vaginal	  sex,	  ever	   	   	   	  	  	  	  	  	  Yes	   25	  (6.0)	   3	  (3.5)	   	  	  	  	  	  	  No	   319	  (94.0)	   84	  (95.6)	   0.34	  Cleaned	  inside	  the	  vagina,	  ever	   	   	   	  	  	  	  	  	  Yes	   80	  (19.2)	   22	  (25.3)	   	  	  	  	  	  	  No	   336	  (80.8)	   65	  (74.7)	   0.20	  HPV	  (any	  genotype)2	   	   	   	  	  	  	  	  	  Positive	   32	  (7.8)	   15	  (17.4)	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  Negative	   378	  (92.2)	   71	  (82.6)	   0.006	  	  	  	  	  	  β-­‐globin	  negative3	   6	   0	   	  1P	  value	  is	  from	  Chi	  squared	  test	  2One	  participant	  did	  not	  provide	  a	  sample	  at	  enrolment	  3Those	  β-­‐globin	  negative	  were	  excluded	  from	  the	  comparison	  
	  
7.2.5 Unmeasured	  variables	  Due	  to	  budget	  constraints,	  we	  were	  unable	  to	  test	  for	  the	  presence	  of	  other	  STIs,	  with	  the	  exception	  of	  HIV,	  since	  voluntary	  counselling	  and	  testing	  for	  HIV	  was	  offered	  at	  the	  final	  visit.	  Girls	  who	  reported	  sex	  at	  any	  point	  during	  the	  study	  were	  verbally	  screened	  for	  symptoms	  of	  STIs	  at	  the	  visit	  they	  first	  reported	  sex,	  and	  every	  subsequent	  visit	  irrespective	  of	  further	  reports	  of	  sex.	  Diagnoses	  were	  syndromic	  and	  included	  vaginal	  discharge	  syndrome	  (VDS),	  genital	  ulcer	  disease	  (GUD)	  and	  pelvic	  inflammatory	  disease	  (PID).	  Only	  5	  of	  the	  106	  (4.7%)	  girls	  who	  reported	  ever	  having	  had	  sex	  were	  diagnosed	  with	  VDS,	  and	  this	  was	  not	  associated	  with	  incident	  HPV	  during	  the	  study.	  No	  diagnosis	  of	  GUD	  or	  PID	  were	  made.	  	  Bacterial	  vaginosis	  (BV),	  a	  predominantly	  asymptomatic	  infection,	  has	  been	  associated	  with	  the	  detection	  of	  HPV	  in	  cross-­‐sectional	  studies[35]	  and	  in	  longitudinal	  follow-­‐up	  of	  women	  in	  the	  USA[36].	  BV	  has	  been	  further	  associated	  with	  a	  reduced	  rate	  of	  clearance	  of	  HPV[36,37].	  Infection	  with	  Chlamydia	  trachomatis,	  another	  reproductive	  tract	  infection	  which	  can	  cause	  asymptomatic	  infection,	  has	  been	  associated	  with	  HPV	  persistence[38].	  It	  is	  possible	  that	  these	  unmeasured	  confounders	  affected	  our	  effect	  estimates	  of	  the	  association	  between	  sexual	  behaviours	  and	  the	  incidence	  and	  clearance	  of	  vaginal	  HPV	  in	  girls	  who	  reported	  sex.	  The	  detection	  of	  these,	  and	  other	  STIs	  such	  as	  Herpes	  simplex	  virus	  type	  2	  (HSV2)	  may	  have	  provided	  insights	  into	  the	  frequency	  unreported	  sex.	  However,	  a	  study	  in	  adolescent	  girls	  in	  the	  USA	  suggests	  that	  HPV	  acquisition	  may	  occur	  before	  bacterial	  STIs[39].	  Although	  HSV2	  has	  been	  shown	  to	  be	  a	  marker	  of	  previous	  sex	  in	  girls	  and	  women	  in	  Mwanza[40],	  measuring	  incident	  HSV2	  would	  have	  required	  regular	  blood	  tests,	  potentially	  reducing	  cohort	  retention.	  Furthermore,	  the	  transmission	  of	  HSV2	  per-­‐sex	  act	  is	  not	  100%	  suggesting	  that	  this	  may	  not	  be	  a	  reliable	  marker	  of	  sexual	  debut[40,41].	  	  Host	  genetics	  (Human	  Leukocyte	  Antigen-­‐type)	  influence	  both	  susceptibility	  to	  HPV	  infection,	  and	  the	  duration	  of	  HPV	  infection[42,43].	  However,	  measurement	  of	  this	  was	  beyond	  the	  budget	  for	  this	  study	  and	  again	  would	  have	  required	  blood	  sampling.	  HPV	  incidence	  and	  persistence	  are	  higher	  in	  HIV	  positive	  women	  compared	  to	  HIV	  negative	  women,	  and	  the	  rate	  of	  clearance	  of	  HPV	  is	  lower[12,44,45].	  In	  this	  study,	  HIV	  testing	  was	  only	  offered	  to	  girls	  who	  reported	  sex,	  and	  only	  accepted	  by	  49	  of	  91	  (53.8%).	  One	  participant	  tested	  HIV	  positive	  and	  was	  excluded	  from	  the	  analysis	  of	  HIV	  incidence	  and	  clearance	  in	  girls	  who	  reported	  sex.	  Participants	  who	  reported	  no	  previous	  sex	  at	  enrolment	  or	  during	  the	  study	  were	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not	  offered	  an	  HIV	  test,	  or	  asked	  about	  their	  HIV	  status.	  One	  participant	  in	  this	  group	  spontaneously	  reported	  being	  HIV	  positive	  (through	  presumed	  mother-­‐to-­‐child	  transmission),	  and	  was	  also	  removed	  from	  the	  analysis.	  Undiagnosed	  HIV-­‐infected	  participants	  in	  both	  groups	  may	  have	  unknowingly	  been	  included	  in	  the	  analysis,	  and	  introduced	  confounding.	  However,	  any	  effect	  is	  likely	  to	  be	  minimal,	  since	  the	  HIV	  prevalence	  in	  Tanzania	  is	  reported	  as	  only	  1.3%	  in	  15-­‐19	  year	  olds[46].	  
7.2.6 Outcome	  misclassification	  Self-­‐administered	  vaginal	  swabs	  were	  used	  for	  specimen	  collection	  in	  this	  study.	  This	  was	  particularly	  challenging	  in	  this	  age-­‐group	  since	  some	  girls	  had	  limited	  knowledge	  of	  their	  anatomy,	  and	  there	  was	  a	  risk	  that	  samples	  may	  reflect	  HPV	  genotypes	  from	  surrounding	  regions	  (e.g.	  external	  genital	  or	  peri-­‐anal	  regions).	  Nurse-­‐assisted	  self-­‐administered	  swabs	  were	  collected	  for	  this	  reason.	  During	  the	  collection	  procedure,	  the	  study	  nurse	  would	  carefully	  observe	  placement	  of	  the	  swab	  and	  request	  repeat	  sample	  collection	  if	  they	  were	  not	  satisfied	  that	  the	  swab	  had	  entered	  the	  vagina.	  Further,	  β-­‐globin	  (a	  marker	  for	  human	  cellular	  DNA)	  was	  considered	  an	  important	  marker	  of	  adequate	  vaginal	  sampling,	  and	  samples	  which	  tested	  negative	  for	  β-­‐globin	  were	  treated	  as	  missing	  in	  all	  analyses.	  In	  girls	  who	  reported	  no	  previous	  sex,	  20	  of	  438	  (4.6%)	  samples	  tested	  were	  negative	  for	  β-­‐globin,	  and	  in	  girls	  who	  reported	  sex,	  30	  of	  353	  (8.5%)	  were	  negative.	  Of	  these	  50	  β-­‐globin	  negative	  samples,	  5	  samples	  contained	  HPV	  DNA.	  These	  possible	  infections	  were	  not	  recorded	  in	  prevalence	  or	  incidence	  estimates.	  It	  is	  possible	  that	  samples	  were	  contaminated	  with	  HPV	  DNA	  during	  testing,	  but	  positive	  and	  negative	  controls	  were	  run	  according	  to	  test	  protocols	  (per	  12	  samples)	  and	  batches	  of	  12	  were	  re-­‐run	  if	  these	  controls	  were	  not	  valid.	  	  Estimates	  of	  the	  duration	  of	  genotype	  specific	  infections	  included	  genotype-­‐specific	  runs	  where	  a	  negative	  or	  missing	  sample	  was	  seen	  between	  two	  positive	  samples.	  This	  approach	  was	  based	  on	  evidence	  from	  studies	  that	  had	  examined	  intermittent	  detection	  of	  HPV	  genotypes[47,48].	  In	  these	  studies,	  two	  samples	  with	  an	  intervening	  negative	  have	  been	  considered	  to	  be	  the	  same	  infection	  if	  those	  detected	  genotypes	  had	  very	  similar	  DNA	  sequences,	  allowing	  for	  intermittent	  non-­‐detection	  over	  a	  short	  period	  of	  time.	  Genotypes	  are	  considered	  to	  be	  the	  same	  ‘variant’	  (i.e.	  the	  same	  infection,	  not	  a	  new	  infection	  with	  the	  same	  genotype)	  if	  the	  DNA	  sequence	  which	  codes	  for	  the	  L1	  protein	  varied	  less	  than	  2%[49].	  A	  study	  in	  the	  USA	  sequenced	  HPV16	  genotypes	  that	  had	  been	  detected	  in	  students	  tested	  every	  4	  months	  who	  have	  an	  intervening	  negative	  sample	  between	  two	  HPV16	  positive	  samples.	  The	  same	  HPV16	  variant	  was	  detected	  at	  visits	  before	  and	  after	  the	  intervening	  negative,	  and	  this	  implied	  persistent	  infection	  rather	  than	  re-­‐infection[48].	  The	  same	  investigators	  repeated	  this	  with	  a	  further	  10	  HPV	  genotypes	  and	  had	  similar	  results,	  where	  genotypes	  could	  be	  intermittently	  absent	  between	  positive	  visits	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during	  4-­‐monthly	  follow-­‐up.	  Again	  these	  were	  classified	  as	  persistent	  and	  not	  newly	  acquired	  infections[47].	  We	  therefore	  followed	  this	  approach	  and,	  in	  situations	  where	  there	  was	  one	  negative	  sample	  between	  two	  positive	  samples	  of	  the	  same	  genotype,	  the	  negative	  sample	  was	  considered	  a	  false	  negative	  and	  this	  constituted	  persistent	  infection	  with	  that	  genotype.	  This	  method	  may	  have	  led	  to	  the	  over-­‐estimation	  of	  HPV	  duration.	  This	  would	  not	  have	  affected	  HPV	  incidence,	  since	  women	  were	  only	  considered	  to	  be	  at	  risk	  of	  HPV	  genotype-­‐specific	  infection	  once.	  A	  further	  study	  to	  investigate	  the	  possibility	  of	  false	  negative	  samples	  is	  planned	  (section	  7.3.2).	  It	  will	  remain	  challenging	  to	  differentiate	  persistent	  infection	  or	  reactivation	  of	  infection	  from	  reinfection	  if	  there	  has	  been	  no	  change	  in	  partner	  since	  theoretically	  the	  same	  HPV	  genotype	  variant	  may	  be	  re-­‐acquired	  in	  the	  female	  partner.	  	  	  After	  first	  sex,	  the	  incidence	  of	  new	  HPV	  infections	  was	  very	  high,	  and	  the	  duration	  of	  infection	  short.	  In	  intervals	  with	  a	  prolonged	  gap	  between	  samples	  (for	  example,	  if	  the	  girl	  didn’t	  attend	  a	  visit	  or	  a	  valid	  sample	  was	  not	  provided),	  it	  is	  possible	  that	  a	  genotype	  may	  have	  been	  acquired	  and	  cleared.	  Any	  infection	  detected	  after	  a	  prolonged	  gap	  may	  not	  have	  been	  the	  first	  time	  the	  genotype	  was	  acquired.	  Therefore	  in	  the	  analysis	  of	  genotype-­‐specific	  incidence	  among	  girls	  after	  reported	  first	  sex,	  if	  there	  were	  gaps	  of	  over	  180	  days	  between	  samples,	  the	  observation	  time	  was	  censored	  at	  the	  date	  of	  the	  last	  available	  sample	  before	  the	  gap.	  However,	  this	  approach	  led	  to	  the	  exclusion	  of	  incident	  infections	  that	  occurred	  after	  gaps,	  particularly	  for	  the	  more	  common	  genotypes.	  	  For	  example,	  all	  incident	  infections	  of	  HPV61	  occurred	  after	  gaps	  in	  observation	  time.	  	  As	  a	  result,	  the	  rate	  of	  HPV61	  was	  underestimated;	  in	  the	  sensitivity	  analysis	  where	  girls	  were	  allowed	  to	  become	  at	  risk	  again	  after	  gaps,	  the	  rate	  of	  HPV61	  was	  10.9	  per	  100	  person-­‐years.	  When	  the	  observation	  time	  after	  the	  gap	  was	  censored,	  the	  rate	  of	  HPV61	  was	  0	  per	  100	  person-­‐years.	  For	  other	  genotypes,	  there	  was	  no	  substantial	  change	  in	  incidence	  rate.	  	  Gaps	  of	  over	  180	  days	  were	  also	  removed	  from	  the	  observation	  time	  in	  the	  analysis	  of	  any	  new	  HPV	  infection.	  However,	  since	  the	  acquisition	  and	  clearance	  of	  an	  HPV	  genotype	  during	  a	  gap	  would	  not	  substantially	  alter	  the	  risk	  of	  infection	  with	  other	  genotypes[50],	  in	  this	  analysis,	  girls	  were	  allowed	  to	  contribute	  at-­‐risk	  time	  after	  the	  gap.	  	  
7.3 Future	  research	  
7.3.1 Fomite	  transmission	  HPV	  was	  associated	  with	  intravaginal	  cleansing	  in	  girls	  who	  reported	  no	  previous	  sex	  at	  enrolment.	  The	  reporting	  of	  intravaginal	  cleansing	  was	  most	  likely	  a	  marker	  for	  under-­‐reported	  sex.	  However,	  mucosal	  HPV	  types	  have	  been	  detected	  on	  fingernails	  of	  adolescent	  girls[51],	  on	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the	  fingernails	  women	  and	  men	  with	  genital	  warts[52],	  and	  on	  toilet	  seats[53].	  The	  ability	  of	  HPV	  to	  remain	  infectious	  to	  mouse	  cells	  after	  desiccation	  for	  up	  to	  7	  days	  has	  also	  been	  shown[54].	  It	  is	  therefore	  possible	  that	  vaginal	  HPV	  infection	  could	  be	  acquired	  from	  shared	  cloths,	  washing	  basins,	  fingers	  or	  external	  genitals,	  since	  intravaginal	  cleansing	  involves	  the	  insertion	  of	  fingers	  or	  a	  cloth	  quite	  deep	  inside	  the	  vagina[55].	  	  	  A	  fomite	  investigation	  study	  is	  therefore	  underway.	  Samples	  have	  been	  collected	  from	  bathroom	  surfaces	  of	  study	  participants	  using	  a	  Dacron	  swab,	  and	  from	  the	  fingertips	  of	  study	  participants	  using	  a	  cervical	  brush	  at	  the	  final	  visit.	  These	  will	  be	  tested	  using	  the	  Roche	  Linear	  Array	  to	  determine,	  in	  the	  first	  instance,	  whether	  HPV	  DNA	  can	  be	  detected	  on	  these	  potential	  fomites.	  If	  HPV	  DNA	  is	  detected,	  further	  studies	  investigating	  viral	  viability	  may	  be	  indicated.	  	  In	  addition	  to	  the	  collection	  of	  samples	  from	  households	  and	  the	  fingertips	  of	  participants,	  we	  have	  collected	  oral	  rinse	  samples	  to	  determine	  the	  prevalence	  of	  oral	  HPV	  in	  the	  study	  population.	  HPV	  is	  associated	  with	  head	  and	  neck	  cancers,	  yet	  little	  data	  are	  available	  on	  oral	  HPV	  prevalence	  in	  sub-­‐Saharan	  Africa[56].	  
7.3.2 Persistent	  infection	  with	  intermittent	  detection	  In	  longitudinal	  follow	  up	  in	  this	  study,	  a	  negative	  sample	  between	  two	  samples	  positive	  for	  the	  same	  genotype	  was	  considered	  a	  false	  negative.	  The	  final	  positive	  sample	  in	  this	  situation	  could	  be	  due	  to	  re-­‐infection	  with	  the	  same	  genotype	  (possibly	  from	  the	  same	  or	  a	  new	  sex	  partner)	  or	  the	  intermittent	  detection	  of	  a	  persistent	  infection.	  Only	  a	  few	  studies	  (and	  none	  from	  Africa)	  have	  sequenced	  the	  HPV	  genome	  of	  pairs	  of	  samples	  where	  there	  was	  an	  intervening	  negative	  sample,	  and	  considered	  this	  a	  false	  negative	  if	  the	  two	  samples	  on	  either	  side	  were	  considered	  the	  same	  ‘variant’,	  determined	  by	  similarities	  in	  the	  HPV	  DNA	  genome[47,57].	  We	  have	  a	  unique	  opportunity	  to	  examine	  longitudinal	  sexual	  behaviour	  data	  and	  HPV	  DNA	  variance	  in	  genotype-­‐specific	  sample	  pairs	  between	  which	  there	  was	  one	  negative	  sample.	  The	  available	  sexual	  behaviour	  data,	  detailing	  whether	  participants	  did	  or	  did	  report	  sex	  with	  the	  same,	  or	  a	  new	  partner	  will	  add	  valuable	  information	  and	  contribute	  to	  the	  understanding	  of	  intermittent	  detection	  of	  HPV	  genotypes	  in	  women.	  This	  study	  is	  currently	  under	  discussion	  with	  ICO.	  
7.3.3 Extending	  the	  age	  of	  vaccination	  in	  Tanzania	  It	  has	  been	  clearly	  established	  that	  providing	  HPV	  vaccination	  to	  girls	  age	  9	  to	  13	  years	  is	  a	  cost-­‐effective	  method	  of	  reducing	  cervical	  cancer[58].	  Modelling	  studies	  in	  high-­‐income	  countries	  have	  suggested	  that	  extending	  the	  age	  of	  vaccination	  to	  older	  girls	  may	  also	  be	  cost	  effective	  (up	  to	  age	  22)[59].	  Modelling	  studies	  in	  low-­‐income	  countries	  are	  necessary	  in	  order	  to	  establish	  the	  potential	  impact	  of	  HPV	  catch-­‐up	  campaigns	  in	  older	  girls	  in	  these	  countries.	  This	  study,	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which	  describes	  genotype-­‐specific	  rates	  of	  HPV	  acquisition,	  will	  provide	  data	  to	  model	  the	  cost-­‐effectiveness	  of	  HPV	  catch-­‐up	  campaigns	  for	  girls	  of	  different	  ages.	  	  	  	  
7.4 Conclusion	  This	  study	  confirms	  the	  extremely	  high	  incidence	  of	  HPV	  in	  adolescent	  girls	  in	  Tanzania	  around	  the	  time	  of	  first	  sex.	  Previously,	  a	  very	  high	  incidence	  was	  seen	  in	  young,	  sexually	  experienced	  women	  in	  the	  same	  region	  of	  Mwanza,	  Tanzania	  at	  74	  per	  100	  person-­‐years[10].	  Similarly,	  a	  very	  high	  cumulative	  incidence	  was	  seen	  in	  young	  women	  in	  the	  1-­‐3	  years	  after	  first	  sex	  at	  39-­‐44%	  in	  Brazil	  and	  the	  USA[4,11,60].	  The	  rate	  of	  HPV	  acquisition	  seen	  in	  the	  study	  presented	  was	  higher	  than	  those	  previously	  reported;	  HPV	  incidence	  was	  225	  per	  100	  person-­‐years,	  and	  cumulative	  incidence	  at	  6	  months	  was	  53%.	  Further,	  the	  duration	  of	  HPV	  infection	  was	  shorter	  than	  that	  reported	  in	  most	  studies[22,23],	  and	  may	  reflect	  rapid	  clearance	  after	  first	  exposure	  to	  the	  virus	  at	  first	  sex.	  	  The	  reporting	  of	  vaginal	  sex	  was	  lower	  than	  expected	  in	  the	  study	  population,	  and	  few	  non-­‐penetrative	  sexual	  behaviours	  (kissing,	  breast	  touching,	  hand-­‐genital	  contact)	  were	  reported.	  It	  is	  likely	  that	  previous	  sex	  was	  under-­‐reported,	  and	  possible	  that	  non-­‐penetrative	  sexual	  behaviours	  were	  infrequently	  practiced	  as	  well	  as	  under-­‐reported.	  The	  study	  confirms	  the	  challenge	  of	  collecting	  accurate	  sexual	  behaviour	  data	  in	  adolescents	  and	  the	  importance	  of	  testing	  alternative	  methods	  of	  interview	  such	  as	  ACASI	  before	  implementing	  them.	  	  Further	  research	  is	  underway	  to	  explore	  the	  possibility	  of	  fomite	  transmission	  of	  HPV	  in	  the	  context	  of	  a	  region	  with	  high	  rates	  of	  intravaginal	  cleansing,	  HPV	  and	  cervical	  cancer.	  Future	  studies	  also	  include	  further	  investigation	  of	  the	  possibility	  of	  intermittent	  detection	  of	  persistent	  HPV,	  and	  a	  study	  of	  oral	  HPV	  prevalence.	  Finally,	  modelling	  the	  most	  appropriate	  upper-­‐age	  of	  vaccination	  will	  be	  performed	  using	  these	  data	  in	  order	  to	  inform	  HPV	  vaccination	  campaigns	  in	  this	  region.	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Annex	  9.	  Colloquial	  terms	  for	  sexual	  behaviours	  Term	  in	  	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Sex	   Ku-­‐do	   sex	   	  Kuchakachuliwa	   sex	   	  Kugongwa	  mshipa	   sex	   	  Ku	  sex	   sex	   	  Kutiana	   sexual	  intercourse	   ?more	  formal	  terminology	  Kuingia	  ngumu	  kutoka	  laini	   hard	  to	  enter,	  soft	  to	  remove	   	  Kuingia	  kavu	  kutoka	  mbichi	   dry	  entering,	  wet	  while	  removed	   	  Malavidavi	   	   	  	  Term	  in	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Kiss	  with	  tongues	  /	  busu-­‐la	  kunyomyana	   Kula	  denda	   Saliva	  sucking	   	  Kula	  uroda	   	   	  	  Term	  in	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Boy	  touching	  girls	  breasts	  /	  Kushika	  matiti	  
Ku-­‐survey	   	   	  Kutomasatomasa	   	   	  kujivinjari	   	   	  	  Term	  in	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Anal	  sex	  /	  Kujamiiana	  kwa	  njia	  ya	  hajakumbwa	  
Kula	  mgongo	   eat	  back	   	  Kula	  tigo	   eat	  tigo	   	  Kupakua	  kisamvu	   eat	  cassava	  leaves	   	  Kufilana	   anal	  sex	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Term	  in	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Boys	  penis	  rubbed	  between	  thighs,	  buttocks	  or	  outer	  genitals	  /	  Kuchezesha	  uume	  kwenye	  mapaja,	  matakoni,	  nje	  ya	  uke	  
Kupiga	  katerelo	   	   	  Kupiga	  puchu	   	   	  	   	   	  	   	   	  	   	   	  	   	   	  	   	   	  	   	   	  	  Term	  in	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Oral	  sex,	  penis	  in	  mouth	  /	  Kuweka	  uume	  mdomoni	  
Kula	  cone	   eat	  cone	  (ice-­‐cream	  cone)	   	  Kula	  muwa	   eat	  sugar	  cane	   	  kula	  ndizi	   eat	  banana	   	  Kula	  muhogo	   eat	  cassava	   	  kula	  tango	   eat	  cucumber	   	  Kula	  pipi	  ya	  kijiti	   eat	  sweet	  roll	   	  Kupiga	  mswaki	   tooth	  brushing	   	  Alamba	   	   	  	  Term	  in	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Oral	  sex,	  mouth	  on	  vagina	  /	  Kulamba	  uke	   Kuzama	  chumvini	   drown	  in	  salt	   	  kula	  pera	   eat	  pear	   	  kula	  apple	   eat	  apple	  	   	  Kufyonza	  embe	   sucking	  mango	   	  Term	  in	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Boy	  touching	  girls	  vagina	  /	  Kushika	  uke	  kwa	  mkono	  
Kupiga	  brush	   brushing	   	  Ku	  survey	   surveying	   	  Kutomasatomasa	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Term	  in	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Girls	  word	  for	  boyfriend	   Kipapatio	   	   	  Basha	  langu	   	   	  boy-­‐friend	   	   	  Ki	  manzi	   boy-­‐friend	   	  Kichuana	   	   	  Mshikaji	  	   boyfriend	   	  Jamaa	  yangu	   	   	  Buzi	   	   	  Shalobalo	   	   	  Wa	  ukeweli	   	   	  HB	   handsome	  boy	   	  My	  Carpet	   	   	  Partiner	   	   	  Asali	  ya	  moyo	   honey	  of	  my	  heart	   	  Baby	  boy	   	   	  Sweetie	   	   	  Special	  boy	   	   	  Honey	   	   	  My	  Chocolate	   	   	  My	  Lover	   	   	  Maabuba	   	   	  La	  Azizi	   	   	  Mshua	   	   	  Pedeshee	   	   These	  terms	  apply	  to	  male	  partner	  over	  35yrs	  old	  
Bakurutu	   	  Sabantele	   	  Fataki	   	  	  Term	  in	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Boys	  word	  for	  girlfriend	   Kifunishi	   parcel	   	  Ki-­‐portable	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Wa	  kuzugia	   	   	  Candy	   	   	  Demu	   girl-­‐friend	   	  Toto	  langu	   my	  baby	   	  Fisi	  maji	  	   ?	  in	  the	  water	   	  Ngau	   	   	  Kichenchede	   	   These	  terms	  apply	  to	  girls	  if	  the	  boy	  has	  multiple	  partners.	  
Kicheche	   	  La	  Wote	   	  Paka	  mapepe	   	  Jamvi	  la	  wageni	   	  girl-­‐friend	   	   	  Kisura	   	   	  Mpondo	   big	  buttocks	   	  Mrembo	   beauty	   	  Mrupo	   	   	  Habipt	   	   	  Kipimajoto	   temperature	  measure	   	  Blanket	   	   	  Ubavu-­‐wangu	   Partner	   	  Nyongo	  mkaliaini	   	   	  	  Term	  in	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Vagina	  /	  Uke	   Kitumba	   	   	  Bakuli	   bowl	   	  Kisima	   well	   	  Buyu	  la	  asali	   bowl	  of	  honey	   	  Chunga	   pot	   	  Andazi	   	   	  Mgodi	   mine	   	  Bulibul	   	   	  Mbuda	   	   	  Kinu	   local	  motor	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Kidondandugu	   chronic	  wound	   	  Mtaro	  wa	  maji	  machafu	   	   	  pochi	   wallet	   	  Kichongeo	   sharpener	   	  Kibumbu	   	   	  	  Term	  in	  English/Swahili	   Swahili	  slang	   Direct	  translation	   Notes	  Penis	  /	  Uume	   Gogo	   big	  penis	   	  Kiboroso	   small	  penis	   	  Pencil	   	   	  Muhogo	  	   cassava	   	  Dudu	   	   	  Alikafimbo	   	   Penis	  which	  cannot	  become	  erect	  Mshipa	   muscles	   	  Mwanafalsafa	   	   	  Mchafuzi	  wa	  mazingira	   	   	  Kidumu	   	   	  Mkoromboko	   	   	  Mchi	   big	  penis	   	  Mashine	   Machine	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Annex	  10.	  Clinical	  outcomes	  
Table	  2.2	  Criteria	  for	  referral	  for	  clinical	  follow	  up	  of	  persistent	  HPV	  at	  study	  completion	  
Participant	  (number)	  
Follow-­‐up	  samples	  which	  
were	  tested	  for	  HPV	  
Criteria	  for	  clinical	  referral	  at	  study	  
completion	  Reported	  sex	  either	  before	  or	  during	  study	  (106).	  
Group	  1.	   All	  samples;	  3,	  6,	  9,	  12,	  15,	  18	  months	  
Three	  consecutive	  positive	  samples	  for	  the	  same	  HR	  HPV	  genotype	  where	  the	  final	  sample	  was	  from	  the	  final	  visit	  attended	  Did	  not	  report	  sex	  either	  before	  or	  during	  the	  study	  but	  randomly	  selected	  (120).	  
Group	  2.	  
6	  month	  samples;	  6,	  12,	  18	  months	   Two	  consecutive	  positive	  samples	  for	  the	  same	  HR	  HPV	  genotype	  where	  the	  final	  sample	  was	  from	  the	  final	  visit	  attended	  Did	  not	  report	  sex	  either	  before	  or	  during	  the	  study	  and	  not	  randomly	  selected	  (277).	  
Group	  3.	  
If	  the	  enrolment	  sample	  was	  positive	  for	  a	  HR	  HPV	  genotype,	  the	  final	  (attended)	  visit	  sample	  was	  tested	  
Sample	  at	  final	  visit	  was	  positive	  for	  the	  same	  HR	  HPV	  genotype	  as	  enrolment	  
	  
Summary	  of	  clinical	  follow-­‐up	  Group	  1	  Of	  the	  106	  girls	  who	  reported	  sex,	  11	  (10.4%)	  met	  criteria	  for	  clinical	  follow-­‐up	  at	  study	  completion.	  One	  participant	  refused	  follow-­‐up,	  and	  10	  girls	  were	  seen	  at	  Bugando	  Medical	  Centre	  (BMC)	  for	  visual	  inspection	  with	  ascetic	  acid	  (VIA).	  None	  had	  abnormal	  findings.	  Group	  2	  Of	  the	  120	  girls	  who	  reported	  not	  having	  had	  sex	  before	  or	  during	  the	  study,	  and	  who	  were	  randomly	  selected	  for	  the	  incidence	  study,	  5	  met	  clinical	  criteria	  for	  follow-­‐up	  at	  study	  completion.	  One	  was	  not	  found,	  and	  one	  refused	  to	  be	  seen	  at	  BMC.	  Three	  underwent	  VIA,	  and	  none	  had	  abnormal	  findings.	  Group	  3	  Of	  the	  277	  girls	  who	  did	  not	  report	  sex	  before	  or	  during	  the	  study,	  and	  who	  were	  not	  randomly	  selected	  for	  the	  incidence	  study,	  9	  had	  HR	  HPV	  at	  enrolment	  into	  the	  study.	  Of	  those,	  5	  had	  the	  same	  HR	  HPV	  genotype	  detected	  at	  the	  last	  visit	  they	  attended	  and	  therefore	  met	  criteria	  for	  clinical	  follow-­‐up.	  Of	  those,	  1	  was	  not	  found,	  and	  2	  refused	  to	  be	  seen	  at	  BMC.	  Two	  underwent	  VIA	  at	  BMC	  and	  none	  had	  abnormal	  findings.	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Annex	  11.	  ACASI	  questions	  Test	  Questions:	  	   Question	   Possible	  responses	   Verbal	  instructions	  –	  for	  ACASI	  on	  laptop	   Skip	  1	   Wewe	  ni	  msichana	  au	  mvulana?	  	  
Are	  you	  a	  boy	  or	  a	  girl	  
Mvulana	  Msichana	   Chagua	  moja	  kati	  ya	  mvulana	  au	  msichana	  
Choose	  one	   	  2	   Una	  umri	  wa	  miaka	  mingapi?	  
What	  is	  your	  age?	   Enter	  number	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  	  
Enter	  number.	  If	  you	  don’t	  know,	  
choose	  I	  don’t	  know	  on	  the	  right	  
	  
	   Unaishi	  na	  nani	  katika	  kaya(nyumba)	  unayoishi?	  	  
Who	  lives	  in	  your	  house	  
with	  you?	  
Baba	  Mama	  Kaka	  Dada	  Shangazi	  Mjomba	  Mama	  mdogo	  Mama	  mkubwa	  Baba	  mdogo	  Baba	  mkubwa	  Babu	  Bibi	  Rafiki	  Ndugu	  wengine	  Watu	  wengine	  
choose	  all	  that	  apply	   	  
3	   Uko	  Tanzania	  kwa	  sasa?	  
Are	  you	  currently	  in	  
Tanzania?	  
Ndiyo	  Hapana	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	  
Choose	  yes	  or	  no.If	  you	  don’t	  
know	  choose	  I	  don’t	  know	  on	  the	  
right	  
	  
4	   Ulishawahi	  kwenda	  sokoni?	  	  
Have	  you	  ever	  been	  to	  
the	  market	  
Ndiyo	  Hapana	  	  
yes/no	  
Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	  
Choose	  yes	  or	  no.If	  you	  don’t	  
know	  choose	  I	  don’t	  know	  on	  the	  
right	  
Skip	  next	  q	  if	  answer	  “no”	  5	   Katika	  miezi	  mitatu	  iliyopita	  ulienda	  sokoni	  mara	  ngapi?	  
	  
In	  the	  past	  three	  
months	  how	  many	  
times	  have	  you	  been	  to	  
the	  market?	  
Mara	  moja	  Mara	  mbili	  Mara	  tatu	  Mara	  nne	  Mara	  tano	  Mara	  sita	  Zaidi	  ya	  mara	  sita	  
Changua	  jibu	  sahihi.	  Au	  unaweza	  ukabahatisha	  jibu	  sahihi.	  	  	  
	  
6	   Ni	  nani	  uliyeongea	  naye	  kwa	  mara	  ya	  mwisho	  kabla	  haujaja	  katika	  haya	  majadiliano?	  	  	  
	  anaweza	  kuwa	  mototo	  au	  mtu	  yeyote.	  Pia	  inawezekana	  ikawa	  jana	  kama	  ulikuwa	  haujaongea	  na	  mtu	  yeyote	  	  
Who	  was	  the	  last	  
Mama	  Baba	  Dada	  Kaka	  Bibi	  Babu	  Shangazi	  Mjomba	  Rafiki	  Mtoto	  Nesi	  Au	  mtu	  yeyote	  ambaye	  hayupo	  kafika	  orodha	  hii	  
Changua	  jibu	  sahihi	  kati	  ya	  haya	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person	  you	  spoke	  to	  
before	  this	  interview?	  
Not	  this	  could	  be	  
anyone	  including	  a	  
small	  baby	  and	  it	  could	  
be	  yesterday	  if	  you	  
didn’t	  speak	  to	  anyone	  
today...	  7	   Huyo	  mtu	  uliyeongea	  naye	  ana	  umri	  wa	  miaka	  mingapi?	  	  
What	  age	  was	  that	  
person	  	  
Zaidi	  ya	  miaka	  kumi	  	  	  Kati	  ya	  miaka	  mitano	  hadi	  kumi	  	  Ananizidi	  siyo	  zaidi	  ya	  miaka	  mitano	  	  Tunalingana	  	  Mdogo	  	  
More	  than	  10yrs	  
More	  than	  5y	  older	  less	  than	  10yrs	  
older	  
older	  but	  less	  than	  5yrs	  
Same	  age	  
younger	  
Changua	  jibu	  sahihi.	  Au	  unaweza	  ukabahatisha	  jibu	  sahihi.	  	  	  	  
	  
	  	  Demographic,	  sexual	  behaviors	  and	  IVP	  questions	  for	  ACASI	  	  In	  Swahili…”are	  you	  ready	  to	  do	  the	  main	  interview?	  If	  you	  need	  help,	  ask	  the	  assistant,	  if	  you	  want	  to	  do	  the	  practice	  again	  choose	  option	  1.	  If	  you	  are	  ready	  to	  do	  the	  main	  interview,	  choose	  2.	  The	  assistant	  will	  sit	  where	  you	  can	  see	  her,	  but	  will	  only	  come	  to	  help	  if	  you	  ask	  her.	  Choose	  1	  to	  do	  the	  practice	  again,	  or	  2	  to	  proceed	  to	  the	  interview”	  	  	  	   Question	   Possible	  responses	   Verbal	  instructions	  –	  for	  ACASI	  on	  laptop	   Skip	  1	   Unafanya	  nini	  kwa	  sasa?	  	  
What	  work	  are	  you	  
doing	  now	  
Nina	  fanya	  kazi	  Ninakaa	  nyumbani	  /	  sina	  kazi	  Ninarudia	  shule	  ya	  msingi	  	  Ninasoma	  shule	  ya	  sekondari	  Nina	  soma	  mafunzo	  ya	  ufundi	  Ninafanya	  kazi	  nyingine	  
Kuchagua	  jibu	  moja	  wapo,kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	   	  
	  2	   Je,	  umeshawahi	  kutumia	  moja	  wapo	  kati	  ya	  madawa	  ya	  kulevya	  yafuatayo	  	  	  	  	  	  
Have	  you	  ever	  taken	  
any	  of	  the	  following...	  
Pombe	  Sigara	  	  Bangi	  Mirungi	  Unga	  Valium	  Heroin	  Gundi	  Petroli	  Ugoro	  Nyingine	  	  Hakuna	  hata	  mmoja	  
Alcohol,	  cigarette,	  marijuana,	  mirungi,	  
cocaine,	  valium,	  heroin,	  gundim	  petrol,	  
glue,	  other,	  not	  one	  of	  these…	  
Kuchagua	  madawa	  yote	  amabayo	  umewahi	  kutumia	  	   	  
3	   Sasa	  umeolewa	  au	  unakaa	  na	  mpenzi	  wako?	  
Are	  you	  married	  or	  
living	  as	  married	  
	  
Nimeolewa	  Ninaishi	  na	  mpenzi	  	  Sijaolewa	  	   Kuchagua	  moja	  kati	  ya	  hayo	  	   	  
4	   Umeshawahi	  kumbusu	  mwanaume/mvulana	  midomoni?	  	  
Have	  you	  ever	  kissed	  a	  
boy	  on	  the	  lips	  
Ndiyo	  Hapana	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4a	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Tangia	  tumeonana	  na	  wewe	  mara	  ya	  mwisho,	  mara	  ngapi	  umeshambusu	  mwanaume	  kwenye	  midomo	  yake?	  	  
Since	  we	  last	  saw	  you	  
how	  many	  times	  have	  
you	  kissed	  a	  boy	  on	  the	  
lips	  	  
	  	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  
	  
5	   Umeshawahi	  kupeana	  denda	  na	  mpenzi	  au	  mume	  wako?	  (kula	  uroda,	  kula	  denda)	  
Have	  you	  ever	  kissed	  a	  
boy	  in	  the	  mouth	  using	  
tongues	  (known	  
as,,,colloquial	  terms)	  
Ndiyo	  Hapana	  	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	   	   	  
5a	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Tangia	  tumeonana	  na	  wewe	  mara	  ya	  mwisho,	  mara	  ngapi	  umeshawahi	  kupeana	  denda	  na	  mpenzi/mume	  wako?	  (kula	  uroda,	  kula	  denda)	  	  
Since	  we	  last	  saw	  you,	  
how	  many	  times.....	  (as	  
above)	  
	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  
	  
6	   Mpenzi	  au	  mume	  wako	  amewahi	  kuchezea	  matiti	  yako?	  (kujivinjari,	  kutomasatomasa,	  ku-­‐survey)	  	  
	  
Have	  you	  ever	  let	  a	  boy	  
play	  with/touch	  your	  
breasts	  
Ndiyo	  Hapana	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	   	  
6a	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Tangia	  tumeonana	  na	  wewe	  mara	  ya	  mwisho,	  mara	  ngapi	  mpenzi	  wako	  amewahi	  kuchezea	  matiti	  yako?	  (kujivinjari,	  kutomasatomasa,	  ku-­‐survey)	  	  	  
Since	  we	  last	  saw	  you,	  
how	  many	  times.....	  (as	  
above)	  	  
	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  
	  
7	   Umeshawahi	  kufanya	  mapenzi	  ya	  kushikana	  na	  mwanaume/mvulana,	  ambapo	  unachezesha	  uume	  wake	  kwa	  mkono	  wako?	  
	  
Have	  you	  ever	  touched	  
a	  boys	  penis	  with	  your	  
hand?	  
Ndiyo	  Hapana	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	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7a	   Tangia	  tumeonana	  na	  wewe	  mara	  ya	  mwisho,	  mara	  ngapi	  	  umeshawahi	  kufanya	  mapenzi	  ya	  kushikana	  na	  mwanaume/mvulana,	  ambapo	  umeshika	  kwa	  mkono	  wako?	  	  
Since	  we	  last	  saw	  you,	  
how	  many	  times.....	  (as	  
above)	  
Wangapi	  =	  XX	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  
	  
8	   Umeshawahi	  kufanya	  mapenzi	  ya	  kushikana	  na	  mwanaume/mvulana,	  ambapo	  anachezesha	  uke	  wako	  kwa	  mkono	  wake?	  (kupiga	  brush,	  kutomasatomasa)	  	  
Have	  you	  ever	  let	  a	  boy	  
touch	  your	  	  vaginal	  
with	  his	  hand?	  	  
Ndiyo	  Hapana	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  	  	  
	  
8a	   Tangia	  tumeonana	  na	  wewe	  mara	  ya	  mwisho,	  mara	  ngapi	  umeishawahi	  kufanya	  mapenzi	  ya	  kushikana	  na	  mwanaume/mvulana,	  ambapo	  anachezesha	  uke	  wako	  kwa	  mkono	  wake?	  (kupiga	  brush,	  kutomasatomasa)	  	  
Since	  we	  last	  saw	  you,	  
how	  many	  times.....	  (as	  
above)	  
Wangapi	  =	  XX	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  	  	  
	  
9	   Je,	  umewahi	  kunyonya	  uume	  wa	  mwanaume/mvulana	  kwenye	  mdomo	  wako?	  (kula	  muhogo,	  kula	  muwa,	  kula	  cone,	  kupiga	  mswaki,	  alamba)	  	  
Have	  you	  ever	  had	  a	  
boys	  penis	  in	  your	  
mouth	  
Ndiyo	  Hapana	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  	  	  
	  
9a	   Tangia	  tumeonana	  na	  wewe	  mara	  ya	  mwisho,	  mara	  ngapi	  umewahi	  kuwekewa	  uume	  wa	  mwanaume/mvulana	  kwenye	  mdomo?	  (kula	  muhogo,	  kula	  muwa,	  kula	  cone,	  kupiga	  mswaki,	  alamba)	  	  
Since	  we	  last	  saw	  you,	  
how	  many	  times.....	  (as	  
above)	  
Wangapi	  =	  XX	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  
	  
10	   Je,	  wanaume/mvulana	   Ndiyo	   Chagua	  “Ndiyo”	  au	  “Hapana”	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amewahi	  kukunyonya	  sehemu	  zako	  za	  siri	  (kwenye	  uke)?	  (kufyonza	  embe,	  kuzama	  chumvini,	  kula	  pera)	  	  
Have	  you	  ever	  had	  a	  
boy	  put	  his	  mouth	  on	  
your	  vvagina?	  
Hapana	   	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  	  
10a	   Tangia	  tumeonana	  na	  wewe	  mara	  ya	  mwisho,	  mara	  ngapi	  wanaume/mvulana	  amewahi	  kukunyonya	  sehemu	  zako	  za	  siri	  (kwenye	  uke)?	  (kufyonza	  embe,	  kuzama	  chumvini,	  kula	  pera)	  	  	  
Since	  we	  last	  saw	  you,	  
how	  many	  times.....	  (as	  
above)	  	  
Wangapi	  =	  XX	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  
	  
11	   Umewahi	  kujamiana	  kwa	  njia	  ya	  haja	  kubwa?	  (Kufilana,	  
kupakua,	  kisamvu,	  kula	  
tigo,	  kula	  mgongo)	  
	  
Have	  	  you	  ever	  had	  
anal	  sex?	  
	   	   	  
11a	   Tangia	  tulipoonana	  na	  	  wewe	  mara	  ya	  mwisho,	  mara	  ngapi	  umewahi	  kujamiiana	  kwa	  njia	  ya	  haja	  kubwa?	  (kufilana,	  kupakua	  kisamvu,	  kula	  tigo,	  kula	  mgongo)	  
Since	  we	  last	  saw	  you,	  
how	  many	  times.....	  (as	  
above)?	  
	  
	   	   	  
12	   Je	  umeshawahi	  kujamiiana	  kwa	  kuingia	  ndani.	  Kwa	  hili	  namaanisha	  pale	  mwanaume	  anapoweka	  uume	  wake	  kwenye	  uke	  wako.	  
(Kuchakachuliwa,	  
Kugongwa	  mshipa,	  Ku	  
sex,	  Kutiana,	  Kuingia	  
ngumu	  kutoka	  laini	  )	  	  
Have	  you	  ever	  had	  
vaginal	  sex?	  	  
(explanation,	  and	  
colloquial	  terms…)	  	  
Ndiyo	  Hapana	  	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  	  
	  
	   ONLY	  ASK	  THIS	  SECTION	  IF	  Q11	  ANSWER	  	  IS	  YES	   	   	  12a	   Je,	  katika	  maisha	  yako	  yote	  mpaka	  sasa	  hivi,	  umewahi	  kujamiiana	   Wangapi	  =	  XX	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	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na	  wapenzi	  wangapi?	  	  	  
In	  your	  whole	  life	  to	  
now,	  how	  many	  
men/boys	  have	  you	  
had	  sex	  with?	  	  	  
wa	  kulia	  	  	  
12b	   Je,	  tangia	  tulipoonana	  mara	  ya	  mwisho,	  mara	  ngapi	  umeshawahi	  kujamiiana	  kwa	  njia	  ya	  uke.	  Kwa	  hili	  namaanisha	  pale	  mwanaume	  anapoweka	  uume	  wake	  kwenye	  uke	  wako?	  	  
Since	  we	  last	  saw	  you,	  
how	  many	  times	  have	  
you	  had	  sex?	  This	  is	  the	  
number	  of	  sex	  acts.	  
	  	  
Wangapi	  =	  XX	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  
	  
13	   Mwanamume	  uliyejamiiana	  naye	  mara	  ya	  kwanza	  alikuwa	  nani	  wako?	  	  
Think	  about	  the	  fitst	  
person	  you	  had	  sex	  with	  
–	  who	  was	  this?	  	  	  
Mume	  	  Mpenzi	  	  Simfahamu	  (tulikutana	  mara	  moja)	  Mtu	  ambaye	  sitaki	  kujamiiana	  naye	  Nyingine	  	  
Chagua	  Moja	  kutoka	  kwenye	  Orodha	  au	  “	  Sijui”	  	  	  ”	  
	  
14	   Mwanamume	  uliyejamaiiana	  naye	  mara	  ya	  kwanza,	  unadhani	  alikuwa	  na	  umri	  gani?	  	  
How	  old	  was	  your	  first	  
lover?	  
Zaidi	  ya	  miaka	  kumi	  	  	  Kati	  ya	  miaka	  mitano	  hadi	  kumi	  	  Ananizidi	  siyo	  zaidi	  ya	  miaka	  mitano	  	  Tunalingana	  	  Mdogo	  
Chagua	  Moja	  kutoka	  kwenye	  Orodha	  au	  “	  Sijui”	  	  	  	  
	  
15	   Mwanamume	  uliyejamiiana	  naye	  mara	  ya	  nwisho	  alikuwa	  nani	  wako	  
	  
Who	  was	  	  your	  first	  lover	  	  
Mume	  	  Mpenzi	  wangu	  	  Simfahamu	  (tulikutana	  mara	  moja)	  Mtu	  ambaye	  sitaki	  kujamiiana	  naye	  Nyingine	  	  
Chagua	  Moja	  kutoka	  kwenye	  Orodha	  au	  “	  Sijui”	  	  	  	  	  
This	  question	  is	  asked	  if	  Q11a	  is	  >1	  	  
16	   Mwanamume	  uliyejamiiana	  naye	  mara	  ya	  mwisho	  unadhani	  alikuwa	  na	  umri	  gani?	  	  
How	  old	  was	  your	  first	  
lover?	  	  
Zaidi	  ya	  miaka	  kumi	  	  	  Kati	  ya	  miaka	  mitano	  hadi	  kumi	  	  Ananizidi	  siyo	  zaidi	  ya	  miaka	  mitano	  	  Tunalingana	  	  Mdogo	  
Chagua	  toka	  kwenye	  orodha	  au	  sijui	  	  	  
This	  question	  is	  asked	  if	  Q11a	  is	  >1	  
17	   Je,	  mlitumia	  kondomu	  mara	  ya	  mwisho	  mlipojamiiana	  	  	  	  
Did	  	  you	  use	  a	  condom	  
the	  last	  time	  you	  had	  sex?	  
Ndiyo	  Hapana	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	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18	   Je	  umeshawahi	  kushawishiwa	  kufanya	  mapenzi	  ili	  upate	  usafiri,	  alama	  bora	  shuleni,	  hela	  za	  matumizi	  madogo	  madogo,	  au	  pesa	  ya	  kununua	  chakula	  nyumbani?	  	  
Have	  you	  ever	  had	  sex	  in	  exchange	  
for	  gift/money	  	  
Ndiyo	  Hapana	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  	  	  	  	  
	  
18a	   Katika	  miezi	  mitatu	  iliyopita	  mara	  ngapi	  ulijamiiana	  kwa	  ajili	  ya	  zawadi/pesa	  	  	  
How	  many	  times	  in	  the	  past	  three	  
moths...as	  above	  	  
Wangapi	  =	  XX	   Ingiza	  namba	  au	  sijui	  	  	  	  
	  
19	   	  Je,	  uliwahi	  kulazimishwa	  na	  mwanaume	  kujamiiana	  naye	  bila	  hiari	  yako?	  	  
Have	  you	  ever	  been	  forced	  to	  have	  
sex	  against	  your	  will?	  	  	  
Ndiyo	  Hapana	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  	  	  
	  
19a	   Katika	  miezi	  mitatu	  iliyopita	  mara	  ngapi	  uliwahi	  kulazimishwa	  na	  mwanaume	  kujamiiana	  naye	  bila	  hiari	  yako?	  	  
How	  many	  times	  in	  the	  past	  three	  
moths...as	  above	  	  
	  	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  
	  
20	   Umewahi	  kujamiiana	  ukiwa	  katika	  siku	  zako	  za	  hedhi?	  	  
Have	  you	  ever	  had	  sex	  whilst	  
menstruating	  	  
Ndiyo	  Hapana	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  	  
	  
20a	   Katika	  miezi	  mitatu	  iliyopita	  mara	  ngapi	  tulipokuona	  uliwahi	  kujamiiana	  ukiwa	  kwenye	  hedhi?	  	  
How	  many	  times	  in	  the	  past	  three	  
moths...as	  above	  	  
	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  
	  
21	   	  Umewahi	  kuwa	  mjamzito	  	  	  	  	  Have	  you	  ever	  been	  pregnant?	  	   Ndiyo	  Hapana	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  
	  
21a	   Umeshabeba	  ujauzito	  mara	  ngapi	  	  How	  many	  time	  have	  you	  been	  
pregnant?	  	  
.	   Ingiza	  idadi,	  	  Kama	  huna	  uhakika	  chagua	  sina	  uhakika	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  
	  
	   THESE	  QUESTIONS	  ARE	  FOR	  EVERYONE	  AGAIN	  22	   Unapokwa	  kwenye	  hedhi	  huwa	  unatumia	  nini	  kuzuia	  damu	  	  	  
What	  do	  you	  use	  to	  catch	  the	  blood	  
during	  menstruation	  
Vitambaa/kanga	  	  	  Chupi	  Karatasi	  ya	  choo	  	  Pedi	  za	  madukani	  	  	  Tampons	  	  
Chagua	  moja	  toka	  kwenye	  orodha	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   Nyingine	  	  Si	  hedhi	  	   	  22a	   Kama	  unatumia	  nguo,	  huwa	  unaiweka	  ndani	  ya	  uke,	  nje	  ya	  uke	  au	  ndani	  na	  nje	  ya	  uke	  
	  
Do	  you	  use	  this	  inside/outside	  the	  
vagina	  or	  both	  
Ndani	  ya	  uke	  peke	  yake	  	  Nje	  ya	  uke	  peke	  yake	  Ndani	  na	  nje	  ya	  uke	   Chagua	  moja	  toka	  kwenye	  orodha	   	  
23	   Umewahi	  kusafisha	  ndani	  ya	  uke	  wako?	  	  
Have	  you	  ever	  cleansed	  
inside	  your	  vagina?	  
Ndiyo	  Hapana	   Chagua	  “Ndiyo”	  au	  “Hapana”	  	  Kama	  hujui	  chagua	  sijui	  kutoka	  orodha	  upande	  wa	  kulia	  	  	  
	  
24	   Je,	  umeishawahi	  kuweka	  vitu	  hivi	  ndani	  ya	  uke	  wako?	  	  	  
Have	  you	  ever	  inserted	  
anything	  inside	  your	  
vagina?	  
limao	  au	  Ndimu	  	  	  	  Mitishamba	  Dawa	  ya	  kuzuia	  wadudu	  kwa	  mfano	  Dettol/Jik	  Sabuni	  ya	  unga	  Ugoro	  	  Nyingine	  	  Au	  sijawahi	  kuingiza	  chochote	  
Chagua	  yote	  ambayo	  yahanahusika	  	  
	  
	  End	  of	  questionnaire.	  You	  can	  go	  back	  through	  the	  questionnaire	  to	  check	  or	  change	  your	  answers	  by	  pressing	  the	  “last	  question”	  button.	  	  Thank	  you	  for	  giving	  us	  this	  information.	  It	  is	  completely	  anonymous,	  and	  safe.	  	  Please	  call	  the	  assistant	  if	  you	  are	  finished.	  	  	  	  
